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Abstract
The adaptive immune response is very important for our survival in that it gives us the capability of
detecting a wide variety of foreign material, allows for the elimination of pathogens, and provides
memory to protect against future attacks by the same pathogen. Key mediators of the adaptive immune
response are CD4+ T cells, which depending on the cytokine milieu, and the activating conditions during
antigen recognition, can differentiate into different effector T cells. One particular type of effector T cell,
Th 17, is highly inflammatory and has been implicated in various autoimmune diseases, such as Multiple
Sclerosis. Three chapters within this thesis investigate the conditions which lead to Th17 differentiation
and the mechanisms involved in their regulation. Th 17 cells can be obtained in vitro by culturing naive
CD4+ T cells with IL-6 and TGF-p under activating conditions. IL-6 was thought to primarily activate
the transcription factor STAT3, which has been shown to be necessary for ThI7 differentiation.
Numerous cytokines activate STAT3, but IL-6 is the most potent inducer of Thl7 cells, so we sought to
find out what is special about IL-6's induction of STAT3. In the first of these three chapters, we propose
a simple genetic network which is capable of translating IL-6's high amplitude, transient STAT3 signal
into a pro-inflammatory response and IL-10's low amplitude, sustained STAT3 signal into an anti-
inflammatory response. This network is able to predict that IL-6 and IL-10 would induce an
indistinguishable anti-inflammatory response in SOCS3-/- cells where IL-6's STAT3 signal is sustained.
In the second of these chapters, we continue our research into the origin of signal specificity in cytokine
signaling by systematically characterizing the activation of STATJ and STAT3 by IL-6, IL-10, IL-21, IL-
27, and different combinations of cytokines in CD4+ T cells. In this analysis we find that the ratio of
STAT3 to STATI activated is the important quantity in determining whether or not a cytokine will be an
inducer of Thl7 differentiation (IL-6, IL-21) or an inhibitor (IL-27). We show that in the absence of
STAT1, that IL-6 and IL-27 are both potent inducers of Thl7 differentiation since they have similar
STAT3 activation profiles. In the third of these chapters, we develop a simple algorithm for clustering
gene activation profiles for intermediate numbers of genes measured (10-50) and use it to analyze a 96-
hour time course of gene activation during Th 17 differentiation for a number of genes of interest.
In order for T cells to differentiate into effector cells, they must first recognize antigen which is presented
on the surface of an antigen presenting cell by a membrane-bound extracellular complex called MHC.
The MHC have a groove which peptide fragments (antigen) are bound in. Without peptide loaded in the
pocket, the MHC are quite unstable so they are synthesized with a generic peptide fragment loaded. A
protein, DM, is responsible for stabilizing the MHC while the generic peptide is ejected and the peptide
fragment of interested is loaded. Two chapters within this thesis investigate the role of DM in peptide
loading / unloading and attempt to characterize the interaction of DM with MHC.
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Chapter 1: Introduction
1.1 Introductory Remarks
All of the topics covered in this thesis involve questions regarding the inner workings of the
adaptive immune system. Before jumping into the specific nature of these questions, I think it is
important to introduce some general immunology concepts in the following subsections of the
introduction. A description of these general concepts is by no means intended to be a
comprehensive review of the literature. Rather, I will discuss the concepts in more broad,
"common knowledge" terms, giving references where needed. Intertwined throughout this
discussion I will introduce all of the questions to be addressed in this thesis and the motivation
behind investigating such questions. In the next to last section of the introduction, I will give an
overview of the remaining chapters.
1.2 Adaptive Immunity
The adaptive immune response is very important for survival in that it gives the host organism
the capability of detecting a wide variety of foreign material, allows for the elimination of
pathogens, and provides memory to protect against future attacks by the same pathogen. Key
mediators of the adaptive immune response are CD4+ T cells, which detect antigen presented on
the surfaces of antigen presenting cells (APC). The APCs break down both endogenous and
foreign material internally and load these fragments into MHC class II molecules forming
peptide-MHC complexes, which are transported to the surface for interaction with T cell
receptors (TCR) expressed on the surface of T cells. Upon ligation of the TCR with a foreign
peptide-MHC complex (pMHC), the T cell can be activated. After activation, the T cell
undergoes extensive proliferation and eventually differentiates into an effector cell which
mediates the immune response.
1.3 TCR Signaling
The process of T cell activation involves the transduction of multiple intracellular
signaling pathways initiated by the TCR upon ligation with pMHC. One outcome of these
signaling pathways is the transcription and secretion of Interleukin 2 (IL-2), which is a cytokine
that induces cellular proliferation. The TCR signaling pathway has been well characterized (a
schematic of the pathway can be found in Figure 1.1). Upon ligation with a peptide-MHC
complex, the kinase Lck is recruited, which then phosphorylates the TCR-( chain and the
immuno-tyrosine activation motifs (ITAMs). The kinase, ZAP-70 can bind to phosphorylated
ITAMs and is activated by Lck. Two methods of regulation for these initial signaling events are
phosphatase activity and Cbl-b-mediated degradation. Cbl-b is a ubiquitin ligase that can bind to
ZAP-70 and mark it for degradation. The degradation process results in the destruction of both
ZAP-70 and the associated TCR'.
Figure 1.1. T cell receptor signaling pathways (from Lin and Weiss, 2001)2
Once activated, ZAP-70 can phosphorylate downstream targets including the membrane-bound
adapter molecule LAT, which spatially organizes downstream signaling pathways. LAT
contains a phosphorylation site that can bind the phospholipase PLCy, and multiple
phosphorylation sites that can bind the adaptor molecules Grb2 and GADS. PLCy cleaves
membrane bound PIP 2 molecules into IP3 and DAG. IP3 leads to both the release of intracellular
Ca2+ stores and an influx of Ca2+ into the cell. This, in turn, results in the activation of NFAT, an
IL-2 transcription factor. DAG leads to the activation of PKC, which subsequently leads to NF-
kB activation, another IL-2 transcription factor. The adaptor molecule GADS binds to the
scaffold SLP-76 and can stabilize the interaction of PLCy with LAT when the two molecules are
bound to adjacent phosphorylation sites. The Tec kinase Itk binds to SLP-76 and is thought to
activate PLCy. Additionally the MAPK pathway can be initiated by the binding of Grb2 to LAT
by the following mechanism. Grb2 recruits the guanine exchange factor, Sos, which can
catalyze the conversion of RasGDP to its activated form, RasGTP. Sos contains an allosteric site
that can be occupied by either RasGDP or RasGTP, which increases its catalytic ability.
RasGTP can activate the MAPKKK Raf, which ultimately leads to the production of the third IL-
2 transcription factor, AP-1. Ras can also be activated by RasGrp, which is activated in the
PLCy pathway through DAG. The primary difference between the two methods of Ras
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activation is that activation through Sos is cooperative, while activation through RasGrp is not .
1.4 Loading of peptides by DM
In Section 1.2 it was described that T cells have receptors which interact with pMHC on APCs,
which give the T cells the ability to scan for foreign material and ultimately set off a response if
any is detected. Therefore, the ability of APCs to take in material from their surroundings, break
it up into peptide fragments, load it into MHCs, and display the pMHC on their surface is an
integral part of the adaptive immune system. MHCs that do not have peptide loaded in them are
unstable and either collapse or form aggregates of multiple empty MHCs (Grotenbreg). To
avoid this issue, they are synthesized loaded with a generic peptide, CLIP. Somehow, the APCs
need to be able to remove CLIP and load in a peptide fragment from engulfed material without
the pocket on the MHC collapsing or the formation of MHC aggregates. This is the role of the
protein, DM. DM's role is to eject the CLIP peptide, stabilize the empty MHC, and load the
peptide of interest.
Having a protein specialize in the removal and additions of peptides seems contradictory, since it
would be assumed that DM would eject the peptide that it has just loaded. The precise role of
DM in this process is investigated in Chapter 2 using photocleavable peptides. These are
peptides that when exposed to UV light, get cleaved and dissociate from MHC. Also in solution
during this process is a labeled peptide which can be measured using a technique called
fluorescence polarization where the signal is indicative of whether or not the labeled peptide is
bound to the much larger MHC molecule. This experimental technique allows for the analysis of
the kinetics of MHC aggregation and peptide loading in the absence of DM, which when
compared to the same experiment done in the absence of UV and presence of DM, allows for
analysis of the role of DM. We further characterize the interaction between pMHC and DM in
Chapter 3 using a Biacore instrument. This is another tool for analyzing the kinetics of
association and dissociation between two molecules.
1.5 Modeling cell signaling networks
During the early years of immunology research in the Chakraborty group, much focus was
placed on studying different problems involving the T cell receptor (TCR) signaling network
discussed in a previous subsection. The TCR pathway had been studied extensively and
therefore most of the relevant pathways were known. Using estimated parameters found
throughout the literature and also heuristic estimates, computer simulations of the TCR pathway
could be performed by treating the pathway as a series of chemical reactions. As an example,
ZAP70 binding to LAT would be one reaction, ZAP70 phosphorylating a tyrosine residue on
LAT would be another reaction, ZAP70 unbinding from LAT would be another reaction.
Simulations could show how downstream markers like ZAP70 activation varied as the strength
of the TCR - pMHC interaction varied.
Due to length scale that these intracellular interactions occur and due to the relatively small
number of molecules involved, the reaction network could not simply be solved using an
Ordinary Differential Equation (ODE) solver like MATLAB. Solving ODEs gives the mean
concentrations that are the solutions at various time points. One could imagine a scenario where
a threshold is imposed on the number of activated ZAP70 molecules which constitutes a T cell
being activated. For a range of parameters, it may appear that the T cell would not be activated
since the ODE solution does not show the number of activated ZAP70 molecules crossing the
threshold at any time point. However, this is just the average solution. Stochastic simulation
allows for the visualization of many different trajectories since it takes into account the
stochastic nature of equations involving small numbers of molecules. In practice, numerous
trajectories could cross the threshold of activated ZAP70 molecules at numerous time points
without the average of all the trajectories ever crossing that threshold. Any conclusions made
based on the ODE solution would be flawed for this reason.
A very useful algorithm, known as the Gillespie algorithm is used throughout the Chakraborty
group to simulate interactions in signaling networks due to its ability to take into account
stochastic effects associated with small numbers of molecules in an easily programmable
manner . For all the reactions in a network, a rate equation can be written in the form of
ai = ki Ci.. (Equation 1.1)
Equation 1.1 where the propensity of reaction i (a) is equal to the rate constant (ki) multiplied by
the concentrations of all the reactants (C ). At every time step in the algorithm, the total
propensity (ao) is computed by summing all of the individual reaction propensities. Next, two
random numbers are generated according to a uniform distribution from 0 to 1. The first random
number (r) is used to compute the time that has elapsed since the last reaction occurred at the
previous time step (t) using Equation 1.2.
T = In (Equation 1.2)
A variable in the algorithm keeps track of the total time elapsed by summing the individual time
steps. Now that the time that the next reaction will occur has been computed, the other random
number (r2) is used to determine the identity of the next reaction (pi) which satisfies the
inequality in Equation 1.3.
,- < r ; a0  (Equation 1.3)0= 0oV a
After the identity of the next reaction is determined, the numbers of molecules for all species are
changed according to the stoichiometry of whichever reaction has occurred. At the next time
step, all of the propensities are recalculated, two new random numbers are generated and the
process continues until the desired reaction time is reached. In practice, Equation 1.3 favors the
occurrence of reactions with the highest propensities, but the random element allows for the
occurrence of reactions with small propensities as well.
Our group has used these methods to investigate a number of problems involving TCR signaling.
The site of interaction between a T cell and an APC during TCR - pMHC binding is known as
the immunological synapse. After early signaling events through the TCR, costimulatory
receptors and signaling molecules begin to congregate in the middle of the synapse, while
adhesion molecules begin to congregate on the edge of the synapse. A series of papers by former
members of the group investigated the role of the synapse in T cell activations,6 ,7. Another
standing problem in immunology at the time was how a TCR could find a small amount of
foreign antigen in a sea of many endogenous peptides and initiate an activation signal. A model
known as the dimer model was illustrated using simulation8 . In this model, it was proposed that
the sea of endogenous pMHC could be used to amplify the signal generated by an antigenic
pMHC through localization of CD4. LCK bound to the cytoplasmic tail of CD4 associated with
the antigenic pMHC - TCR interaction could then activate the ITAMs of neighboring TCR's
bound to endogenous pMHC.
Ashok Prasad, a post doc in the group, added more detail to the basic TCR models by adding in
the downstream signals which are localized by LAT. He used this model investigate the origin
of the sharp boundary that discriminates the positive and negative selection of thymocytes9 .
Jayajit Das used modeling to investigate properties of RAS signaling'. Dennis Wylie expanded
17
our algorithms from spatially homogenous systems (a well-mixed system) to spatially
I0inhomogeneous systems where spatial effects of signaling matter.
1.6 Cytokines
All of the previous models in our group, as discussed in the previous subsection, focused on TCR
signaling. However, T cells receive many more signals than just through their TCRs. T cells
have various costimulatory receptors on their surface, such as CD28 and CTLA-4, which interact
with ligands, B7-1 and B7-2, on the APCs. These signals further regulate whether or not a T cell
gets activated by providing either a supplemental signal (CD28) or an inhibitory signal (CTLA-
4).
In addition to costimulatory receptors, there are also cytokine receptors on the surface of T cells.
Cytokines are extracellular signaling molecules which help skew the immune response towards
whatever is needed locally. Many of the cytokines are members of the interleukin family and all
have names in the form of Interleukin # (IL-#). Many of these signal through the Jak-STAT
pathway and may also activate a MAPK pathway. Frequently in the literature the term, cytokine
milieu, appears which is in reference to the composition of cytokines that are present locally.
During T cell differentiation into various effector types, the cytokine milieu often determines
which type of effector T cells will dominate. As an example, if primary T cells are in the
presence of IL-4 during differentiation, the resulting effector cells will be Th2 cells (described in
the next subsection). IL-4 is secreted by Th2 cells which serves to further induce the T cells
around them to become Th2 and also to inhibit the development of Thl or Thl7 cells. In this
manner, cytokines serve as an additional means of shaping the nature of the immune response.
1.7 Effector T cells
Effector cells arise when naive T cell get activated and have undergone differentiation over the
course of several days. Up until recently, it was thought that there were only two main
categories of effector T cells, T helper I cells (ThI) or T helper 2 cells (Th2). Now, several new
effector types have been described including Thl7 cells, Th9 cells, Trl cells, etc. In this section,
I will focus on three of the major types, Thl7, Thi and Th2, which can be seen in Figure 1.2.
Th17 cells were discovered in the context of Multiple Sclerosis where it was discovered that
there was a lot of the cytokine IL-17 present in the lesions. It was found that the IL-17 was
coming from a previously uncharacterized effector cell, which became known as Th 17 cells, due
to their ability to secrete IL-17. Soon two groups, including Vijay Kuchroo's group, found that
Thl 7 cells could arise in vitro by added TGF-p and IL-6 in the presence of some form of TCR
stimulation.
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2007)".
WL-
STAT4
I23
IL-4R
L-12
2R Host defense
(Intracellular pathogens)
SAUtoimmunity
IL-23
R Host defense
cr-C> (Extracellular pathogens)
Inflammation
Autoimmunity
Host defense
r_---i> (parasites)
Allergy
Asthma
into different effector types. Figure modified from (Bettelli,
As seen in Figure 1.2, effector cell types are classified according to the cytokines that they
secrete, which in turn dictate the nature of the immune response. Each expresses a master
transcription factor which drives its lineage: T-bet for Thl, RORyt for Thl7, and GATA-3 for
Th2. It is thought that Thl cells specialize in the defense against intracellular pathogens, while
Th17 cells specialize in the defense against extracellular pathogens. Th2 cells specialize in
defense against parasites. These are not strict definitions of function, rather they are summations
of some different functions observed by the given effector type. Th17 cells are highly
inflammatory and have been implicated in numerous autoimmune diseases, including multiple
sclerosis as described above. Th17 cells are currently a hot topic in research due to their
involvement in autoimmune disease as well as their relatively new status within the field. The
remainder of the introduction will revolve around problems involving Thl 7 differentiation.
1.8 Th17 versus Treg differentiation
There are two types of regulatory T cells, iTreg and nTreg, which both serve as a check on the
immune system in the periphery. They are characterized by their expression of the transcription
factor Foxp3 and their ability to inhibit the proliferation of T cells. nTregs arise during thymic
selection and are thus are beyond the scope of this thesis. Inducible Tregs (iTregs) arise from
primary T cells after several days of TCR stimulation in the presence of TGF-p (Figure 1.3).
The differentiation conditions for Tregs are surprisingly similar to that of Th 17 cells, which arise
from primary T cells in the presence of TCR stimulation, TGF-p, and IL-6. Determining how
the addition of IL-6 can change a Treg-inducing TGF-p signal into a Thl7-inducing signal began
as the primary focus of this thesis.
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Figure 1.3. T cell differentiation into either Tregs or Thl 7 cells. Figure modified from Bettelli,
2007.
We were recruited by Vijay Kuchroo (thesis committee member) to use our computational skills
to determine how the signaling pathways of IL-6 and TGF-P overlap to give Thl7 cells. The
obvious place to start was to look at the components of the TGF-p signaling pathway (Figure
1.4) and the IL-6 signaling pathway (Figure 1.5). TGF-p induces the activation of SMADs.
Upon activation, the SMADs form a trimer which allows for access to the nucleus. This is about
the simplest signaling network possible in that the transcription factor is induced at the receptor
without any signaling cascades. Through the Jak-STAT pathway, IL-6 induces what we believed
to be mainly pSTAT3. Upon activation, pSTATs form a dimer which reveals a nuclear targeting
sequence and allows for their access into the nucleus. Given the simplistic nature of these two
pathways, it is not obvious how they would overlap at the membrane-proximal level. Thus, they
must likely overlap at the transcriptional level. It should be noted that there is also a MAPK
pathway induced by both IL-6 and TGF-p, which will not be considered in this thesis.
Figure 1.4. TGF-p signaling pathway obtained from BioCarta's website (www.biocarta.com).
Figure 1.5. IL-6 signaling pathway obtained from Biocarta's website (www.biocarta.com).
1.9 Approach for studying Th17 versus Treg differentiation
With no obvious overlap between the IL-6 and TGF-P pathways on paper, we needed some way
to approach the problem of understanding the difference between Th 17 and Treg differentiation.
Being a chemical engineer, a good way to start is by constructing a process flow diagram of the
problem (Figure 1.6). Through membrane-proximal signaling, IL-6 induces pSTAT3 and TGF-p
induces pSMAD. These transcription factors feed into a genetic network, which leads to the
differentiation into Th 17 cells. In the absence of IL-6, the genetic network leads to Tregs. In the
absence of TGF-p, the genetic network leads to a pro-inflammatory response. We focused our
research efforts on characterizing the membrane-proximal signaling using flow cytometry
(Chapter 5) and characterizing the genetic network by following the activation of numerous
genes over the course of several days using PCR (Chapter 6).
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Figure 1.6. Effective process flow diagram of the cytokine signals that lead to Th 17
differentiation and the techniques to be used to characterize the important sections of the
diagram.
1.10 Cytokine specificity
In the literature, it seemed that the consensus was that IL-6 primarily induced pSTAT3.
However, numerous cytokines activate STAT3 and behave very differently to IL-6. We began to
appreciate this problem in the context of IL-6 and IL-10 signaling. IL-6 induces a pro-
inflammatory response, while IL-10 induces an anti-inflammatory response, despite both
signaling through STAT3. Before even approaching the problem of understanding the inner
workings of Thl7 differentiation, we were faced with the issue that we had no way
mathematically to distinguish an IL-6 induced STAT3 signal from an IL-10 induced STAT3
signal. Through a literature review, it was learned that IL-6 induces a transient STAT3 signal,
while IL-10 induces a sustained STAT3 signal. In both cases, pSTAT3 is exposed to exactly the
same genetic network, but the transient signal leads to a pro-inflammatory response while the
sustained signal leads to an anti-inflammatory response. In Chapter 4, we show that a very
simple genetic network can use changes in signal duration to lead to two different cellular
outcomes. Therefore, cells can utilize signal duration as a means of distinguishing between two
different cytokines despite them activating the same transcription factor.
The case considered in Chapter 4 was simpler since it was just two cytokines, IL-6 and IL-10
which had been characterized experimentally in the literature in the same experiment. In the
context of Th17 differentiation, we knew of four cytokines of interest, IL-6, IL-10, IL-21, and
IL-27 (Figurel.7). These were all chosen due to their effects on Th17 differentiation and
because they all activate the same two transcription factors STATl and STAT3. As discussed
before, IL-6 induces Thl7 differentiation when combined with TGF-p. It was generally thought
that IL-10 would inhibit Thl7 differentiation since it is an anti-inflammatory cytokine, but its
24
effect had not been observed at the start of this study. IL-21 was known to be secreted during
Thl7 differentiation, reinforcing the Thl7 lineage. In the absence of IL-6, IL-21 is a weak
inducer of Th 17 cells when combined with TGF-p. IL-27 was known as a main inhibitor of
Th 17 differentiation.
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Figure 1.7. Cytokine signaling pathways and their effects on Th 17 differentiation when
combined with TGF-p signaling. Some of the information used in the construction of this figure
is from (Delgoffe, 2011)12.
In Chapter 5, we explore the origin of signal specificity in the context of Th 17 differentiation
amonugst pSTAT1 and pSTAT3 inducing cytokines by measuring experimentally in Vijay
Kuchroo's lab how each cytokine activates these transcription factors over the first four hours of
stimulation. It was very important, in order to compare the cytokines, that we characterize the
cytokines in the same study. Other studies had characterized 1 or 2 of the cytokine's STAT
signals at a time, which did not allow for comparing the cytokines. We observe the effects of
how these activation profiles change when multiple cytokines are present. We also observe
whether or not these cytokines behave similarly when their pSTAT activation profiles are made
to be similar.
(It may be confusing to the reader that early in this subsection it is noted that IL-6 primarily
activates STAT3 and then in Figure 1.7, it is shown to activate STATI as well. This figure is
based on our experiments in Chapter 5 and not what we had seen in the literature when the work
in Chapter 4 was performed.)
1.11 Overview of experimental techniques to be used
Three main experimental techniques were used in the preparation of Chapter 5, which is the
primary results section of this thesis. In the next three subsections, I will briefly describe the
techniques. For a more detailed description, refer to Appendix 1.
1.11.1 FACS
Flow cytometry was used to reliably and repeatably measure pSTATl and pSTAT3 levels in
CD4+ T cells. T cells were stimulated with various cytokines for varying amounts of time in an
incubator. After, the cells were collected and fixed. They were then permeabilized and
antibodies for pSTATI and pSTAT3 were added. The cells were then run on a flow cytometer
which measured both pSTAT1 and pSTAT3 levels based on the intensity of the colors on the
individual antibodies.
1.11.2 EMSA
A compounding variable in the STAT characterization study was that pSTATI and pSTAT3 can
exist in homodimers (pSTATI-pSTATl, pSTAT3-pSTAT3) or heterodimers (pSTATI-
pSTAT3) which could have different properties. We sought a technique to be able to
characterize the ratio of these different forms in the nucleus of the T cells after stimulation with
different cytokines for varying amounts of time. FACS cannot give insight into these ratios since
there are different antibodies for pSTAT1 and pSTAT3 which may have different affinities or
intensities and thus the levels measured using FACS cannot be compared. A technique called
electrophoretic mobility shift assay (EMSA) could be used to accomplish this. In this assay, a
labeled oligomer that all three dimeric forms can bind to is combined with the nuclear extracts
from the T cells of interest. The mixture is then run on a non-denaturing gel using
electorophoresis. The labeled oligomer is relatively small and travels with ease through the gel if
nothing is bound to it. If any of the dimeric forms binds to the oligomer, it moves slowly. Due
to subtle differences in molecular weights, the gel can then be visualized and bands appear with
intensities proportional to the relative amounts of the dimeric forms. The oligomer used is part
of the C-fos gene known as hSie'" 4 . This technique did not end up being used due to difficulty
in interpreting its results. However, since a protocol was developed, it seemed relevant to
include it in this thesis.
1.11.3 Thl7 differentiation
To compare how different cytokine pairs affected Th17 differentiation, we needed to have a
standardized way of performing Th 17 differentiations and measuring the results. Naive CD4+ T
cells (CD62L high CD25-) were sorted on a FACS ARIA and then plated on flat-bottom 24-well
plates coated with a-CD3 / a-CD28 (Note: If APCs were to be used for stimulation, uncoated
plates were used). The cytokines of interest were added along with TGF-P, and neutralizing
antibodies for IFN-y and IL-4 before placing the plate in an incubator for 48 hours. At 48 hours,
the cells were moved to a new uncoated plate and IL-23 was added. At 96 hours, the cells were
collected and restimulated with PMA and lonomycin for 3-4 hours in the incubator. The cells
were then fixed and stained for measurement of intracellular IL-I 7a.
1.12 Thesis Overview
All of the chapters were introduced in the previous subsections, but to understand how
everything fits together, I will use this subsection to reiterate the content of each of the chapters.
Chapter 2 and 3 are reprints of two manuscripts that resulted from a collaboration with Kai
Wucherpfennig's lab to try and further the understanding of the role of DM in the loading and
unloading of pMHC (Chapter 2), as well as understanding the nature of the interaction between
DM and pMHC (Chapter 3). These were side projects that do not necessarily relate to the central
theme of cytokine specificity and Th 17 differentiation, but do relate to immunology and did
result in two publications and thus are included in this thesis.
Chapter 4 is a reprint of a manuscript where we sought to show that a simple genetic network
capable of distinguishing between transient and sustained signals could account for the fact that
IL-6 induced pSTAT3 leads to a pro-inflammatory response while IL-10 induced pSTAT3 leads
to an anti-inflammatory response without needed to resort to unknown species or receptor
specific conformational changes of STAT3. This simple study is how we began to appreciate the
nuances of cytokine specificity when two cytokines signal through the same transcription factor
but lead to different results. It is a fine illustration of how two cytokines can unexpectedly
behave similarly when their signals are made to be similar. In this case, if IL-6 is made to induce
a sustained pSTAT3 signal, it behaves exactly like IL-10 in inducing an anti-inflammatory
response.
Chapter 5 is a pre-print of a manuscript that will eventually be submitted for publication. It is
also the culmination of my 3 years of doing experiments in Vijay Kuchroo's lab and should be
considered the main chapter of the thesis. In this chapter, I seek to characterize IL-6, IL-10, IL-
21, and IL-27 signaling and ultimately determine why these cytokines behave differently in the
context of Th17 differentiation despite signaling through the same transcription factors. We
show that the ratio of pSTAT3 to pSTATJ induced is the important distinguishing variable
between the different cytokines and that only considering that amplitude of one or the other
transcription factors leads to faulty conclusions. This ratio is what we believe dictates cytokine
specificity in the context of Th 17 differentiation. Even though IL-27 is considered an inhibitory
cytokine, we show that it is a potent inducer of Thl7 cells in the absence of STATI since it
induces a very similar pSTAT3 profile to that induced by IL-6 in these cells.
In Chapter 6, I present an algorithm that can be used to analyze time courses of gene activation
as measured by PCR for intermediate system sizes (10-50 genes). The algorithm is used to
analyze the measurements made over the course of 96 hours of Th 17 differentiation that was
used to be a pilot study to determine points of interest to measure using a gene array. We find
different clusters of genes that behave similarly in different phases of the differentiation process.
These could then be tested experimentally for their significance. In the time course, we observe
that the master transcription factor for Tregs (Foxp3) and the master transcription factor for Th 17
cells (RORyt) seem to oppose each other in that if one transcription factor is high, the other is
always low. This study is meant to be an initial attempt at characterizing the genetic network
important in Thl 7 differentiation.
In Chapter 7, I make some concluding remarks.
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Chapter 2: The Role of DM in Peptide Association
Portions reprinted from "Empty Class II Major Histocompatibility Complex Created by Peptide
Photolysis Establishes the Role of DM in Peptide Association" by Gijsbert M. Grotenbreg,
Melissa J. Nicholson, Kevin D. Fowler, Katherine Wilbuer, Leah Octavio, Maxine Yang, Arup
K. Chakraborty, Hidde L. Ploegh, and Kai W. Wucherpfennig, JBC, 282, 2007 21425-21436,
10.1074/jbc.M702844200.
2.1 Contributions
My contribution to this work consisted of mathematical modeling to determine the interactions
between molecules and the associated rate constants depicted in Figure 2.7 based on the
experimental data collected by the other authors on the paper. All of the modeling work
described in Section 2.4.7 (and the corresponding associated work in Appendix 2) was
performed by myself with some assistance by Leah Octavio and Maxine Yang. Arup
Chakraborty assisted in the writing of these sections.
2.2 Introduction
Major histocompatibility complex (MHC) molecules are cell surface proteins that present
peptides to antigen-specific receptors on T cells. The Class II MHC products are specialized in
sampling endosomal compartments to acquire these peptides. Delivery of newly synthesized and
assembled Class II MHC proteins to endo-lysosomal compartments is assured by means of the
transient association of the MHC up heterodimer with the invariant chain, a protein endowed
with both chaperone function and an address code" . In endosomal compartments, the invariant
chain is destroyed, yielding a Class II MHC product occupied with an invariant chain-derived
remnant, the CLIP peptidel. The HLA-DM (DM) molecule, itself incapable of binding peptide,
facilitates replacement of CLIP with antigenic peptides6-0 . The action of DM is not limited to the
Class II MHC/CLIP complex and extends to Class II MHC-peptide complexes more generally.
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Such editing by DM favors presentation to CD4 T cells of those peptides that are most resistant
to peptide displacement by DM 9' 1[17
DM is a membrane-anchored heterodimer that belongs to the extended family of proteins with a
MHC fold but lacks a functional peptide-binding groove 8 ' 19. Mutagenesis experiments
identified lateral surfaces on DM and DR molecules that are involved in the interaction between
the two proteins. On the DR side, these mutations span the entire length of the ectodomain and
are localized to the al and P2 domains 0 . On the DM side, an extended interaction surface has
been mapped that also spans the entire length of the ectodomain2 1 . These data support a model in
which lateral interactions between DM and DR molecules induce a conformational change that
destabilizes the DR-bound peptide. It has been proposed that DM disrupts one or several
hydrogen bonds between the peptide backbone and conserved DR residues, which could account
for the fact that DM accelerates dissociation of peptides that are highly diverse in sequence-'
22. However, DR-peptide complexes vary substantially in susceptibility to DM and peptide, and
DR residues along the entire length of the binding site can affect susceptibility to DM2 3. These
data suggest that DM causes a more global conformational change of the peptide-binding site.
High affinity peptides form stable, long-lived complexes with DR molecules that have a half-life
of days to weeks. Purified, soluble DM greatly increases the rate at which labeled peptides
6, 9, 12dissociate from DR molecules at an acidic pH , '2. In such experiments, DM obviously also
accelerates the binding of labeled peptides to DR molecules, but it has been difficult to discern
whether accelerated peptide binding is solely due to the increased availability of binding sites or
also due to a direct contribution of DM to peptide association. The detailed mechanism of DM
catalysis has resisted elucidation, partly because of this difficulty of measuring independently the
contributions to peptide dissociation and peptide association. Isolating the contribution of DM to
peptide association would require a homogenous population of empty Class II MHC molecules
in a peptide-receptive state. In theory, empty Class II MHC molecules could be generated by
dissociating bound peptide, but empty molecules tend to aggregate during the prolonged
incubation periods that would be required. An alternative approach that has been pursued
consists of the production of recombinant molecules refolded from denatured DR chains in the
absence of peptide, but the majority of such molecules (-95%) bind peptides only slowly,
apparently because conversion to more active conformer(s) is required25 ,26
Because of these technical challenges, two different models have been proposed regarding the
interaction of DM with DR molecules. According to the first model, DM interacts only with DR-
peptide complexes but not empty DR molecules and catalyzes the interconversion between
transient and stable DR-peptide complexes26 . The second model proposes that DM interacts with
both DR-peptide complexes and empty DR molecules and that DM acts as a molecular
chaperone that rescues empty DR molecules at an acidic pH27 28. Resolution of this issue
requires a novel approach with which empty DR molecules can be generated rapidly and
synchronously. An intriguing new development has been the generation of conditional ligands
for Class I MHC molecules. Toebes et al. 29synthesized photocleavable ligands for Class I MHC
molecules and reconstituted the relevant subunits into an assembled Class I MHC complex. UV
irradiation resulted in cleavage of the bound peptide and rapid departure of the cleavage
fragments from the binding pocket.
Here, we apply this chemistry to generate empty Class Il MHC molecules. The experiments
make use of a human Class II MHC molecule, the expression of which predisposes its carrier to
multiple sclerosis, HLA-DR2 (DRA, DRBI*1501), and a photocleavable peptide based on a T
cell epitope of human myelin basic protein (MBP 85 _99)30 31. Rapid, early binding events were
followed with a fluorescence polarization (FP) readout, in which the fraction of emitted
fluorescent light that retains polarization is proportional to the amount of MHC-bound
fluorescent reporter peptide, because of a slower tumbling speed of the MHC-peptide complex
compared with free peptide . The presence of DM substantially accelerated peptide binding to
such empty DR molecules under all of the reaction conditions tested. Mathematical models show
excellent concordance with the experimental data for a model wherein DM contributes
significantly to peptide association through formation of a complex with empty Class II MHC
molecules. We propose that this DM-DR complex represents a peptide-loading complex that
facilitates antigen presentation by rapid peptide capture, analogous to the MHC class I peptide-
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2.3 Experimental Methods
Peptide Synthesis and Photocleavage
Peptides were constructed manually with the aid of Fmoc (N-(9-fluorenyl)methoxycarbonyl)-
based solid phase peptide chemistry using standard protocols. The photolabile 3-amino-3-(2-
nitro)phenyl-propionic acid (Anp) residue was incorporated at the positions indicated in Fig. 2.1
as described previously 29. Details of the synthesis of MBP-C647 and MBP-N647 are provided in
the Appendix 2. Photocleavage was examined by preparing a stock solution of lyophilized
peptide in Me 2SO (10 mg/ml). This stock was diluted in H20, and 200-pl aliquots were added to
a 96-well plate on ice. Two UV sources were used, both of which induced efficient photolysis: a
Stratalinker 2400 UV cross-linker (Stratagene, La Jolla, CA) fitted with lamps emitting at a
wavelength of 365 nm and a dedicated long wavelength UV lamp (Blak Ray BIOOAP, UVP,
Upland, CA; wavelength of 365 nm). Aliquots were taken at different time points to determine
the kinetics of photolysis by liquid chromatography/mass spectrometry or matrix-assisted laser
desorption/ionization time-of-flight (MALDI-TOF) mass spectrometry. For liquid
chromatography/mass spectrometry analysis, an HP/Agilent 1100 HPLC system (UV detection
at 214 nm) equipped with an analytical C18 column (2.1 mm x 50 mm, 3.5-ptm particle size) was
used in combination with buffers H20, 0.085% trifluoroacetic acid (A) and MeCN, 0.085%
trifluoroacetic acid (B), which was coupled to an LCT mass spectrometer (Waters, Milford, MA)
with an electrospray interface. MALDI-TOF mass spectrometry was performed using a Waters
MALDI Micromass spectrometer (Waters, Milford, MA) and 3,5-dimethoxy-4-hydroxycinnamic
acid as a matrix.
Protein Expression and Purification
Soluble DR2 with covalently linked CLIP peptide (1 pm) was loaded with DNP-labeled
photocleavable peptides (10 tm) following linker cleavage with thrombin 34 overnight at 30 'C in
50 mm sodium citrate, pH 5.2, 100 mm NaCl, 1% octylglucoside, protected from light. Free
peptide was removed from the protein complex by HPLC gel filtration (Superose 6, GE
Healthcare Bio-Sciences Corp, Piscataway, NJ). The fraction containing the DR2-peptide
complex was then affinity-purified on an anti-DNP HPLC column34 . The yields of the purified
complexes are listed in Table A2.1 in Appendix 2. Soluble DM was produced from stably
transfected Drosophila melanogaster-derived S2 cells as described previously9' 5
FP Assay
Association of MBP-488 was monitored by FP as described previously . The assay was
performed in black polystyrene 384-well flat bottom plates (Coming, Coming, NY) with a
nonbinding surface, and the reactions were protected from external light and evaporation with an
aluminum foil seal (Excel Scientific, Wrightwood, CA) when the plate was not in the reader. The
data were acquired using a Victor3V plate reader (Perkin-Elmer Life Sciences) with 485/20 and
530/30 filter sets to track FP of the Alexa-488 (Invitrogen) label. Typically, the experiments
were performed in citrate buffer (50 mm sodium citrate, 150 mm sodium chloride, pH 5.2) in a
final volume of 40 ptl. FP values were recorded at ambient temperature. The data were acquired
from triplicate wells, and wells that contained only the fluorescent MBP-488 peptide were used
to determine base-line FP values.
In experiments where FP was monitored in a cuvette, a QM-7 fluorometer was used (Photon
Technology International, Lawrenceville NJ). DR2-MBP-P4* was UV-cleaved at the same
conditions as above but 7.5-fold concentrated relative to the binding reaction. MBP-488 was
added to a quartz cuvette containing 1300 pl of buffer, and the FP followed over time to generate
a base line and stabilize the temperature to 20 'C before DR2 and DM addition. Photocleaved
DR2 with or without DM was rapidly injected in a volume of 200 pl into the cuvette using a
spring-loaded 200-pl Hamilton syringe (CR700-200, Hamilton Company, Reno, NV). A small
opening in the cover of the reader allowed the injection to be performed while the FP was being
measured. The reaction was under constant mixing with a magnetic stirrer. FP values were
measured for 10 min after DR2 addition at a speed of I reading/s.
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Figure 2.1. Design of photocleavable peptides. (A) Peptides based on the MBP85 99 sequence
were synthesized to contain a nonproteinogenic amino acid (Anp, blue circles) that undergoes
photocleavage when exposed to 365-nm UV light. MBP-488 is the reporter peptide used
throughout, and it carries an Alexa-488 at the P5 Cys residue. MBP-C647 and MBP-N647 are
peptides onto which Alexa-647 is appended C- or N-terminally to photocleavable MBP-P4* and
were used to monitor the departure of cleavage fragments from DR2. (B) Model of MBP-P4*
peptide and major cleavage products formed upon exposure to UV light. Cleavage occurs
between the P3 and P4 positions, thus separating the major DR2 anchor residues (P1 Val and P4
Phe)30.
Binding of Photocleavable Peptides to DR2
Freshly cleaved DR2-CLIP complex (final concentration 100 nm) and MBP-488 (final
concentration 10 nm) were added to citrate buffer containing 1% octylglucoside. Photocleavable
DNP-labeled peptides were added to these reactions at different concentrations (3-fold dilution
Dnp
Dnp
I.
series, highest concentration of 250 pm) and incubated overnight at 37 'C. The amount of bound
MBP-488 was then determined by FP, and the ability of the photocleavable peptides to compete
for binding of MBP-488 to DR2 was compared with the MBP85 .9 9 index peptide (Table A2. 1).
Photocleavage and Exchange
In a typical experiment, a stock solution of DR2-MBP-P4* was deposited into several wells
(maximum volume of 50 il/well) of a 96-well V-bottom plate (Corning Inc., Corning, NY),
placed on ice, and allowed to cool. In a separate 96-well plate (no UV control), the samples were
shielded from UV light with aluminum foil but otherwise treated identically. The plates were
then placed directly under a preheated UV lamp fitted with a UV source emitting at 365 nm
(Blak Ray B I OAP, UVP, Upland, CA). After 2-10 min of UV irradiation, the contents of wells
were pooled (no signs of solvent evaporation were apparent at this point), and 30 pl were
dispensed into appropriate wells of a 384-well plate, preloaded with MBP-488 alone or a mixture
of DM and MBP-488. Following mixing, the 384-well plate was transferred to the FP reader.
The FP values were measured at regular intervals, and the data was collected in triplicate.
Separation of Empty DR2 Molecules from Cleavage Fragments
DR2-MBP-P4* was photocleaved at a concentration of 3 pm as described above. I ml of the
photocleaved product was loaded onto a HPLC gel filtration column (Superose 6) with 50 mm
sodium citrate, 150 mm sodium chloride, pH 5.2, as the mobile phase to separate free peptide
fragments from empty DR2 molecules. The protein concentration in collected fractions was
determined using the Coomassie Plus protein assay reagent (Pierce). The purified molecules
were then assayed by FP for their ability to bind MBP-488. In each experiment, the purification
and reaction set-up time required 1.5-2 h starting at the end of photocleavage.
2.4 Results
2.4.1 Design and Properties of Photocleavable Peptide Ligands
The structure of DR2 complexed with the MBP85 .99 peptide 30 served as the point of departure for
the design of photocleavable ligands. We applied the strategy first described by Schumacher and
co-workers 2 9 for Class I MHC products and synthesized peptides that contained an Anp residue
at the indicated positions (Fig. 2.1A). Peptide binding to Class II MHC molecules is stabilized by
cooperative hydrogen bond networks and anchor residues nestled deep into the peptide-binding
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groove . A panel of peptides was synthesized that placed the Anp residue between the known
anchor residues Val89 (P1) and Phe92 (P4) and critical hydrogen bonds such that, upon cleavage,
two fragments would be generated, neither of which was expected to fulfill the criteria for strong
binding on its own. We refer to Class Il MHC molecules loaded with a photocleavable ligand as
caged Class II MHC products. The peptides (MBP-Pl* to MBP-P5*) were further fitted with a
DNP group through a 4-aminobutyric acid spacer to allow affinity purification of the properly
loaded DR2 complex. A model based on the crystal structure of MBP85 .9 9 illustrates the close
proximity of the nitro-substituent on the aromatic ring to the backbone of MBP-P4* (Fig. 2.1 B),
which accounts for the photochemical liberation of the N-terminal amide and C-terminal nitroso-
fragments at the relatively long wavelength of 365 nm, at which proteins are essentially
transparent.
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Figure 2.2. Affinity of photocleavable peptides for DR2 and kinetics of MBP-P4* cleavage. (A)
Photocleavable peptides MBP-Pl* to MBP-P5* were examined for their ability to compete with
MBP-488 (10 nm) for DR2 binding (100 nm). MBP-P4* bound most tightly. (B) and (C)
Photocleavage of MBP-P4* was rapid both in solution or bound to DR2. (D) Mass spectrometry
of intact peptide (top panel, 2+ and 3+ ions) and photocleaved peptide (bottom panel, I+ ions)
showing major cleavage products of molecular weights 1002.6 (C-terminal fragment) and 1091.6
(N-terminal fragment).
2.4.2 Affinity of the Peptide Ligands for DR2 and Efficiency of Photocleavage
The peptide ligands were next used to generate complexes with DR2. A Chinese hamster ovary
cell-derived DR2 preparation, in which the CLIP peptide was attached covalently to the DR2 p-
chain, was exposed to thrombin, upon which the CLIP peptide could be readily exchanged in
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DM-independent fashion for other ligands. To avoid confounding effects of a mixture of DR2
loaded with MBP-P4*, DR2-CLIP, and empty DR2, a DNP moiety installed at the N terminus of
the photocleavable peptide was used for retrieval of the correspondingly loaded DR2 molecules
on an anti-DNP affinity matrix. This final purification step ensured that all DR2 molecules used
as input for subsequent reactions were occupied homogeneously with the photocleavable peptide.
We identified one MBP-derived ligand, MBP-P4*, for which the caged DR2 complex could be
obtained in yields comparable with the DR2-MBP8 5 _99 complex. The affinity of DR2 binding by
photocleavable ligands (MBP-Pl* to MBP-P5*) was explored by means of a competition assay
(Fig. 2.2A and Table A2.1), confirming that the substitution of Phe92 of the MBP85 .99 peptide
(the P4 anchor in context of DR2) for Anp least affected the affinity (3-fold) for DR2. Therefore,
the caged complex that contained MBP-P4*, which most closely matched the affinity of the
MBP85 .99 index peptide for DR2, was chosen as substrate for peptide exchange reactions in the
following experiments.
Each of the photocleavable peptides was examined individually for its ability to undergo
chromatic cleavage. Electron spray ionization mass spectroscopy was used to follow the
disappearance of the dominant triple-charged ion species of the parent peptide. In the
representative case of MBP-P4* (Fig. 2.2B), photocleavage was largely complete after 2 min of
irradiation. Photocleavage proceeded with similar efficiency when the peptide was bound to DR2
(Fig. 2.2C). In addition to the expected reaction products of UV fragmentation that were
identified with certainty (Fig. 2.2D), electron spray ionization mass spectroscopy as well as
MALDI-TOF spectra showed several additional unidentified cleavage products, whereas the
index MBP85 99 peptide was unaffected by UV irradiation (data not shown).
2.4.3 Functional Properties of DR2 Molecules Synchronously Liberated from Bound
Peptide
The ability to quickly arrive at an empty state allowed us to examine the association of peptides
with Class II MHC and revisit the role of DM in peptide loading. This method differs
significantly from published procedures that use refolded empty Class II MHC as a starting
37, 38point . Such preparations contain a mixture of species that actively bind peptide, that slowly
convert to an active form, or that are inactive. Furthermore, the conformations that may be
accessed by a properly loaded Class II MHC molecule upon loss of its peptide ligand may well
differ from those of Class II MHC products generated in the complete absence of a ligand.
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Figure 2.3. Rapid binding of peptide to DR2 following photocleavage of MBP-P4*. Different
DR2-peptide complexes (150 nm) were left unilluminated (-UV) or exposed to UV light (+UV)
in the presence of MBP-488 (30 nm) for 2 min. Association of MBP-488 was followed by FP
after photocleavage. (A) Rapid association of MBP-488 occurs upon UV irradiation of DR2-
MBP-P4*, but not in control reactions. (B) and (C) High affinity MBP 85 99 peptide could not be
displaced (B) and slow binding to DR2 molecules with the lower affinity CLIP peptide (C) was
observed. (D) The rate of MBP-488 association was compared for reactions with and without
DM. DM was present during photocleavage at an equimolar concentration to DR2, and MBP-
488 was added after photocleavage.
Tracking of early stages of peptide association was important for examining the functional
properties of DR2 molecules immediately following photocleavage of MBP-P4*. We used an
Alexa-488-labeled version of the MBP8 5 _99 peptide (MBP-488, Fig. 2.IA) as a fluorescent
reporter peptide in the FP assay. In the absence of UV irradiation, the DR2-MBP85 -99 complex
was stable (Fig. 2.31B), showing no evidence for peptide exchange over the time course followed.
The DR2-CLIP complex was less stable, with a slow increase in FP values over the 100-min
observation window (Fig. 2.3C). In the absence of UV irradiation, the DR2-MBP-P4* complex
showed peptide exchange behavior intermediate to that of the DR2-MBP85 .99 and DR2-CLIP
complexes (Fig. 2.3A, blue curve), consistent with their affinity rank order (MBP > MBP-P4* >
CLIP).
When the identical assay was performed upon UV irradiation, neither peptide binding to the
preformed DR2-CLIP nor to the DR2-MBP85 99 complex was affected. In contrast, we observed a
steep increase in peptide association for the DR2-MBP-P4* complex upon UV exposure (Fig.
2.3A, red curve). In this experiment, the MBP-488 reporter peptide was included during
photocleavage, and the reaction had already proceeded significantly when the first data points
could be recorded, even though photocleavage was performed for 2 min on ice. Therefore, in the
absence of DM, rapid peptide association occurs to what we propose are newly vacated DR2
molecules.
We then assessed the potential contribution of DM to MBP-488 association following
photocleavage of the bound peptide. DM was added before photocleavage at an equimolar
concentration relative to DR2 (150 nm), and MBP-488 was then added to measure peptide
association. As shown above, the peptide binding reaction proceeded rapidly following
photocleavage in the absence of DM, but DM further accelerated the rate of peptide association
(Fig. 2.3D). There may be several explanations for this DM-dependent increase in the kinetics of
peptide association: removal of residual uncleaved MBP-P4*, removal of cleavage fragments
from the peptide-binding site, or, alternatively, a direct contribution of DM to peptide
association.
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Figure 2.4. Photocleavage generates labile, short-lived DR species that rapidly bind peptide. (A)
DR2-MBP-P4* (160 nm) was photocleaved for 10 min on ice in the presence (red line) or
absence (blue line) of MBP-488 (220 nm). When peptide was present during photocleavage, the
reaction proceeded rapidly (10 min on ice) to ~100 mP, whereas peptide association was slower
when the peptide was added following photocleavage (<100 FP after 50 min). Time 0 is defined
by the addition of MBP-488 following photocleavage (blue line). (B) Dose-dependent
acceleration of peptide association to empty DR2. DM was present at different concentrations
(150 nm to 5 ptm) during photocleavage (10 min, 160 nm DR2-MBP-P4*), and MBP-488 was
added (330 nm) after photocleavage. Saturation was not observed because of the lower affinity
of soluble DM for soluble DR compared with full-length molecules.
2.4.4 The DR2 Conformer Created by Peptide Photocleavage Is Short-lived
Mass spectrometry showed that DR2-bound MBP-P4* was cleaved at a rate similar to that of free
MBP-P4* (Fig. 2.2, B and C), and incomplete cleavage could thus not account for the increased
rate of peptide association in the presence of DM. Acceleration of peptide association was
observed even when photocleavage was extended to 10 min (Fig. 2.413). Extension of
photocleavage also demonstrated that the peptide-receptive DR2 conformer created by
photocleavage was short-lived (Fig. 2.4A). During UV cleavage, significant quantities of MBP-
488 rapidly bound to uncaged DR2 (Fig. 2.4A). In contrast, the reaction kinetics were
substantially different when MBP-P4* was photocleaved in the absence of MBP-488. More than
50 min at a more favorable temperature (room temperature) were required to reach 100 mP, a
reading reached in less than 10 min on ice when MBP-488 was available in the course of
photocleavage in slight molar excess (220 nm MBP-488 to 160 nm DR2). Photolysis of MBP-
P4* thus creates a peptide-receptive intermediate of DR2. This critical conformer is short-lived
and converts to other species that bind peptide with substantially slower kinetics.
2.4.5 DM Forms a Complex with Empty DR That Maintains Rapid Peptide Binding
Properties over Extended Periods of Time
In the absence of DM, the initial rate of MBP-488 binding was slower when the photocleavage
time was extended from 2 to 10 min (compare Fig. 2.3D and Fig. 2.4B). When DM was present
during the I 0-min photocleavage period, peptide binding was more rapid. Association kinetics of
MBP-488 were dependent on the DM concentration (Fig. 2.4B), consistent with the modest
affinity of soluble DM for DR39. Only a fraction of DR molecules would be expected to be
bound to DM at a given time at the DM concentrations used here.
To assess the effect of DM on the very early phase of the reaction, we used a cuvette-based
system in which FP values could be tracked continuously. The reaction was initiated by the
addition of DR2 and DM to a cuvette already containing MBP-488. Although DM clearly
accelerated peptide association when addedfollowing photocleavage, a substantial initial burst of
peptide binding was seen only when DM was present during photocleavage (Fig. 2.5A). We
infer that formation of the DM-empty DR peptide-loading complex in this experimental setting is
optimal when DR molecules have just lost their peptide.
How stable is the DM-empty DR peptide-loading complex? We uncaged DR2 molecules in the
absence of DM, added DM, and then assessed peptide binding upon delayed addition of the
MBP-488 peptide (Fig. 2.5B). DR2 molecules progressively lost activity with longer incubation
times in the absence of DM, and only slow kinetics of peptide association were observed with
10-min to 2-h delays following photocleavage (Fig. 2.5B). In contrast, the rapid peptide binding
properties of the DM-DR complex were maintained even with prolonged incubation times prior
to the addition of peptide (11 min to 2 h) (Fig. 2.51B). The observed differences are inconsistent
with the interpretation that DM merely removes residual uncleaved MBP peptide from DR2.
Mass spectrometry shows that the vast majority of MBP-P4* is photocleaved even when bound
to DR2. Maintenance of the rapid peptide binding properties of the DM-DR complex over
extended periods of time is a remarkable trait in view of the rapid decay of active DR in the
absence of DM.
2.4.6 The Contribution of DM to Peptide Association Is Not Due to Cleavage Fragments
Could retention of the peptide cleavage fragments affect the results of peptide binding
measurements? We considered this explanation unlikely, given the strategic placement of the
photocleavage site in the center of the peptide. We nevertheless designed three experiments to
directly address this issue. We separated empty DR2 molecules from cleavage fragments by size
exclusion chromatography and confirmed removal of fragments by monitoring absorbance of the
DNP tag (350 nm) and mass spectroscopy (data not shown). We then compared the contribution
of DM to peptide binding (Fig. 2.6, A and B) and obtained comparable results. Could the add-
back of cleavage fragments affect the kinetics of peptide association in the presence or absence
of DM? Even at a concentration equimolar to DR2 (150 nm), cleavage fragments did not affect
the kinetics of peptide association in the presence or absence of DM and regardless of DR:DM
ratios (Fig. 2.6, C and D). We conclude that the reaction is primarily dependent on the
concentration of DM because of its low affinity for soluble DR2.
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Figure 2.5. Analysis of early, rapid binding events. (A) Photocleaved DR2-MBP-P4* (160 nm)
DM (160 nm) was injected into a cuvette containing 220 nm MBP-488 to monitor the early
stages of the peptide binding reaction by FP, immediately upon the addition of DR2. When DM
was present during photocleavage, a rapid burst of binding was observed. The rate of MBP-488
association was intermediate when DM was added following photocleavage. Association in the
absence of DM was slower. (B) Incubation of DM with empty DR2 restores and maintains the
highly active DR2 conformer. DR2-MBP-P4* was photocleaved for 10 min in the absence of
DM. Association of MBP-488 was then compared between reactions with or without DM (1
tm). After different preincubation times (0-2 h), the DR/DM mix or DR alone was injected into
a cuvette containing 50 nm MBP-488, and the FP values were monitored continuously.
Finally, we synthesized two peptide derivatives based on the MBP-P4* peptide, but onto which
an Alexa-647 fluorophore was installed at a single Cys residue either at the N or C terminus of
the photocleavable peptide (Fig. 2.lA, MBP-N647 and MBP-C647, respectively). Without UV
treatment, the complexes containing MBP-N647 and MBP-C647 were stable for at least 100 min
(Fig. A2.1). Upon UV irradiation the decrease in FP is biphasic, with a rapid initial phase that
cannot be captured because irradiation and FP measurements must necessarily be conducted in
two different geometries. As soon as measurements can be made, the FP signal has already
reached nearly plateau levels, with only a slow decay phase that follows for both MBP-N647 and
MBP-C647 (Fig. A2.lA). In the same experiment, the association of MBP-488 was recorded.
The low FP signal in the 488-nm channel in the absence of UV cleavage indicates that DR2 is
firmly loaded with either MBP-N647 or MBP-C647, neither of which are displaced by the mere
addition of free MBP-488 (Fig. A2.lB in Appendix 2). Photolysis of these caged MHC
molecules enables the loading of MBP-488 in a single phase kinetic fashion. Cleavage of the
caged DR2 complex is therefore rapid, and retention of both N- and C-terminal fragments is
significantly less than association of MBP-488 with DR2. DM-dependent removal of cleavage
products therefore does not appear to be a rate-determining factor for MBP-488 binding.
Displacement of MBP-N647 and MBP-C647 by the addition of DM alone, in the absence of UV
irradiation (Fig. A2.1 C) shows the expected acceleration of exchange for MBP-C647 (compare
with Fig. 2.3D). However, the DR2-MBP-N647 is less responsive to inclusion of DM. This
suggests that the presence of the fluorophore at the N terminus of the photocleavable peptide
may sterically hinder access of DM2, whereas a C-terminal addition of a fluorophore does not.
2.4.7 Experimental Observations Are Integrated by a Mathematical Model of the Kinetic
Processes
For a deeper mechanistic understanding of the role of DM in facilitating peptide association, we
developed mathematical models of the pertinent processes (Fig. 2.7) to fit our experimental
observations. Our kinetic data obtained with and without DM can be used to examine the
veracity of plausible models for the role of DM after peptide is released from the MHC-binding
pocket upon UV irradiation. We developed mathematical models for different hypotheses, and
calculations showed whether they do or do not compare well with the experimental data. This
allowed us to eliminate certain models from further consideration and led us to a plausible model
for how DM may function post-peptide removal. We began by considering whether the
following hypothesis could fit the kinetic data when no DM was added during UV irradiation,
pMHC p*MHC A eMHC -*fpMHC (Equation 2.1)
where pMHC is the peptide-loaded DR, p*MHC is the species with the peptide photocleaved,
eMHC is the empty DR molecule, andfpMHC is DR loaded with the peptide present in solution.
The quantities labeled as k, are the rate coefficients characterizing the kinetics of the
corresponding reactions. Ordinary differential equations describing the kinetics of this simple
pathway were then developed (see Appendix 2). A nonlinear regression scheme available as part
of the MATLAB suite of programs was used to fit the kinetic constants in this model to the
experimental data. This hypothesis could not fit the experimental data (not shown) because it
cannot account for the second slow phase of peptide binding.
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Figure 2.6. Peptide cleavage fragments do not account for DM contribution to peptide
association. DR2-MBP-P4* was photocleaved for 5 min, and peptide fragments were removed
from DR2 on a HPLC gel filtration column. (A) and (B) The contribution of DM (I gim) to the
kinetics of MBP-488 (I gim) association was compared between reactions with photocleaved
DR2-MBP-P4 * (1 gin) from which cleavage fragments had been removed (B) or not removed
(A) by Superose 6 size exclusion chromatography. (C) and (D) Cleavage fragments added back
at different concentrations (D) were without effect on reactions with DR2 molecules not
subjected to gel filtration (C) at concentrations of 150 nm DR2-MBP-P4*, 150 nim MBP-488,
and I gm DM. (D) Photocleaved peptide fragments were added back at concentrations ranging
from 15 nim to 150 im (DR2 at 150 nm) following purification of DR2 by size exclusion
chromatography. The cleavage fragments also did not affect association of MBP-488 in the
absence of DM (-DM).
This is not surprising, because this hypothesis does not account for the fact that DR can unfold or
aggregate to form species that are not receptive to peptide binding. Thus, we examined the
following hypothesis, which includes this feature.
pMHC V p*MHC -* eMHC kfpMHC
k9 k-9
iMHC (Equation 2.2)
The symbols are the same as before, except that iMHC denotes the inactive conformer or
aggregates of DR. It does not make sense to treat aggregates and unfolded conformers of DR as
separate species because our experimental data cannot distinguish these species. Fitting this
model to the experimental data without DM yields excellent fits as seen in Fig. 2.7B. The best fit
parameter values were determined to be: k2 = 9.92 x 10-5 nm 1 min-, k7 = 1.00 min-', k8 = 1.00
min-', k9 = 1.24 x 10-4 nmI min-', k.9 = 1.39 x 10-4 min-, and n = 2. n is the effective number of
MHC molecules involved in the inactive form. A wide range of k9, k.9, and n values are capable
of producing the same quality of fit. This emphasizes that the experimental data cannot
distinguish between unfolding (n = 1) and aggregation (n > 1). The model is quite sensitive to the
value of k2, because a value very close to 9.00 x 10- nm-1 min-' is necessary to capture the
behavior at the initial times.
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Figure 2.7. Model showing the rate constants used in mathematical models of peptide loading in
the presence and absence of DM. (A) Peptide-loaded MHC (pMHC), empty MHC (eMHC), and
fluorescent peptide-loaded MHC (fpMHC) are shown in the absence of DM (top row) and
interacting with DM (bottom row). Peptide photocleavage creates a short-lived MHC molecule
with bound cleavage fragments (p MHC), whereas incubation in the absence of peptide creates
an inactive form (iMHC). eMHC remains in a peptide-receptive form only for short periods of
time, but eMHC bound in the DM-eMHC complex (boxed) remains active for extended periods
of time. (B) The hypothesis represented by Equation 2.2 fits the experimental data without DM
very well. The initial concentration of pMHC was 150 nm, and the amount of MBP-488 added
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after 10 min of UV was 200 nm. (C) The model represented by Equation 2.3 fits the
experimental data well in the presence of variable amounts of DM. The initial concentration of
pMHC was 150 nm, and the amount of MBP-488 added after 10 min of UV was 200 nm. DM
addition occurred at the same time as MBP-488 addition. A summary of the concordance
between experimental data and the kinetic model for conditions not shown here is provided in
the supplemental information. Because of uncertainties associated with the length of time
required to add MBP-488 and to take the first reading, it was assumed that 30 s elapsed during
this process for all DM experiments. Because the no DM data were read last, it was assumed that
2 min elapsed before the first reading. The values of the delay times were chosen to improve the
quality of the fit. We also carried out the analyses assuming that the elapsed times were
negligible. None of the qualitative conclusions changed upon making this assumption; only the
quantitative comparisons with experimental data were less precise at short times.
Thus, we conclude that a key aspect of the mechanism is that the aggregated/unfolded DR
molecules can slowly revert to the active conformer when peptide is present in excess. This is the
origin of the second slow phase of peptide uptake in the data shown in Fig. 2.3D.
The kinetic parameters obtained by fitting this model (Equation 2.2) to the data without DM
reflect reactive processes that should proceed in the same way if DM is added. So, we then fixed
the values of these parameters to those described above and considered a model for the
additional processes that can occur when DM is added. Our experimental findings showed that
DM can restore a DR conformer that is peptide-receptive, and we model this by positing that DM
binds DR molecules to create a species that can bind peptides. Then, by fitting the experimental
data to the following model that includes these processes, we asked whether the DM-bound DR
molecules could bind peptides more or less rapidly than the empty receptive DR molecules in the
absence of DM.
DM-eMHC -fpMHC
k-5
k10 Ik-10V
pMHC p*MHC A eMHC fpMHCk9 k-9
iMHC (Equation 2.3)
The model represented by Equation 2.3 fits the experimental data well in the presence of variable
amounts of DM (Fig. 2.7C). The parameters, k2, k7, k8, k9, k-9, and n, were kept constant at values
determined previously (Fig. 2.7B), and the new parameters fit the data best for the following
values: k5 = 5.62 x 10-4 nm-' min', k-5 = 6.65 x 10-6 nm-' m ', ko = 0.59 nm' min', and k- a =
177.57 min-. Multiple combinations of parameter values are capable of producing the same fit;
however, k5 must be at least two times greater than k2 to capture the observed experimental
behavior. We also studied a model where DM could also bind to the inactive form of DR
(iMHC) directly and create a stabilized peptide-receptive form. Even in this model, the
experimental data can be fit only if k5 is greater than k2 . Thus, it appears that DM-bound DR
molecules bind peptide more rapidly than the receptive conformer of DR alone.
Of course, we are aware that our parameter sensitivity analysis and the space of models we have
explored are not exhaustive. Nevertheless, the experimental data and the values of parameters
obtained from the kinetic analyses suggest the following mechanistic picture. DM binds DR to
stabilize it from unfolding and aggregating. The binding also probably leads to a conformational
change in DR. The resulting conformation may be very favorable for peptide binding to the DR
groove because it stabilizes the corresponding transition state. This may underlie the faster rate
of peptide binding to the DM-stabilized DR compared with the receptive state of DR alone
because peptide binding to the latter may proceed via an induced fit mechanism with associated
free energy costs that are no longer relevant for DM-bound DR.
2.5 Discussion
Peptide binding may at first glance appear to be a rather simple process, in which a peptide
interacts with an available Class II MHC site. Closer inspection reveals the presence of multiple
distinct species of different behavior and stability 12, 26, 40: (i) stable DR-peptide complexes from
which peptides dissociate at very slow rates (half-life of days to weeks); (ii) a transition state
induced by DM from which peptide dissociates rapidly; (iii) a labile empty DR conformer that
rapidly binds peptide, but is short-lived; (iv) inactive and aggregated forms; and (v) DM-bound
empty DR molecules that are stable and bind peptide rapidly.
Two different models of DM action have been proposed: either DM interacts with both empty
27, 28 26
and peptide-loaded species or only with peptide-loaded Class II MHC molecules2 . Pulse-
chase experiments demonstrated a transient association of DR with DM. When invariant chain
degradation was blocked by leupeptin, DM could be retrieved in complex with DR molecules
together with a 21 -kDa N-terminal fragment of the invariant chain. Furthermore,
immunoprecipitation experiments showed that purified DM binds to DR/CLIP27 . Mass
spectrometry-based analysis of bound peptides demonstrated that DM-DR complexes
immunopurified from cells were largely devoid of peptides, suggesting that DM continues to
interact with DR molecules following peptide dissociation. Furthermore, the presence of DM
prevented aggregation of DR molecules at acidic pH. DM was therefore proposed to act as a
chaperone that prevents inactivation of empty DR molecules28 . More recent experiments showed
that DM interacts only with peptide-filled DR molecules and that DM catalyzes peptide
exchange by facilitating a conformational change in the peptide-binding complex. This study26
utilized empty DR molecules refolded from Escherichia coli inclusion bodies in the absence of
peptide. DM had little or no effect on the conversion between peptide-receptive and -averse DR
or on the rapid bimolecular binding reaction between empty DR and free peptide. The
stabilization observed previously was attributed to an effect on the peptide binding reaction. DM
would prevent inactivation indirectly through catalysis of productive binding in a reaction that
competes with inactivation2 6
The dissection of key steps in peptide binding thus requires approaches with which critical,
short-lived intermediates can be generated rapidly and synchronously. We created caged Class II
MHC molecules from which peptide could be rapidly removed. Chinese hamster ovary cell-
produced soluble DR2 molecules were converted, in DM-independent fashion, into DR2
complexes with photocleavable peptide and purified by means of an affinity tag attached to the
peptide. This approach ensured that the input population of DR2 molecules was homogeneous
with respect to peptide occupancy and ruled out DM contamination of the reactants. With the
photocleavable Anp amino acid replacing the Phe92 residue at the P4 anchor position, MBP-P4*
retained the highest affinity for DR2. This is a relatively minor change in the overall peptide
topology, because the aromatic character of the amino acid side chain is preserved, and the P4
pocket is sufficiently large to accommodate a nitro-substituent on the phenyl side chain. When
UV-irradiated, the caged complex is quickly converted into an uncaged peptide-receptive DR2
species. The peptide fragments themselves have negligible affinity for DR2, based on
experiments that made use of N- or C-terminally derivatized peptides (MBP-C647 and MBP-
N647), in which the departure of both of the anticipated cleavage products was monitored
independently (Fig. A2.1) or when MBP-P4* fragments were added back to empty DR2 purified
by size exclusion chromatography (Fig. 2.6D). The cleavage fragments had no effect on the
progression of binding of MBP-488 to empty DR2, neither in the presence nor in the absence of
DM.
Comparison of peptide binding reactions under different conditions allowed us to identify key
factors that determined the magnitude of the DM contribution to peptide association.
Acceleration of peptide association by DM was most pronounced with delayed addition of DM,
such as experiments in which DM was added following photocleavage (Fig. 2.4), the duration of
photolysis was extended from 2 to 10 min in the absence of DM (Fig. 2.5B), or cleavage
fragments were removed by gel filtration chromatography (Fig. 2.6D). Thus, DM not only
stabilizes an active, peptide-receptive DR2 conformer, but it can also restore such a conformer
when the DR molecule lacks contact with peptide for extended periods of time. Restoration of
the active conformation of DR by DM may be explained by two mechanisms: DM may bind to
multiple DR species and cause the transition from a less active conformer to the active form, or it
may bind to active DR species that are short-lived in its absence and indirectly favor the
equilibrium toward the active conformer. Particularly notable in these experiments is that
reactions with and without DM did not reach the same equilibrium, indicating that a substantial
fraction of DR2 molecules is lost to the competing inactivation/aggregation reaction when the
active conformer is not restored and maintained by DM. In the presence of DM, the active
conformer is stable because near identical peptide association kinetics were observed when
peptide addition was delayed for 2 h compared with reactions in which peptide was added
directly after photocleavage (Fig. 2.5B).
Could the observed DM contribution be due to the removal of residual intact peptide or even
cleavage fragments from the binding site? The following findings argue against this explanation:
(i) Mass spectrometry demonstrated rapid cleavage of MBP-P4*, regardless of whether it was
free in solution or DR2-bound. (ii) Monitoring of the DNP group based on its unique absorbance
at 350 nm during separation of DR2 from cleavage fragments by size demonstrated removal of
DNP-tagged peptide. (iii) The FP method measures the fraction of peptide that is DR2-bound
versus peptide that remains free in solution. At equimolar quantities of peptide and DR,
substantial changes in FP thus only occur when a considerable fraction of DR2 molecules bind
peptide. (iv) The DM contribution to peptide association is more pronounced with longer
photolysis times. If acceleration of peptide association were due to removal of residual peptide or
peptide fragments, this effect should be diminished by longer photolysis times.
This study resolves the controversy of whether DM acts only on peptide-loaded DR species 2 6 or
whether it also acts as a chaperone that stabilizes empty DR molecules27 28 . We demonstrate that
DM forms a complex with empty DR molecules that binds peptide with faster kinetics than DR
molecules that just lost their peptide cargo, indicating that DM plays an important role in the
peptide association stage. The differences in the conclusions reached by Zarutskie et al.26 and
this study are probably related to the DR preparations that were utilized. Zarutskie et al.26
utilized empty DRl molecules refolded in the absence of peptide from E. coli inclusion bodies.
The majority of these refolded molecules (-95%) are in a peptide nonreceptive state, apparently
resistant to the action of DM. In contrast, newly vacated DR molecules maintain the ability to
interact with DM for at least some time.
We propose that DM forms a peptide-loading complex with empty DR that plays an important
role in rapid peptide capture. Peptides are short-lived in cells because of proteolytic attack4 1 , and
rapid binding may be essential for display of a diverse array of peptides, many of which contain
cleavage sites for proteases present in the peptide-loading compartment.
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Chapter 3: Further Analysis of the Interaction of DM with pMHC
Portions reprinted from "HLA-DM captures partially empty HLA-DR molecures for caltalyzed
removal of peptide" by Anne-Kathrin Anders, Melissa J. Call, Monika-Sarah E. D. Schulze,
Kevin D. Fowler, David A. Schubert, Nilufer P. Seth, Eric J. Sundberg, and Kai W.
Wucherpfennig, Nature Immunology, 12, 2011 54-61, 10.1038/ni.1967, C 2011 Nature America,
Inc.
3.1 Contributions
After the study described in Chapter 2, I continued my collaboration with Kathrin Anders and
Kai Wucherpfennig. To further study the interaction of DM with MHC, they designed a 3-stage
Biacore experiment. The surface of the instrument was coated with DM. In stage 1, pMHC was
run through the system, which caused the binding of the pMHC with DM and the ejection of the
peptide leaving a stable MHC-DM complex on the surface. In stage 2, buffer was run through
the machine, which led to a slow, linear decline of the signal which corresponded to the off-rate
of empty MHC from the DM bound to the surface. In stage 3, free peptide was run through the
machine, which rapidly binded to the MHC, causing its release from the DM on the surface and a
rapid drop in the signal.
In "normal" Biacore experiments, koff and kon are determined in a two stage process. In stage 1,
molecule A is run through the machine which has molecule B on the surface., causing the
formation of AB and a rise in the signal. In stage 2, buffer is run through the machine and A is
swept away as it unbinds from B. This is a relatively simple analysis that every instrument can
do internally since the equation involving the sought parameters is easily derived analytically.
The complication with our system is that there are 3 stages and at least 3 species. The signal is
directly proportional to molecular weight of what is bound on the surface. DM, empty MHC
(eMHC), and peptide-loaded MHC (pMHC) all have significantly higher molecular weights than
the peptide, which makes it difficult to distinguish between eMHC and pMHC. Further
complicating the system is that there can be different conformations of these species that have
wildly different rate constants associated with them. It is impossible to distinguish between
conformations since there is no molecular weight change and thus no signal change.
Extensive attempts to fit a reliable model to their data, which would have allowed the
determination of all relevant rate constants of association and dissociation, were unsuccessful
due to the inability to distinguish what was actually bound to the surface in terms of
conformations, etc. All that could be determined from the modeling was that the basic model in
stage 3 of peptide binding to the MHC and detaching from the DM will never fit the data. Stage
3 curves of dissociation were always two exponential in nature, whereas this simple model
would never give more than 1 exponential as a solution. Essentially, the peptide needed a fast
route to the eMHC-DM complex and then the pMHC-DM would have to break up quickly
getting rid of the signal. This fast path to signal decay is I exponential in nature. However,
there needs to be a slower route to the decay since after a brief strong drop in the signal, there
was a slow decay. No adaption to this model could hinder this fast path to decay meaning that
steric issues of the peptide binding to eMHC could not be the answer. The most likely solution
was that there was an equilibrium between a peptide receptive eMHC bound to DM and a non-
peptide receptive eMHC bound to DM. As described earlier, there is no way to distinguish
between these two states looking at the signal so anything we came up with was just speculation,
which is why it ultimately was not included in the manuscript.
However, my regular meetings with Kathrin about the issues with modeling led to my suggestion
that they try to use a linker to secure the peptide in place, which would reduce the number of
stages to 2 and the number of species to 2 (DM or pMHC-DM) making conventional Biacore
analysis possible. There were concerns that the linker may interrupt binding of pMHC and DM
artificially. These discussions though, led them to investigate the role of various anchor residues
and lengths of peptide on the binding with DM, which led to the novel results in the paper. This
is why I was included as an author. There was a lot of work that was put into the modeling even
though it never made it to publication.
3.2 Introduction
Efficient surveillance of the surface of antigen-presenting cells by CD4' T cells requires long-
lived display of peptides bound to major histocompatibility complex class II (MHCII) molecules.
High-affinity peptides are kinetically trapped in the peptide-binding groove and dissociate
extremely slowly (within days to weeks at 37 'C) 2. Such stable binding is enabled by a
conserved hydrogen-bonding network between the MHC helices and the backbone of bound
peptides, as well as by occupancy of MHC pockets by peptide side chains".
Empty MHCII molecules quickly lose their ability to rapidly bind peptide and aggregate5' 6.
Before the arrival of MHCII in the late endosomal peptide-loading compartment, the binding
groove is protected by the CLIP (class II-associated Ii peptide) segment of the invariant chain7.
Cleavage of the invariant chain in the late endosomal compartment leaves the CLIP peptide in
the binding groove8 ' 9; CLIP is bound with a wide range of affinities by different allelic forms of
MHCIIO. HLA-DM (human) and H2-DM (mouse) serve a critical role in antigen presentation by
MHCII by accelerating the removal of CLIP and by editing the peptide content of MHCII
molecules such that the display of high-affinity peptides is favored9, 11-20. HLA-DM also acts as a
chaperone that maintains empty MHCII in a highly peptide-receptive state21-23. Mass
spectrometry analysis of HLA-DM-MHCII complexes purified from antigen-presenting cells has
shown them to be largely devoid of peptide.
Crystal structures of MHCII, HLA-DM and H2-DM have been available for many years (since
1993 (MHCII) and 1998 (HLA-DM and H2-DM)), but it has been challenging to define the
molecular mechanisms of HLA-DM-catalyzed peptide exchange4, 24. 25 Comprehensive
mutagenesis has identified large lateral surfaces of HLA-DM and HLA-DR required for their
interaction; of particular interest are HLA-DR residues in the vicinity of the N terminus of the
peptide (Phe51 and Glu40 of HLA-DRat)26,27. The proximity of the HLA-DM-interaction site to
the N terminus of the peptide has also been demonstrated by covalent attachment of a peptide to
a surface-accessible cysteine residue at position 46 of HLA-DMp and subsequent loading of this
HLA-DM-linked peptide into the HLA-DRl peptide-binding groove. Such a complex is stable
when HLA-DM is linked to the C terminus of the peptide, but HLA-DM catalyzes rapid peptide
dissociation when linked to the N terminus of the peptide28
Two main models of HLA-DM action have been proposed. The first model suggests that HLA-
DM breaks some of the conserved hydrogen bonds between the peptide backbone and the MHC
24,29 30helices2 , whereas the second model proposes more global conformational changes . The first
model has been supported by functional data showing that the rate of HLA-DM-induced peptide
dissociation is proportional to the intrinsic rate of peptide dissociation for all peptides and
MHCII molecules tested29. These data suggest that bonds conserved in all peptide-MHCII
interactions are targeted by HLA-DM, such as conserved hydrogen bonds formed by HLA-DRa
Phe5l, HLA-DRa Ser53 and HLA-DRp His8l near the N terminus of the peptide2 4 . An initial
report indicated that HLA-DRP His8l was the target of HLA-DM action3 1 , but other studies have
shown that substitution of this residue does not result in less susceptibility to HLA-DM32' 3.
Furthermore, individual substitution of all MHC side chains that form conserved hydrogen bonds
to the peptide backbone (nine hydrogen bonds in total) did not identify a substitution that
resulted in less susceptibility to HLA-DM32 . Finally, loss of hydrogen bonds to the main-chain
atoms of HLA-DRa Phe51 and HLA-DRa Ser53 enhances susceptibility to HLA-DM rather than
diminishing it, which suggests that these hydrogen bonds are not direct targets of HLA-DM'.
The second model of HLA-DM action proposes that HLA-DM globally distorts the MHCII
binding groove rather than breaking a small number of hydrogen bonds. Analysis of a large
number of HLA-DR-peptide complexes has shown that the intrinsic stability of any one complex
is a poor predictor of susceptibility to HLA-DM and that interactions along the entire length of
the groove affect susceptibility to HLA-DM3 0 . Dynamic light-scattering and circular-dichroism
studies have further indicated that HLA-DR undergoes conformational changes after peptide
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A central problem in defining the mechanism of HLA-DM-catalyzed peptide exchange is that it
remains unknown which HLA-DR-peptide conformers interact with HLA-DM. We report here
that the interaction of HLA-DM with HLA-DR was highly dependent on the occupancy of the
peptide-binding groove, with high-affinity peptides destabilizing empty HLA-DR-HLA-DM
complexes. Furthermore, HLA-DM bound only to HLA-DR-peptide conformers in which key
interactions between the N terminus of the peptide and the HLA-DR molecule had already been
lost because of peptide motion.
3.3 Methods
HLA-DM expression
Soluble HLA-DM proteins carried a C-terminal BirA tag (GLNDIFEAQKIEWHE; HLA-DMU)
or protein C tag (HLA-DMP) on the extracellular domain. Two N-linked glycosylation sites
(HLA-DMa N165D and HLA-DMp N92D) were removed to diminish heterogeneity, which left
the HLA-DMa N 15 glycosylation site . Sft9 Spodoptera frugiperda insect cells were infected
with recombinant baculovirus at a multiplicity of infection of>5, and proteins were purified after
3 d by affinity chromatography with an Anti-Protein C Affinity Matrix (Roche Applied Science);
aggregates and impurities were subsequently removed with a Superose 6 gel-filtration column
(GE Healthcare Bio-Sciences Corp.).
Site-specific biotinylation of the BirA tag used a protein concentration of 2-3 mg/mI at a molar
ratio of 20:1 (HLA-DR to BirA). Reactions proceeded for 2 h at 30 'C in the presence of biotin
(100 tM), ATP (10 mM) and protease inhibitors. Excess biotin was removed by dialysis, and
biotinylation was confirmed by mobility shift with streptavidin after migration through native
polyacrylamide gels.
HLA-DR expression
Peptides were synthesized by Peptide 2.0 and JPT Peptide Technologies. Soluble HLA-DR-
CLIP complexes were produced with stably transfected Chinese hamster ovary cell lines in
hollow fiber bioreactors, as described4 8 . CLIP (PVSKMRMATPLLMQA) was covalently
attached via a thrombin-cleavable linker at the N terminus of the appropriate HLA-DRp chain
(DRB1*0101, DRB1*0401 or DRBI*1501).
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For covalent attachment of peptides, soluble HLA-DRl proteins were generated with a cysteine
residue at position 58 (G58C) or position 65 (V65C) of HLA-DRa. The low-affinity CLIPow
mutant (SKARMATGALAQA; substituted anchor residues underlined) was covalently attached
to the N terminus of the HLA-DRIp chain (DRBl*0101) to enable efficient exchange after
linker cleavage with human rhinovirus 3C protease (provided by J. Fraser). This protease site
enabled cleavage under conditions of low temperature (4 'C) that minimized dissociation of
CLIPi,0 before peptide loading. These HLA-DR variants were produced with a baculovirus
system. Soluble HLA-DR proteins were purified via affinity chromatography with monoclonal
antibody to HLA-DR (L243; American Type Culture Collection); aggregates and impurities
were removed with a Superose 6 gel-filtration column. Depending on the construct, covalently
linked CLIP or CLIPiow was cleaved with thrombin (Novagen; EMD Chemicals) or 3C protease.
The former cleavage used 20 units thrombin per mg of protein for 1.5 h at 25 'C; the latter used
50 ptg 3C protease per mg of protein under reducing conditions (2 mM reduced glutathione) for 2
h at 4 'C. Protein purity and completeness of cleavage were assessed by SDS-PAGE.
Peptide loading and production of disulfide-linked HLA-DR-peptide complexes
The key aspects of covalent linkage of very low-affinity peptides to DRI were as follows: use of
an HLA-DRI-peptide complex with very low affinity as the input protein (HLA-DRI-CLIPI0 w);
accelerated dissociation of this low-affinity peptide from H LA-DRI by the small molecule J10-1
that accelerates peptide loading; and use of redox conditions that enabled efficient formation of a
disulfide bond between the HLA-DRa helix and incoming peptide. Most peptides with a DNP
group were labeled via a lysine side chain at the peptide C terminus; HA(306-318) C-terminal
truncation variants were labeled via the lysine side chain at position P-1. DNP-labeled peptides
were exchanged overnight at 25 'C, 30 'C or 37 'C (depending on the HLA-DR and peptide)
onto cut HLA-DR-CLIP complexes (5 gM) at a 10- to 20-fold molar excess of peptide in citrate-
phosphate buffer (pH 5.3) in the presence or absence of the Ji0-I small molecule49 . Unbound
peptide was removed with a Superose 12 gel-filtration column (GE Healthcare Bio-Sciences) and
loaded complex was separated from other HLA-DR species by affinity chromatography with an
anti-DNP- 1 column (Biotrend Chemikalien). The absorbance of DNP and protein was monitored
at 350 nm and 280 nm, respectively 49.
DNP-labeled HA peptides with a cysteine at position P3 or P6 were reduced in 500 pM
glutathione and were added to 3C-cleaved HLA-DRI protein with cysteine substitution;
reactions were then incubated for 2 h in the presence of 50 pM J10-1 and 750 pM glutathione.
Reactions were then shifted for 2 h to oxidizing conditions (950 pM oxidized glutathione) to
promote disulfide bond formation. Unbound peptide and unloaded complex were removed by gel
filtration and DNP affinity chromatography as described above. Disulfide linkage of HA
peptides was confirmed on the basis of lower motility of HLA-DRa by SDS-PAGE.
SPR
Streptavidin chips (GE Healthcare) were primed and normalized before immobilization of
ligand. Biotinylated HLA-DM proteins (ligand) were diluted to a concentration of 0.5 pig/ml in
HBS-EP buffer (GE Healthcare), and 500 RU protein (usually HLA-DM Mut2 and wild-type
HLA-DM) was immobilized in two consecutive flow cells on a streptavidin chip at a flow rate of
2-10 pl/min at 25 'C unless indicated otherwise. A BlAcore 3000 (GE Healthcare) was used for
SPR experiments at 25 'C (range, 20-37 'C). For experiments at a different temperature, the
chip was again normalized after the change in temperature was complete. HLA-DR-peptide
complexes were purified by gel-filtration chromatography before SPR experiments for the
removal of aggregates. HLA-DR-peptide complexes (analyte) were diluted into the running
buffer just before injection and were injected in the appropriate concentrations and conditions
(stage 1). This was followed by buffer (stage 2) and injection of peptide (stage 3). Chips were
regenerated by injection of 50-100 gM high-affinity peptide for the respective HLA-DR.
Experiments were done in degassed 50 mM citrate-phosphate buffer (pH 5.35) with 150 mM
NaCl and 0.06% C12 E9 detergent (Calbiochem; EMD Chemicals) unless indicated otherwise.
Results were calculated by subtraction of binding in the reference flow cell (HLA-DM Mut2 in
most cases) from binding in the wild-type HLA-DM flow cell.
Peptide-binding assay
FP assays were done as described 47. MBP(85-99) was labeled at position P5 (lysine-to-cysteine
substitution) with a maleimide derivative of Alexa Fluor 488 (Molecular Probes) 47. HLA-DR-
peptide complexes were incubated with Alexa Fluor 488-labeled MBP(85-99) or HA(306-318)
in a volume of 40 ptl in black polystyrene 384-well flat-bottomed plates (Coming) in the
appropriate conditions and binding of labeled peptide was measured with a Victor 3 V multilabel
plate reader (PerkinElmer). Measurements were made in triplicate.
3.4 Results
3.4.1 Peptide destabilizes HLA-DR-HLA-DM complexes
HLA-DM-catalyzed peptide exchange is a multistep process that has been difficult to study
mechanistically because most assays do not isolate individual steps but instead represent a
mixture of multiple rates. We developed a real-time surface plasmon resonance (SPR) assay to
directly study the individual steps of the interaction of HLA-DR with HLA-DM (Fig. 3.1). We
oriented HLA-DM on streptavidin chips through C-terminal site-specific biotinylation so that the
large lateral surface required for binding to HLA-DR was fully accessible. We generated soluble
HLA-DR-CLIP complexes with a cleavable CLIP linker. In SPR experiments, it is critical to use
suitable control proteins to ensure the specificity of binding; we therefore identified HLA-DM
and HLA-DR mutants with loss of activity in a real-time peptide-binding assay based on
fluorescence polarization (FP; Fig. 3.1 a, c). Substitution of one arginine residue at position 98 of
HLA-DMa with alanine (R98A; called 'HLA-DM Mutl' here) resulted in less HLA-DM activity,
whereas an additional substitution of the arginine residue at position 194 of HLA-DMa with
alanine (R98A and R194A; called 'HLA-DM Mut2' here) resulted in loss of activity (Fig. 3.la).
The SPR binding data closely correlated with those functional data, showing little binding of
HLA-DR to HLA-DM Mutl and no binding to HLA-DM Mut2 (Fig 3.1b). Also, an HLA-DR2
(DRBI*1501) mutant with substitution of the serine residue at position 53 with aspartic acid
(HLA-DRa S53D) that was unresponsive to HLA-DM in the FP assay (Fig. 3.lc) failed to bind
to HLA-DM, as assessed by SPR (Figure 3.1d and Fig. A3.1 in Appendix 3). This mutant HLA-
DR2 bound peptide with kinetics similar to those of wild-type HLA-DR2 (Fig. 3.lc), which
indicated correct folding.
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Figure 3.1. Peptide disrupts the long-lived complex of empty HLA-DR and HLA-DM. (a-d)
Specificity of the SPR assay. (a) Effect of wild-type HLA-DM (DM WT), HLA-DMa R98A
(DM Mutl) and HLA-DMa R98A-R194A (DM Mut2) on the binding of Alexa Fluor 488-
labeled MBP(85-99) (30 nM) to HLA-DR2 (150 nM), measured by FP and presented in
millipolarization units (mP). (b) SPR analysis of the binding of HLA-DR2-CLIP (2 PM) by
wild-type and mutant HLA-DM (pH 5.35, 25 pl/min, 30 'C) injected for 5 min (stage 1),
followed by buffer (stage 2) and 1 pM MBP(85-99) (stage 3), presented in resonance units (RU)
as HLA-DM flow cell - reference flow cell (reference is streptavidin here). (c) Binding of
labeled MBP(85-99) to wild-type HLA-DR2 (DR2 WT) or the HLA-DRa S53D mutant (150
nM; DR2 Mut) with (+ DM) or without HLA-DM (25 nM). (d) Binding of HLA-DM by wild-
type or mutant HLA-DR2--CLIP (1 pM) injected for 5 min, followed by buffer and 10 pM CLIP
peptide of amino acids 87-101 (CLIP(87-101)). (e) Dissociation of the HLA-DM-HLA-DR2
complex by peptide, assessed by injection of high-affinity MBP(85-99) (MBP) or the MBP P4D
analog (1 pM). Data are representative of two (a,c,d) or more than three (b,e) independent
experiments.
In these SPR experiments, we injected HLA-DR-CLIP complexes over the HLA-DM surface
(stage 1), followed by injection of buffer (stage 2; Fig. 3.1b,d). Unexpectedly, the dissociation of
HLA-DR from HLA-DM during stage 2 was very slow, even though soluble HLA-DM and
HLA-DR are thought to interact only weakly36. We reasoned that the catalytic activity of HLA-
DM removed the HLA-DR-bound CLIP, which exited with the buffer flow, whereas peptide
remains available for rebinding in typical tube-based experiments. We therefore postulated that
injection of peptide would destabilize the complex of HLA-DM and empty HLA-DR. Indeed,
injection of a high-affinity peptide of myelin basic protein amino acids 85-99 (MBP(85-99))
induced dissociation of HLA-DR2 from HLA-DM (Fig. 3.le). A single amino-acid mutant of
MBP(85-99) with very low affinity for HLA-DR2 (substitution of phenylalanine at position P4
with aspartic acid (MBP P4D)) induced minimal dissociation at the same peptide concentration
(1 pM; Fig. 3.le). We obtained similar binding profiles at flow rates of 15-50 pl/min (Fig.
A3.2), which indicated that rebinding (mass transport) was negligible. Injection of an antibody to
the DNP group on peptides showed that the complex of HLA-DM and HLA-DR in stage 2 did
not contain bound peptide (Fig. A3.3).
The rate of peptide-induced dissociation of HLA-DM-HLA-DR (stage 3) correlated closely with
the affinity of these peptides for the HLA-DR2-binding site, both for sets of CLIP mutants (Fig.
3.2a-d) and for sets of MBP(85-99) mutants (Fig. 3.2e,f), regardless of which peptide anchors
were replaced. Peptides with high affinity for HLA-DR2, such as CLIP P4F (CLIP with
substitution of the alanine residue at position P4 with phenylalanine; Fig. 3.2c) or MBP(85-99)
(Fig. 3.2f), induced faster dissociation of HLA-DM-HLA-DR than did peptides of lower affinity.
Peptides with very low affinity, such as MBP P4D, did not induce dissociation at low
concentrations (such as I uM; Fig. 3.1 e) but led to some dissociation at higher concentrations (10
gM; Fig. 3.2e).
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Figure 3.2. Rate of HLA-DM-HLA-DR complex dissociation is determined by peptide affinity.
(a,b) Effect of CLIP and mutant CLIP on the dissociation of HLA-DM-HLA-DR, assessed by
injection of 5 pM HLA-DR2-CLIP (5 min, pH 5.35, 15 pl/min, 30 C), followed by buffer and
wild-type or mutant CLIP (10 pM). (c) Competition assay of the binding of CLIP peptides
(threefold dilution: 10 p.M to 14 nM) to HLA-DR2 (100 nM) versus Alexa Fluor 488-labeled
MBP(85-99) (10 nM); the median inhibitory concentration (IC50 ) is plotted against the rate of
peptide-induced dissociation of HLA-DM-HLA-DR (from a,b). (d) Effect of CLIP and two
CLIP mutants, injected in stage 3 (0.5-100 pM), on the rate of dissociation of HLA-DR from
HLA-DM. (e) Effect of MBP(85-99) and mutants on HLA-DM-HLA-DR dissociation, injected
in stage 3 as in a. (f) Effect of MBP peptide affinity on the HLA-DM-HLA-DR dissociation rate,
presented as the median inhibitory concentration determined by competition assay (as in c)
versus dissociation rate (from e). Data are representative of two independent experiments (a-f)
and more than three additional independent experiments under similar conditions (a-c,e,f;
triplicate samples in c,f).
3.4.2 Slow binding to HLA-DM by high-affinity complexes
The fact that peptide binding induces dissociation of HLA-DM-HLA-DR complexes suggests
that the HLA-DR-bound peptide probably also has a considerable effect on the reverse process;
that is, the binding of HLA-DR to HLA-DM (Fig. 3.3). Initial experiments showed that HLA-DR
molecules with covalently bound peptides did not bind to HLA-DM (Fig. 3.3); this was true for
both HLA-DR2-CLIP and HLA-DR1 (DRBI*0101) linked to a low-affinity CLIP variant
(HLA-DR1-CLIPio,), even though binding was readily detectable after linker cleavage (Fig.
3.3a,b). These results could be explained either by steric hindrance caused by the linker attached
to the N terminus of the HLA-DRp chain or by a substantial affinity gain resulting from covalent
peptide attachment (rebinding of peptide is probably extremely rapid). The linker is flexible and
also not in the immediate proximity of the predicted HLA-DM-interaction site, which makes the
latter explanation more plausible.
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Figure 3.3. High-affinity HLA-DR-peptide complexes interact slowly with HLA-DM. (a) SPR
assay of the binding of HLA-DM by HLA-DR2-CLIP (5 1 DM), with (Cut DR2-CLIP) or without
(Uncut DR2-CLIP) cleavage of the peptide linker by thrombin, injected for 5 min, followed by
buffer (stage 2) and 20 iM CLIP(87-101) (stage 3). (b) SPR assay of the binding of HLA-DM
by HLA-DRI-CLIPi., (5 ptM), with (Cut DR1-CLIPio0 w) or without (Uncut DR1-CLIPioW)
cleavage by the 3C protease, injected for 2 min, followed by buffer and HA(306-318) (50 jiM).
(c) SPR assay of the binding of HLA-DM by HLA-DR2 preloaded with CLIP or MBP (2 pM)
and injected for 5-7 min, followed by buffer and 10 pM CLIP(87-101). (d) SPR assay of the
binding of HLA-DM by HLA-DR2 preloaded with high-affinity MBP(85-99) and injected for 10
min, followed by buffer (stage 2) and 5 gM MBP(85-99) (stage 3). (e) SPR assay of the binding
of HLA-DM by HLA-DRl preloaded with CLIP or HA (10 pM) and injected for 5-7 min,
followed by buffer and 50 jM HA(306-318). (f) SPR assay of the binding of HLA-DM by
HLA-DRI preloaded with high-affinity HA(306-318) and injected for 10 min, followed by
buffer (stage 2) and 50 pM HA(306-318) (stage 3). (g) SPR assay of the binding of HLA-DM by
HLA-DR4 preloaded with CLIP or HA (2 piM) and injected for 5-7 min, followed by buffer and
50 pM HA(306-318). Assays were done at 25 'C (a,b) or 37 'C (c-g) and at a pH of 5.35 and a
rate of 15 jl/min. Data are representative of three (a,c,e) or two (b,d,fg) independent
experiments.
We next examined the effect of peptide affinity on the association of HLA-DR with HLA-DM
using HLA-DR molecules loaded with single peptides; we synthesized peptides with a
dinitrophenol (DNP) tag for affinity isolation of homogenous HLA-DR-peptide complexes.
There was strong binding of HLA-DM by the low-affinity HLA-DR2-CLIP complex, but much
slower binding by the high-affinity HLA-DR2-MBP(85-99) complex (Fig. 3.3c,d). We also
observed this effect for HLA-DR4 preloaded either with low-affinity CLIP or high-affinity
influenza hemagglutinin peptide of amino acids 306-318 (HA(306-318); Fig. 3.3g). CLIP binds
with high affinity to HLA-DR137, and binding of the HLA-DRI-CLIP complex to HLA-DM was
also slow (Fig. 3.3e). Nevertheless, there was concentration-dependent binding to HLA-DM by
the high-affinity HLA-DR2-MBP(85-99) and HLA-DRI-HA(306-318) complexes (Fig.
3.3d,f), which indicated that both low-affinity and high-affinity HLA-DR-peptide complexes
bound to HLA-DM in this SPR assay, but with different rates. In a functional peptide-binding
assay, the rate of HLA-DM-catalyzed binding of a fluorescence-labeled peptide was 8.5% when
the high-affinity HLA-DR2-MBP(85-99) complex rather than the low-affinity HLA-DR2-CLIP
complex was used as input protein. In the SPR assay, the rate of binding of HLA-DM by HLA-
DR2-MBP(85-99) was 11.5% compared with the rate of binding by HLA-DR2-CLIP (Fig.
A3.4), which demonstrated overall agreement between the SPR and peptide-binding assays.
Published studies with full-length HLA-DR and HLA-DM molecules isolated from cells have
reported a stronger interaction of HLA-DM with HLA-DR-CLIP than with HLA-DR-peptide
complexes21, 38; also, a published SPR experiment has shown stronger binding of immobilized
soluble HLA-DM to detergent-solubilized full-length HLA-DR-CLIP than to HLA-DR-peptide
complexes39. In both sets of experiments, a complex mixture of peptides was bound to these cell-
derived HLA-DR-peptide complexes. In the experiments we have reported here, the differences
in binding were much greater because we used purified low-affinity and high-affinity HLA-DR-
peptide complexes. Comparison of the HLA-DR-CLIP binding data for these three allelic forms
(HLA-DRI, HLA-DR2 and HLA-DR4) also showed large differences in the HLA-DM-binding
kinetics. HLA-DR2-CLIP bound with the fastest kinetics and HLA-DRl-CLIP bound with the
slowest kinetics (Fig. 3.3c,eg). We also observed large differences among these allelic forms in
peptide-induced dissociation of HLA-DM-HLA-DR complexes, with complexes containing
HLA-DR2 being more sensitive to peptide-induced dissociation than those containing HLA-DRI
or HLA-DR4 (Fig. 3.3c,e,g).
3.4.3 Binding to HLA-DM requires partial peptide dissociation
The results obtained with covalently linked peptides (Fig. 3.3a,b) raised the questions of whether
HLA-DR molecules with fully bound peptides do not bind to HLA-DM and whether partial
release of the bound peptide is actually required to generate a HLA-DM-sensitive conformer. To
investigate this, we generated HLA-DRI molecules to which peptides could be covalently
attached in one of the pockets so that peptide termini could be truncated without peptide loss
(Fig. 3.4). We covalently linked mutant hemagglutinin peptides either in the P6 pocket or the P3
site by replacement of the HLA-DRa valine at position 65 or glycine at position 58 with
cysteine; both residues are located on the HLA-DRa-chain helix. We made these complexes with
an HLA-DRI molecule with a very low-affinity peptide as the input protein, and we chose redox
conditions that enabled efficient formation of a disulfide bond between the peptide and the HLA-
DRa-helix. We generated a large set of such complexes (Table 3.1) that we affinity-purified with
DNP affinity tags on the peptides to ensure the absence of empty HLA-DR or HLA-DR species
loaded with other peptides (Fig. A3.5). We named these peptides according to the site of
covalent linkage (HA 6 and HA 3 for linkage in the P6 pocket or the P3 site, respectively) and the
length of the peptide, with full-length HA spanning from the P-2 to the P1 positions (HA P-2-
P11; Table 3.1). We confirmed full occupancy by monitoring the ratio of absorbance at 280 nm
(HLA-DR) to that at 350 nm (DNP group on peptide). Also, we immunoprecipitated HLA-DRI
molecules with linked HA 6 P2-P11 peptide by conformation-sensitive antibodies to HLA-DRa
and HLA-DRp (Fig. A3.6).
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Figure 3.4. HLA-DM binds with fast kinetics to HLA-DR-peptide complexes without an
engaged peptide N terminus. (a,b) Hydrogen-bonding network between HLA-DRl and full-
length, covalently linked HA(306-318) (a) or a linked HA mutant peptide lacking three N-
terminal residues (b). Numbers along peptide 'backbone' (P 2 to P, 1; between HLA-DR helices)
indicate peptide position. The valine at position 65 in the HLA-DRa chain was replaced with
cysteine to enable the formation of a disulfide bond with a cysteine at position P6 of HA (HA 6).
(c) Space-filling model of the empty HLA-DRI groove showing residues contacted by two N-
terminal peptide residues (red) and the PI anchor (green). (d-f) Binding to HLA-DM by HLA-
DR] with linked HA6 peptides (5 pM), injected for 2 min (pH 5.35, 15 pl/min, 25 'C), followed
by injection of buffer. Data are representative of at least three (d,f) or two (e) independent
experiments.
Table 3.1. HA-P 6 and HA-P 3 cysteine peptide variants.
Name Sequence Change or substitution
HA-P6Cys (cysteine residue at P6)
HA6  PKYVKQNCLKLAT
HA6 P1A PKAVKQNCLKLAT P1 Tyr-to-Ala substitution
HA6 P1G PKGVKQNCLKLAT P1 Tyr-to-Gly substitution
HA6 P.1-P 1 1  KYVKQNCLKLAT P-2 truncation
HA6 P1-P11 YVKQNCLKLAT P-2 and P-1 truncation
HA6 Pime-Pi Me-YVKQNCLKLAT P-2 and P-1 truncation; N-methylation of P1 Tyr
HA6 P1Gme-Pna Me-GVKQNCLKLAT P-2 and P-1 truncation; substitution of P1 Tyr
with N-methylated Gly
HA6 P2-p 11 a VKQNCLKLAT P-2, P-1 and P1 truncation
HA6 (N-DNP) PKYVKQNCLKLAT N-terminal DNP label
HA6 P-2-P6  PKYVKQNC P7, P8, P9, P10 and P11 truncation;
I I_ N-terminal DNP label
HA-P 3Cys (cysteine residue at P3)
HA3  PKYVCQNTLKLAT
HA3 P1G PKGVCQNTLKLAT P1 Tyr-to-Gly substitution
HA3 Pime-Pi Me-YVCQNTLKLAT P-2 and P-1 truncation; N-methylation of P1 Tyr
HA3 P1Gme-Pna Me-GVCQNTLKLAT P-2 and P-1 truncation; substitution of P1
Tyr with N-methylated Gly
HA3 P2-pra VCQNTLKLAT P-2, P-1 and P1 truncation
HA3 P3-p 1 a CQNTLKLAT P-2, P-1, P1 and P2 truncation
HA 6 peptides have a threonine-to-cysteine substitution at position 6, and HA 3 peptides have a
lysine-to-cysteine substitution at position 3. All peptides except HA 6 (N-DNP) and HA 6 P- 2-P6
have a DNP group attached through a C-terminal lysine. Underlining indicates P1 anchor
residues.
aHLA-DR-peptide complexes that bind rapidly to HLA-DM.
Covalent attachment of the high-affinity HA(306-318) peptide in the P6 pocket (HA 6; Fig. 3.4a)
yielded a complex that failed to bind to HLA-DM, as assessed by SPR (Fig. 3.4a,d). We then
systematically truncated the full-length HA peptide (which spanned from position P-2 to
position P11) from the N terminus, which resulted in loss of conserved hydrogen bonds between
the peptide backbone and the HLA-DR helices. Removal of the P-2 residue (peptide HA 6 P-1-
Pi1 ) resulted in loss of hydrogen bonds to Phe51 and Ser53 of HLA-DRa, and further truncation
of P-1 (peptide HA 6 PI-Pi1) also eliminated a hydrogen bond to His8l of HLA-DRp (Fig. 3.4a).
Deletion of these two N-terminal peptide residues was not sufficient for binding to HLA-DM
(Fig. 3.4d). However, we observed strong binding to HLA-DM after further truncation of the
tyrosine at P1 (peptide HA 6 P2-P 11), a critical anchor residue for binding of HLA-DR140 (Fig.
3.4b-d). In contrast, truncation of five C-terminal residues (HA 6 P- 2-P 6) resulted in little binding
to HLA-DM; the small amount of apparent binding was possibly caused by an overall increase in
protein mobility due to loss of five peptide residues (Fig. 3.4e).
To determine whether the effect noted above was due solely to removal of the P1 anchor residue,
we tested full-length peptides with substitution to alanine or glycine at Pl. Replacement of the
P1 tyrosine anchor with alanine (HA 6 PIA) or glycine (HA 6 PiG) resulted in only a small amount
of binding to HLA-DM (Fig. 3.4f). In contrast, substantial binding was enabled by simultaneous
loss of the P1 side chain (P1 glycine) and the two N-terminal residues (PiGme-PI, where 'Gme'
indicates methylation of the glycine residue at the N terminus; Fig. 3.4f). Substantial binding to
HLA-DM therefore requires release of both the P1 anchor and the peptide residues N-terminal to
it.
Loss of the P1 anchor could enable dissociation of a longer peptide segment toward the P6
position, which could be required for binding to HLA-DM. To address this possibility, we
moved the covalent attachment site from the P6 pocket to the P3 site by replacement of the
glycine residue at position 58 of HLA-DRa with cysteine (Table 3.1). Again, removal of
positions P-2 and P-1 did not permit binding to HLA-DM (HA 3 Pime--P11; where 'P1 me' indicates
methylation of the P1 position; Fig. 3.5a) but further removal of the P1 side chain (HA 3 PiGme-
P 1 ) or the P1 residue (HA 3 P2 -Pn 1) resulted in rapid binding of these two complexes to HLA-
DM (Fig. 3.5a). Notably, additional truncation of the P2 residue (HA 3 P3-P 1 1) seemed to slow
the binding to HLA-DM (Fig. 3.5b), which indicated that disengagement of the P1 anchor and
two N-terminal peptide residues was sufficient for binding to HLA-DM. The asparagine at
position 82 of HLA-DRp forms bidentate hydrogen bonds to the peptide backbone at position
P2, and replacement of this asparagine with alanine increases the intrinsic dissociation rate of the
HA peptide >3,000-fold, which indicates that it has a dominant role in stabilizing peptides in the
binding groove32 41. Loss of the peptide residue at position P2 may thus result in lower activity
of such an HLA-DR-peptide complex due to absence of these critical hydrogen bonds. These
results show that HLA-DM binds only to HLA-DR-peptide complexes with a disengaged
peptide N terminus but not to complexes in which the peptide is fully bound.
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Figure 3.5. Truncated peptides covalently linked through peptide position P3 also bind HLA-
DM. (a,b) Binding of HLA-DM by HLA-DR1-peptide complexes (5 pM) in which the glycine
at position 58 of the HLA-DRa chain was replaced with cysteine to permit the formation of
disulfide bonds with HA peptides carrying a cysteine at the position P3 (HA 3), assessed as in
Figure 3.4. Data are representative of three (a) or two (b) independent experiments.
3.4.4 Important role for HLA-DRa Trp43 in binding to HLA-DM
The tryptophan at position 43 of HLA-DRa directly interacts with the tyrosine at position P1 and
is partially accessible on the lateral surface of the HLA-DRa segment consisting of positions 40-
54 (Fig. 3.6a), which has been proposed to be involved in binding to HLA-DM. Conservative
substitution of that tryptophan with phenylalanine resulted in much lower susceptibility to HLA-
DM in a peptide-binding assay (Fig. 3.6b), and by SPR we observed little binding to HLA-DM
by this mutant (Fig. 3.6c). This substitution also accelerated spontaneous release of labeled
MBP(85-99) from HLA-DR2 (Fig. 3.6d), a property that would actually be expected to increase
binding to HLA-DM, given the data shown above. We also directly compared a panel of four
HLA-DR mutants for HLA-DM-catalyzed peptide exchange and binding to HLA-DM (Fig.
3.6e,f). Three HLA-DRa mutants (W43F, S53D and S53H) had much lower activity in both
assays, whereas one mutant (G49S) had enhanced activity. These data show that the binding of
HLA-DR to HLA-DM as well as HLA-DM-catalyzed peptide exchange require the same HLA-
DR residues and hence involve the same binding site on HLA-DR.
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Figure 3.6. HLA-DRct Trp43 is important for interaction with HLA-DM. (a) HLA-DRct model
showing the surface accessibility of Trp43 and its interaction with the P1 tyrosine of HA(306-
318), as well as the interaction of hydrophobic residues in the HLA-DRa segment of positions
40-54 with the P1 anchor (Trp43, Ala52 and Phe54) and residues associated with the HLA-DM
interaction (Glu40, Phe51 and Ser53). The segment of HA(306-318) from P-2 to P2 is presented
as a stick model. (b) FP analysis of the dissociation of Alexa Fluor 488-labeled MBP(85-99)
from wild-type or mutant (W43F) HLA-DR2 over a range of HLA-DM concentrations
(horizontal axis). (c) Binding of HLA-DM by wild-type or mutant (W43F) HLA-DR2 with
bound CLIP (1 pM; pH 5.35, 30 'C, 15 pl/min), followed by buffer and 5 pM CLIP(87-101). (d)
FP analysis of the dissociation of Alexa Fluor 488-labeled MBP(85-99) from preloaded wild-
type or mutant (W43F) HLA-DR2 complexes (100 nM) in presence of 10 gM unlabeled
MBP(85-99) competitor peptide (pH 5.4, 25 'C). (e,f) FP assay (e) and SPR assay (f) of four
HLA-DRa chain mutants in the conditions in b (e) and c (f). Data are representative of two
independent experiments.
3.4.5 High energy barrier for binding to HLA-DM
Peptide exchange in the presence or absence of HLA-DM is highly dependent on both
temperature and pH"' 1' 1. HLA-DRl-CLIPI, and HLA-DR2-CLIP showed a steep
temperature dependence for binding to HLA-DM (Fig. 3.7a and Fig. A3.7) that is unusual for
protein-protein interactions. However, binding of HLA-DM by HLA-DRI with a covalent
peptide lacking three N-terminal peptide residues (HA 6 P2-P, i) was much less temperature
dependent (Fig. 3.7b,c), which demonstrated that dissociation of the N terminus of the peptide
represents an important component of the energy barrier. With peptides of higher affinity, this
energy barrier is expected to be even larger. On the basis of the association and dissociation
kinetics of the binding of the covalent HLA-DRI-HA6 P2-P 1 1 complex to HLA-DM, we
calculated a dissociation constant of 1 gM (Fig. 3.7d), which is consistent with the Michaelis
constant of ~0.75 pM for the enzymatic reaction executed by HLA-DM39 . Notably, both on-rates
and off-rates increased to a similar extent with temperature, and the affinity was therefore
maintained over this temperature range (Fig. A3.8a-c).
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Figure 3.7. Large energy barrier for the binding of HLA-DR-peptide to HLA-DM. (a,b)
Binding of HLA-DM by HLA-DR1-CLIPio (1 jM, a) or HLA-DRI-HA 6 P2-Pii (1 pM, b)
injected at various temperatures (key; 15 p./min, pH 5.35), followed by buffer and 50 p.M
HA(306-3 18). (c) Binding at 250-270 s of the association phase in a,b (Fig. A3.6a), plotted
against the corresponding temperature. (d) Affinity of HLA-DM for HLA-DR 1-HA6 P2-P1 i
injected at various concentrations (key) as in a; results were fitted with a 1:1 Langmuir binding
model by BLAevaluation software. (e,f) Binding of HLA-DM by HLA-DR-CLIPio, (5 pM; e)
or HLA-DR1-HA6 P2-Pi (5 M; f) injected for 2 mi at 25 C as in a at various pH values
(key). (g) Binding at 91-110 s of the association phase in e,f (and for HLA-DR2-CLIP; not
presented in e,f), plotted against pH, with binding at pH 5.0 set as 1.0. Data are representative of
two (a,e) or three (b,d,f) independent experiments.
HLA-DM has a sharp pH optimum in the acidic range found in late endosomes"' 2. As expected,
the binding of HLA-DR-CLIP to HLA-DM was increased by lowering of the pH from 5.5 to 4.6
88
(Fig. A3.9a). However, peptide-binding experiments with HLA-DR2 molecules rendered empty
by photocleavage of the bound peptide showed that peptide binding was faster at higher pH23
(Fig. A3.9b). Consistent with that result, peptide-induced dissociation of the complex was slower
at a pH of 4.6 (Fig. A3.9a). HLA-DRI with a covalent truncated peptide (HLA-DRI-HA 6 P2-
P 1 ) showed 40% of maximal binding to HLA-DM at a pH of 7.0, whereas complexes with a
full-length peptide (HLA-DR1-CLIPio, and HLA-DR2-CLIP) did not bind to HLA-DM at this
pH (Fig. 7e-g). Furthermore, raising the pH during stage 2, at which empty HLA-DR dissociates
from HLA-DM, had little to no effect on dissociation rates (data not shown). The pH-facilitated
release of the N terminus of the peptide therefore explains in part the low pH optimum of the
binding of HLA-DR-peptide to HLA-DM.
3.4.6 Model of interaction between HLA-DM and HLA-DR
The results presented above can be integrated into a new model of DM action (Fig. A3.10) in
which HLA-DR molecules with fully engaged peptides do not interact with HLA-DM until the
N-terminal part of the peptide dissociates from the HLA-DR-peptide complex because of
spontaneous peptide motion. HLA-DM captures this short-lived transition state and peptide
quickly departs after binding to HLA-DM. The empty HLA-DM-HLA-DR complex retains the
ability to quickly bind a new peptide over extended periods of time. If an interacting peptide has
low affinity, HLA-DM may catalyze its removal (editing), whereas binding of a high-affinity
peptide is more likely to induce dissociation of the HLA-DM-HLA-DR complex. The resulting
high-affinity HLA-DR-peptide complex has a low likelihood of rebinding HLA-DM. This model
is consistent with a large body of published work in the field, including the identification of
empty HLA-DR-HLA-DM complexes in cells and the demonstration of an editing function of
HLA-DM and H2-DM that drives the selection of high-affinity peptides 4 -2' 4 3.
3.5 Discussion
Our results here have shown that two related mechanisms protect high-affinity peptides from
rapid removal by HLA-DM: the binding of such peptides in the HLA-DR groove induces
dissociation of HLA-DM, and HLA-DM only slowly rebinds to such high-affinity HLA-DR-
peptide complexes. These mechanisms explain how editing by HLA-DM produces HLA-DR-
peptide complexes with high intrinsic stability for long-lived display on the cell surface. Forced
linkage of HLA-DM and HLA-DR through leucine zipper dimerization domains attached to
HLA-DMp and HLA-DRp chains results in rapid dissociation of both low-affinity and high-
affinity peptides (a half-time of 10 s or 2 min, respectively, for CLIP or HA(306-318) bound to
HLA-DRl), which shows the importance of rapid dissociation of the HLA-DR-HLA-DM
complex in keeping high-affinity peptides in the binding groove 7 .
HLA-DR molecules with full-length peptides covalently linked at position P3 or P6 did not bind
to HLA-DM. However, efficient binding resulted after removal of two N-terminal residues (P-I
and P-2) and truncation of the PI side chain that serves as the main anchor for many HLA-DR-
bound peptides4 . Removal of the peptide side chain at position P1 alone resulted in only weak
binding to HLA-DM. The two peptide residues N-terminal to the P1 anchor (P-2 and P-I) form
conserved hydrogen bonds to Phe5l and Ser53 of HLA-DRa and His8l of HLA-DRp 3; in
addition, the side chains of Phe51 and Ser53 of HLA-DRa are critical for the action of HLA-
DM. These results show that HLA-DM interacts with HLA-DR molecules only when the P1
pocket is vacant and conserved N-terminal hydrogen bonds to HLA-DR are disrupted; loss of
either set of interactions is not sufficient for substantial binding to HLA-DM. Consistent with
those results, it has been shown that filling of the P1 pocket by substitution of the residue at
HLA-DRp position 86 (glycine to tyrosine) results in much lower susceptibility to HLA-DM 44
and that loss of hydrogen bonds between the N terminus of the peptide and Phe51 and Ser53 of
HLA-DRa results in greater susceptibility to HLA-DM (six- to ninefold greater)34. HLA-DM
thus interacts only with HLA-DR conformers in which a critical part of the binding site is
already empty.
The segment of HLA-DRa consisting of positions 40-54 not only forms three hydrogen bonds
with the backbone of the N-terminal peptide segment (HLA-DRa positions 51 and 53) but also
makes substantial hydrophobic contacts that pack against the P1 pocket. Published mutagenesis
studies have shown that Phe51 and Glu40 of HLA-DRa are important for susceptibility to HLA-
DM2 6 , and our studies here have shown that the side chains of Ser53 and Trp43 of H LA-DRa are
also critical. Trp43 of HLA-DRa is of particular interest because it interacts with the P1 anchor
and is also partially solvent accessible in an area that has been linked to the interaction with
HLA-DM. Even a conservative substitution, from tryptophan to phenylalanine, resulted in much
less binding to HLA-DM, even though this substitution resulted in a moderately higher off-rate
of HLA-DR-bound peptide (a change predicted to increase binding to HLA-DM). Phe51 and
Ser53 of HLA-DRa (hydrogen bonds to the peptide) and Phe54 and Ala52 of HLA-DRa
(hydrophobic contacts with the PI anchor) are located on an extended strand at the N-terminal
side of the HLA-DRa-chain helix that may readily adopt a new conformation when the close
interactions with the N terminus of the peptide and the P1 anchor are lost. This specific area of
the HLA-DRa chain shows greater flexibility than do the HLA-DR helices, as shown by higher
B-factors in crystal structures of MHCII 4. Molecular-dynamic simulations of the peptide-
occupied state have further shown that the segment of HLA-DRa consisting of positions 50-59
45shows greater mobility than do the long helices that flank the peptide-binding groove4.
All proteins are in constant motion, and local motions may lead to transient loss of interactions in
part of the binding groove. We propose that N-terminal truncation of HA(306-318) bound to
HLA-DR1 mimics a transient conformation in which part of the peptide has temporarily left the
binding site. Structurally, the hydrogen bonds formed by the amino acids at positions 51 and 53
of HLA-DRa and position 81 of HLA-DRP are surface exposed, whereas other conserved
hydrogen bonds to the peptide backbone are sheltered by the helical walls of the binding
groove 24. In the absence of HLA-DM, the most likely outcome is rebinding of this peptide
segment in the groove. HLA-DM seems to have a higher affinity for fully empty HLA-DR
molecules than for partially peptide-filled HLA-DR molecules, as the dissociation rate of empty
HLA-DR-HLA-DM complexes (stage 2) is much lower (-12%) than that of covalent HLA-DR-
peptide complexes lacking the N-terminal peptide segment. When HLA-DM senses the loss of
interactions surrounding the N terminus of the peptide, its higher affinity for the empty state
could shift the equilibrium from a partially peptide-filled form to a fully empty form.
The binding of HLA-DR--peptide to HLA-DM showed a temperature dependence that is highly
unusual for protein interactions. The temperature dependence was less steep for truncated HLA-
DR-peptide complexes, which suggests that a substantial part of the input energy for binding to
HLA-DM is required for dissociation of the N-terminal peptide segment. HLA-DM can catalyze
peptide exchange for a wide variety of HLA-DR-peptide complexes, but the enhancement of
peptide dissociation by HLA-DM varies substantially among HLA-DR-peptide complexes. In
one study, the enhancement of peptide dissociation by HLA-DM for high-affinity HLA-DR-
peptide complexes ranged from 1.4-fold to 227-fold 0 . Our SPR data showed slow binding to
HLA-DM by high-affinity HLA-DR-peptide complexes, which suggests that the initial binding
event is a rate-limiting step. How frequently such HLA-DR-peptide complexes assume a
conformation compatible with binding to HLA-DM is probably influenced by many factors,
including the tightness with which the N-terminal peptide segment is bound and how the binding
energy is distributed along the groove. Some high-affinity peptides may become almost resistant
to the action of HLA-DM because the HLA-DM-interacting conformation is accessed only
infrequently.
Finally, we observed that allelic HLA-DR variants showed differences in susceptibility to the
action of HLA-DM (fast binding for HLA-DR2-CLIP; intermediate binding for HLA-DR4-
CLIP; slowest binding for HLA-DRl-CLIP). These differences in on-rates were explained in
part by differences in affinity for CLIP; HLA-DRi has a high affinity for CLIP, whereas HLA-
DR4 binds CLIP with very low affinity37, 46. However, additional factors seem to contribute,
because HLA-DR4-CLIP complexes bound to HLA-DM with slower kinetics than did HLA-
DR2-CLIP complexes. Also, peptide-induced dissociation of the HLA-DM-HLA-DR complex
seems to be more efficient for HLA-DR2 than for HLA-DRI or HLA-DR4. The structural
mechanisms that contribute to these differences in HLA-DM-binding kinetics may be complex
and will need to be carefully delineated. These results also raise the possibility that MHCII
polymorphisms, including those associated with autoimmune diseases, not only change the
specificity of MHCII-binding pockets but also broadly affect the peptide repertoire by modifying
the kinetics of HLA-DM-catalyzed peptide editing.
3.6 References
1. Lanzavecchia, A., Reid, P.A. & Watts, C. Irreversible association of peptides with class II
MHC molecules in living cells. Nature 357, 249-252. (1992).
2. Jensen, P.E. Long-lived complexes between peptide and class II major histocompatibility
complex are formed at low pH with no requirement for pH neutralization. J. Exp. Med. 176, 793-
798 (1992).
3. Stem, L.J. et al. Crystal structure of the human class II MHC protein HLA-DRI complexed
with an influenza virus peptide. Nature 368, 215-221 (1994).
4. Brown, J.H. et al. Three-dimensional structure of the human class II histocompatibility
antigen HLA-DR1. Nature 364, 33-39 (1993).
5. Germain, R.N. & Rinker, A.G., Jr. Peptide binding inhibits protein aggregation of invariant-
chain free class II dimers and promotes surface expression of occupied molecules. Nature 363,
725-728 (1993).
6. Rabinowitz, J.D. et al. Formation of a highly peptide-receptive state of class II MHC.
Immunity 9, 699-709 (1998).
7. Roche, P.A. & Cresswell, P. Invariant chain association with HLA-DR molecules inhibits
immunogenic peptide binding. Nature 345, 615-618 (1990).
8. Riberdy, J.M., Newcomb, J.R., Surman, M.J., Barbosa, J.A. & Cresswell, P. HLA-DR
molecules from an antigen-processing mutant cell line are associated with invariant chain
peptides. Nature 360, 474-477 (1992).
9. Morris, P. et al. An essential role for HLA-DM in antigen presentation by class II major
histocompatibility molecules. Nature 368, 551-554 (1994).
10. Stebbins, C.C., Loss, G.E., Jr., Elias, C.G., Chervonsky, A. & Sant, A.J. The requirement for
DM in class Il-restricted antigen presentation and SDS-stable dimer formation is allele and
species dependent. JExp Med 181, 223-234 (1995).
11. Sloan. V.S. et al. Mediation by HLA-DM of dissociation of peptides from HLA-DR. Nature
375, 802-806 (1995).
12. Denzin, L.K. & Cresswell, P. HLA-DM induces CLIP dissociation from MHC class II alpha
beta dimers and facilitates peptide loading. Cell 82, 155-165 (1995).
13. Sherman, M.A., Weber, D.A. & Jensen, P.E. DM enhances peptide binding to class II MHC
by release of invariant chain-derived peptide. Immunity 3, 197-205 (1995).
14. Nanda, N.K. & Sant, A.J. DM determines the cryptic and immunodominant fate of T cell
epitopes. JExp Med 192, 781-788 (2000).
15. Katz, J.F., Stebbins, C., Appella, E. & Sant, A.J. Invariant chain and DM edit self-peptide
presentation by major histocompatibility complex (MHC) class II molecules. J. Exp. Med 184,
1747-1753 (1996).
16. Lich, J.D., Jayne, J.A., Zhou, D., Elliott, J.F. & Blum, J.S. Editing of an immunodominant
epitope of glutamate decarboxylase by HLA-DM. J. Immunol. 171, 853-859 (2003).
17. Lovitch, S.B., Petzold, S.J. & Unanue, E.R. Cutting edge: H-2DM is responsible for the large
differences in presentation among peptides selected by I-Ak during antigen processing. J.
Immunol. 171, 2183-2186 (2003).
18. Pathak, S.S., Lich, J.D. & Blum, J.S. Cutting edge: editing of recycling class II:peptide
complexes by HLA-DM. J. Immunol. 167, 632-635 (200 1).
19. Lazarski, C.A. et al. The kinetic stability of MHC class II:peptide complexes is a key
parameter that dictates immunodominance. Immunity 23, 29-40 (2005).
20. Lazarski, C.A., Chaves, F.A. & Sant, A.J. The impact of DM on MHC class Il-restricted
antigen presentation can be altered by manipulation of MHC-peptide kinetic stability. J. Exp.
Med 203, 1319-1328 (2006).
21. Denzin, L.K., Hammond, C. & Cresswell, P. HLA-DM interactions with intermediates in
HLA-DR maturation and a role for HLA-DM in stabilizing empty HLA-DR molecules. JExp
Med 184, 2153-2165 (1996).
22. Kropshofer, H., Arndt, S.O., Moldenhauer, G., Hammerling, G.J. & Vogt, A.B. HLA-DM
acts as a molecular chaperone and rescues empty HLA-DR molecules at lysosomal pH. Immunity
6, 293-302 (1997).
23. Grotenbreg, G.M. et al. Empty class II major histocompatibility complex created by peptide
photolysis establishes the role of DM in peptide association. JBiol Chem 282, 21425-21436
(2007).
24. Mosyak, L., Zaller, D.M. & Wiley, D.C. The structure of HLA-DM, the peptide exchange
catalyst that loads antigen onto class II MHC molecules during antigen presentation. Immunity 9,
377-383 (1998).
25. Fremont, D.H., Crawford, F., Marrack, P., Hendrickson, W.A. & Kappler, J. Crystal
structure of mouse H2-M. Immunity 9, 385-393 (1998).
26. Doebele, R.C., Busch, R., Scott, H.M., Pashine, A. & Mellins, E.D. Determination of the
HLA-DM interaction site on HLA-DR molecules. Immunity 13, 517-527 (2000).
27. Pashine, A. et al. Interaction of HLA-DR with an acidic face of HLA-DM disrupts
sequence-dependent interactions with peptides. Immunity 19, 183-192 (2003).
28. Stratikos, E., Mosyak, L., Zaller, D.M. & Wiley, D.C. Identification of the lateral interaction
surfaces of human histocompatibility leukocyte antigen (HLA)-DM with HLA-DRI by
formation of tethered complexes that present enhanced HLA-DM catalysis. JExp Med 196, 173-
183 (2002).
29. Weber, D.A., Evavold, B.D. & Jensen, P.E. Enhanced dissociation of HLA-DR-bound
peptides in the presence of HLA-DM. Science 274, 618-620 (1996).
30. Belmares, M.P., Busch, R., Wucherpfennig, K.W., McConnell, H.M. & Mellins, E.D.
Structural factors contributing to DM susceptibility of MHC class II/peptide complexes. J
Immunol 169, 5109-5117 (2002).
31. Narayan, K. et al. HLA-DM targets the hydrogen bond between the histidine at position
beta8l and peptide to dissociate HLA-DR-peptide complexes. Nat Immunol 8, 92-100 (2007).
32. Zhou, Z., Callaway, K.A., Weber, D.A. & Jensen, P.E. Cutting edge: HLA-DM functions
through a mechanism that does not require specific conserved hydrogen bonds in class II MHC-
peptide complexes. JImmunol 183, 4187-4191 (2009).
33. Ferrante, A. & Gorski, J. Cutting edge: HLA-DM-mediated peptide exchange functions
normally on MHC class II-peptide complexes that have been weakened by elimination of a
conserved hydrogen bond. JImmunol 184, 1153-1158 (2010).
34. Stratikos, E., Wiley, D.C. & Stern, L.J. Enhanced catalytic action of HLA-DM on the
exchange of peptides lacking backbone hydrogen bonds between their N-terminal region and the
MHC class II alpha-chain. JImmunol 172, 1109-1117 (2004).
35. Zarutskie, J.A. et al. A conformational change in the human major histocompatibility
complex protein HLA-DRI induced by peptide binding. Biochemistry 38, 5878-5887 (1999).
36. Weber, D.A., Dao, C.T., Jun, J., Wigal, J.L. & Jensen, P.E. Transmembrane domain-
mediated colocalization of HLA-DM and HLA-DR is required for optimal HLA-DM catalytic
activity. JImmunol 167, 5167-5174 (200 1).
37. Chicz, R.M. et al. Predominant naturally processed peptides bound to HLA-DR1 are derived
from MHC-related molecules and are heterogeneous in size. Nature 358, 764-768 (1992).
38. Kropshofer, H. et al. Editing of the HLA-DR-peptide repertoire by HLA-DM. Embo J 15,
6144-6154 (1996).
39. Vogt, A.B., Kropshofer, H., Moldenhauer, G. & Hammerling, G.J. Kinetic analysis of
peptide loading onto HLA-DR molecules mediated by HLA-DM. Proc Natl AcadSci USA 93,
9724-9729 (1996).
40. Jardetzky, T.S. et al. Peptide binding to HLA-DRI: a peptide with most residues substituted
to alanine retains MHC binding. EMBO J9, 1797-1803 (1990).
41. McFarland, B.J., Katz, J.F., Beeson, C. & Sant, A.J. Energetic asymmetry among hydrogen
bonds in MHC class II*peptide complexes. Proc Natl Acad Sci USA 98, 9231-9236 (2001).
42. Reay, P.A., Wettstein, D.A. & Davis, M.M. pH dependence and exchange of high and low
responder peptides binding to a class II MHC molecule. EMBOJ11, 2829-2839 (1992).
43. Sanderson, F., Thomas, C., Neefjes, J. & Trowsdale, J. Association between HLA-DM and
HLA-DR in vivo. Immunity 4, 87-96 (1996).
44. Chou, C.L. & Sadegh-Nasseri, S. HLA-DM recognizes the flexible conformation of major
histocompatibility complex class II. JExp Med 192, 1697-1706 (2000).
45. Painter, C.A., Cruz, A., Lopez, G.E., Stem, L.J. & Zavala-Ruiz, Z. Model for the peptide-
free conformation of class II MHC proteins. PLoS One 3, e2403 (2008).
46. Patil, N.S. et al. Rheumatoid arthritis (RA)-associated HLA-DR alleles form less stable
complexes with class I-associated invariant chain peptide than non-RA-associated HLA-DR
alleles. JImmunol 167, 7157-7168 (2001).
47. Nicholson, M.J. et al. Small molecules that enhance the catalytic efficiency of HLA-DM. J
Immunol 176, 4208-4220 (2006).
48. Day, C.L. et al. Ex vivo analysis of human memory CD4 T cells specific for hepatitis C
virus using MHC class II tetramers. J Clin Invest 112, 831-842 (2003).
49. Call, M.J. et al. In vivo enhancement of peptide display by MHC class II molecules with
small molecule catalysts of peptide exchange. JImmunol 182, 6342-6352 (2009).
Chapter 4: Signal Duration Can Determine Choice of Gene
Transcription Program
Portions reprinted from "A model for How Signal Duration Can Determine Distinct Outcomes of
Gene Transcription Programs" by Kevin D. Fowler, Vijay K. Kuchroo, and Arup K.
Chakraborty, In preparation.
4.1 Introduction
In many examples in biology, a single transcription factor is able to activate multiple genes
(1,2,3). Also, different receptors are able to activate the same transcription factor, but each leads
to unique outcomes (4,5,6). How signal specificity is attained with all of this redundancy has
long interested researchers. Manipulation of signal duration through the use of feedback loops,
phosphatases, and ubiquitin ligases is one mechanism by which cells attain signal specificity
when multiple receptors utilize the same pathway. For instance, both nerve growth factor (NGF)
and epidermal growth factor (EGF) signal through the MAPK pathway, but NGF is able to
generate a sustained ERK signal, while EGF generates a transient signal; sustained and transient
signals in this case result in two different outcomes through the same pathway (6,7). It was
recently discovered that NGF signaling leads to a positive feedback loop in the MAPK pathway,
while EGF leads to a negative feedback loop, and this disparity accounts for the differences in
signal duration (8). One mechanism cells can use to translate signal duration into different
outcomes at the gene transcription level is through manipulation of immediate early gene (IEG)
stability (9). ERK induces transcription of the IEG products and then can bind to and
phosphorylate them. The phosphorylated form of the IEG is less susceptible to degradation
allowing it to further assist in the activation of downstream programs. Transient signals are
unable to induce the protected form of the IEG products and the signal degrades. The net result
is that the signal propagates through the genetic network for sustained signals or dies out for
transient signals.
A simpler example of two receptors sharing the same signaling pathway, but leading to two
different outcomes, is the IL-6 and IL-10 receptor. Both receptors activate signal transducer and
activator of transcription 3 (STAT3), which forms dimers upon phosphorylation and enters the
nucleus where it acts as a transcription factor. Despite the simplicity of the pathway, the two
receptors induce different cellular behaviors: IL-6 elicits a pro-inflammatory response, while IL-
10 signaling leads to an anti-inflammatory response (10). The anti-inflammatory response by IL-
10 acts on a number of cell types including antigen presenting cells (APCs) and is characterized
by the induction of gene products by STAT3, which inhibit the transcription of inflammatory
genes (11). One key distinction between the two pathways is that the inhibitor, suppressor of
cytokine signaling 3 (SOCS3) induced hv STAT3 can bind to the IL-6 receptor, but cannot bind
to the IL-10 receptor. This leads to IL-6 inducing a transient STAT3 signal, while IL-10 induces
a sustained STAT3 signal (10). Two independent experiments demonstrated that blocking
SOCS3's ability to inhibit IL-6 signaling leads to an anti-inflammatory response
indistinguishable from that induced by IL-10 in macrophages (12,13).
Recent work by Behar et. al. is an example of how mathematical modeling can be utilized to
propose various network architectures in which cells can make decisions by signaling through
multiple receptors with shared components, while retaining signal specificity (14,15). These
models focus on signal events upstream of transcription. We sought to identify a simple
transcriptional model that would allow cells to make decisions based entirely on the duration of
the input signal to the transcriptional network. Developed in the context of how signal duration
manipulation by SOCS3 can lead to different outcomes from the IL-6 and IL-10 signaling
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pathways, our model focuses on the choice whether to produce a generic inflammatory gene
product I or a generic anti-inflammatory gene product A when activated by a common
transcription factor pSTAT3.
4.2 Model
4.2.1 Transcriptional network model development
A transcriptional network was formulated to allow the cellular decision of whether to be pro-
inflammatory or anti-inflammatory to be made by changes in activated pSTAT3 signal duration.
The network consists of two genes (I and A) that are activated by the same transcription factor
(Figure 4.1). The essential feature of such a network must be that a transient pSTAT3 signal
leads to dominant production of the inflammatory gene (I), while a sustained pSTAT3 signal
leads to dominant production of the anti-inflammatory gene A. In reality, there are many
inflammatory and anti-inflammatory genes, but we will adopt a coarse-grained view of the
system where all of these genes will be characterized by generic representative genes I and A,
respectively. In the model, pSTAT3 dimers (pSTAT3) are allowed to bind to the promoter
region of gene I (Ig) and gene A (Ag)
pSTAT3+I " >pSTAT3- I
off.TJ
pSTAT3+A ""7 > pSTAT3-A
where the on and off rates can be different for the two genes. Different epigenetic modifications
of the two genes could mean that one gene is more accessible than another, thus the possibility
for different rates.
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Figure 4.1. Transcriptional network that allows for cellular decisions based on signal duration.
The "signal" in this mechanism is the ability of pSTAT3 to induce transcription of I or A. The
cellular decision is based on the relative amounts of protein I or A produced. In this mechanism
I can induce its own transcription in the absence of signal, pSTAT3. Protein A can bind to
inflammatory gene I and inhibit its transcription.
DNA-bound pSTAT3 can induce transcription of I mRNA (Im) and A mRNA (Am), via reactions
assumed to be assumed first order
pSTAT3-I, '" >I,,,+pSTAT3+I,
pSTAT3- A, "" > A,,, + pSTAT3+ A,
where the rate constants of the form ktr,,T should be read as the transcription of I in the presence
of transcription factor, T (pSTAT3 dimer). It is assumed that the associated transcription factors
unbind each time a transcription reaction is carried out. Due to the simplicity of the network, it
was easy to also construct a model where transcription factors do not unbind each time mRNA is
transcribed to verify that the qualitative behavior would not change. We found multiple
combinations of parameters that lead to the same qualitative behavior in both models (Appendix
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4), so we will only present results for the case where transcription factors unbind each time the
transcription reaction is carried out.
After transcription, the mRNA of I and A can be translated to fully functional proteins in
assumed first order processes
A. k11'1 IA
where species I and A represent the fully functional proteins.
The model also contains two types of feedback loops, which make the network sensitive to signal
duration. Inflammatory protein I is allowed to bind to its own promoter and induce its own
transcription in the presence or absence of pSTAT3 as given by
I+[pSTAT3]g " f [P STAT3]II , '' Ii+[pSTAT3]+I,+I
where [pSTAT3] indicates that pSTAT3 may or may not be present. If pSTAT3 is present, it is
assumed that the rate of transcription is governed by whichever rate constant, ktrx,ii or kt, 1 r, is
greater. The ability of I to induce its own production in the absence of the signal through a
positive feedback loop allows for the production of I even for a fast decaying signal as long as
the decay rate of I is small enough to allow for the initiation of the positive feeback loop. The A
gene has no positive feedback loops so it is entirely dependent on the signal and thus will not be
produced in appreciable quantities by transient signals.
The network also contains a negative feedback loop where anti-inflammatory protein A is able to
bind to the promoter of gene I and impede its transcription according to
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A+[pSTAT3, I]I " > "' >I,, + [pSTAT3, I]+I+A
where [pSTAT3,I] indicates that either pSTAT3 or I is bound to gene 1. The ability of A to
negatively regulate I is important in creating a regime where A can win out. If the inhibition is
strong enough (ktrx,1,A<<0), A can shut down the production of I if A is present in great enough
quantities. Sustained signaling may permit this scenario.
Another important aspect of the network is that all species, except genes, can decay at assumed
first order rates
pSTAT3 -d*gT > X
[I, A] kdcg > X
[I.,, A,,, I *" >dp X
where [] represents either I or A. Biologically, the deactivation of I or A would be caused by
ubiquitin ligases or phosphatases in the nucleus, which are assumed to be present in large enough
concentrations so that the reactions are first order. The parameter, kdeg,T, is a measure of the
duration of the signal. Large values of kdegT indicate a highly transient signal, whereas small
values kdeg,T indicate a relatively sustained signal. In the context of IL-6 and IL-10 signaling,
kdeg,T is modified by ability or inability of SOCS3 to inhibit pSTAT3 signaling. We begin the
simulation just after appreciable amounts of SOCS3 have been induced, which means that the
signal has reached its maximum value and then begins to decay at time zero. For IL-6, this
occurs at about 30 minutes after signaling has begun (13). Deactivation / degradation of I and A
is allowed to occur whether or not the proteins are bound to genes. We also considered the case
where deactivation / degradation of pSTAT3, I, and A is not allowed to occur when the
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molecules are bound to genes and found by sensitivity analysis that this does not significantly
affect the qualitative results of the model (Appendix 4).
4.3 Results and Discussion
4.3.1 Genes I and A exhibit different responses to changes in signal duration
Rate laws were written for each of the reactions in the model and the corresponding chemical
master equations were solved using the Gillespie algorithm (16). We explicitly considered
stochastic fluctuations in the number of molecules in this system via the Master equations
because genes are often present in small copy numbers. The solution of the mean field equations
could lead to the identification of signaling thresholds that in reality cannot be met due to
fluctuations. For instance, the mean field solution to the model equations obtained via
MATLAB predicts that the number of I molecules never reaches 50 molecules at any point in
time for the set of parameters identified in Table 4.1 using a signal degradation rate of 0 (Figure
4.2A). However, the Gillespie algorithm shows that half of the trajectories of I cross 50;
therefore it would be inaccurate to conclude that I never reaches the signaling threshold of 50
molecules (Figure 4.2A).
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Table 4.1. Table of parameters used in the model. The results presented were robust to a range
of parameters as indicated by the sensitivity analysis (Appendix 4).
koni~l 0.015 molec-' min-' ktrx, 1  1.0 min-
konTA 0.015 molec-1 min-' ktrIA 0 min-
kon,1,l 0.015 molec-' min-' ktrii 0.5 min-'
konl 0.015 molec~1 min-' ktrlA 0.5 min-'
koff.TI 0.5 min' kdegT 0-10 min-'
koffTA 0.5 min- kdeg 0.001 min'
koff 1  0.5 min' kdegn 0
koffAl 0.01 min-' pSTAT3o 100 molec.
k", 1.0 min-' I 2 molec.
ktrx,A.T 0.1 min Ag 2 molec.
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Figure 4.2. A-molecules are expressed in greater numbers for a sustained signal (KdegT = 0 min-
'). (A) Time course trajectories for molecule I obtained by solution of the model equations using
a mean field ODE solver (red curve) and ten times using the Gillespie Algorithm (10 blue
curves). (B) Time course trajectories for molecule A obtained by solution of the model
equations using a mean field ODE solver (red curve) and ten times using the Gillespie Algorithm
(10 blue curves). (C) Histogram for molecule I obtained by solving the model equations using
the Gillespie Algorithm 1000 times and recording the number of molecules at 2000 min. (D)
Histogram for molecule A obtained by solving the model equations using the Gillespie
Algorithm 1000 times and recording the number of molecules at 2000 min. Parameters for the
model were obtained from Table 4.1.
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We are more interested in the general qualitative behavior of the genetic network as opposed to
fitting the results to actual data, so no attempt was made to use experimentally derived
parameters relevant to a specific system. As a result, it is important to use sensitivity analysis to
verify that the qualitative results of the model are robust over a range of parameters. Sensitivity
analysis was performed according to the procedures outlined in the Appendix 4. The basic
procedure was to divide all the parameters into nine different classes and testing all combinations
of low, medium, and high values for each parameter class (Table A4. 1). We then determined if
the response could be switched from pro-inflammatory response to an anti-inflammatory
response by changing the signal degradation rate for a given parameter set. In an initial search,
1809 parameter sets were identified that led to the desired qualitative behavior (Appendix 4).
A snapshot of the qualitative behavior of the model can be obtained by considering two values of
kaeg,T with all other parameters fixed at the values given in Table 4. 1. A value of 1 for keg.T
corresponds to a transient signal, whereas a value of 0 for kdegT corresponds to a sustained signal.
Sensitivity analysis revealed that the mRNA degradation rate did not alter the results (Figure
A4.6), so the rate of degradation for I and A mRNA was set to 0. We consider the case where
the rate of transcription of I is the same whether its induced by pSTAT3 or by itself (i.e. ktrxar =
krx,1,1) and where the transcription of A is slower than the transcription of I (i.e. ktx,A,T < ktrx,,I,
ktru). The qualitative results are robust to a range of parameters including the case where the
rate of transcription of I and A is the same and the case where the rate of transcription of A is
greater than I as determined by parameter sensitivity analysis (Appendix 4).
For sustained signals, the number of I molecules peaks at early times and then degrades, while
the number of A molecules increases steadily through time (Figure 4.2A and Figure 4.2B).
There are no negative feedback loops on A, and so, for sustained signals, the increase in its
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molecular levels is only hindered by its degradation. This is the cause for its steady increase
with time. Conversely, I is strongly affected by the negative feedback loop at later times.
Protein A is in high concentration at later times and is statistically likely to be bound to both
copies of the I genes. In the parameter range chosen, A is able to bind tightly to the I gene and
shuts down its production at later times. Once I production is shut down, the level of I gradually
decreases due to its degradation / deactivation. The combined effect of the negative feedback
loop and the degradation / deactivation reaction causes the peak in the number of I molecules at
early times (Figure 4.2A).
An alternative way of viewing the data is to run 1000 trajectories, determine the molecular levels
of I and A at "long times" (time = 2000 min), and construct a histogram. For sustained signals,
the distributions appear similar in shape; however, I is at much lower levels than A (Figure 4.2C
and Figure 4.2D). Therefore, these cells would appear to be producing mostly protein A if
assayed at long times. This implies that the cells have made the decision to activate the anti-
inflammatory gene program for sustained signals, an idea which will be explored in more detail
in the next section.
For transient signals, the molecular levels of I increase gradually with time in some of the
trajectories, while A remains at or around zero in all of the trajectories (Figure 4.3A and Figure
4.3B). Protein A is entirely signal-dependent so it is not able to be produced in significant
quantities when the signal degrades too quickly. As a result, the negative feedback loop is not
effective for highly transient signals and the production of I is limited only by its ability to
initiate the positive feedback loop. For this particular degradation rate, kdeg,T = 1, only some of
the trajectories of I led to nonzero amounts, which is clearly observed in the long time histogram
(Figure 4.3C). The bistability that results is entirely stochastic in nature, evident by the fact that
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the mean field time trajectory for I follows the average of the nonzero curves (Figure A4.1) (17).
Bistability results from the "roll of the dice" in determining whether or not the positive feedback
loop is initiated before the signal and resulting I molecules degrade. It appears that bistability
develops at approximately kdeg,T= 0.4 min~' (Figure 4.4). As the signal becomes more transient
in nature, an increasing number of I trajectories remain at 1=0. In many biological systems
bistability serves as a tool in making cellular decisions, but in this system it is simply a
breakdown mechanism that does not have relevance, and may simply be a nuisance (18, 19, 20).
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Figure 4.3. I-molecules are expressed in greater numbers for a transient signal (Kleg,T=
1.0 min-'). (A) Time course trajectories for molecule I obtained by solution of the model
equations using a mean field ODE solver (red curve) and ten times using the Gillespie Algorithm
(10 blue curves). (B) Time course trajectories for molecule A obtained by solution of the model
equations using a mean field ODE solver (red curve) and ten times using the Gillespie Algorithm
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(10 blue curves). (C) Histogram for molecule I obtained by solving the model equations using
the Gillespie Algorithm 1000 times and recording the number of molecules at 2000 min. (D)
Histogram for molecule A obtained by solving the model equations using the Gillespie
Algorithm 1000 times and recording the number of molecules at 2000 min. Parameters for the
model were obtained from Table 4.1.
In silico knock-out experiments can be performed where either the positive or negative feedback
loops are removed. When the positive feedback loop is removed, the results for sustained signals
are virtually unchanged since the negative feedback loop dominates (Figure A4.2). For the
transient case, both I and A would remain at approximately zero since both would be entirely
signal dependent. The end result of blocking the positive feedback loop is that the cell would
activate the anti-inflammatory gene program for sustained signals or neither program for
transient signals. When the negative feedback loop is knocked out, the results for transient
signals remain unchanged since the positive feedback loop dominates the behavior (Figure
A4.3). For sustained signals, both I and A would be produced in significant quantities. There
would no longer be a peak in I at short times, but a steady increase as a function of time. The
end result of blocking the negative feedback loop is that the cell would choose the pro-
inflammatory gene program for transient signals. The model predicts that both programs would
be initiated for sustained signals, but this is likely not biologically relevant since the ability of
anti-inflammatory genes to act "anti-inflammatory" has been removed by the deletion of the
negative feedback loop. Therefore, sustained signals would likely lead to pro-inflammatory cells
in this system. If both feedback loops were removed, both I and A would be entirely signal
dependent and would exhibit similar qualitative behavior (Figure A4.4). The end result of
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blocking both the positive and negative feedback loops is that the cell would choose both I and A
for sustained signals or neither for transient signals. Again, since the negative feedback has been
deleted, it would likely be observed that the cells are pro-inflammatory for sustained signals or
neither for transient signals.
4.3.2 Tuning signal duration as a tool for cellular decisions
From the two test values of kdeg,T, it appears as if this mechanism could be a viable tool for
making cellular decisions based entirely on signal duration modification. To further probe this
idea, we constructed the following in silico experiment. Thousands of I and A trajectories
similar to those obtained in the last section were generated for keg,i values ranging from 0 to 10
with all other parameters fixed at the values given in Table 4.1. It is assumed that the
downstream gene programs (inflammatory or anti-inflammatory) activated by I or A are only
initiated when the respective molecules cross a threshold value in molecular number at any point
in the time trajectory. To measure this computationally, the maximum point in each trajectory
was compared to a threshold value and the number of I and A trajectories crossing the threshold
was recorded for each value of kdegT. The percent of I or A trajectories crossing the threshold
directly corresponds to the percent of cells that exhibit pro-inflammatory or anti-inflammatory
responses in an equivalent biological experiment since each trajectory corresponds to 1 cell.
Cells with sustained signals (kdegT < 10-3) clearly exhibit an anti-inflammatory response while
cells with transient signals (0.02 < kdegT<l) clearly exhibit an inflammatory response (Figure
4.4A and Figure 4.4B). There is a small crossover region for mildly transient signals (10-3 <
kdeg,T< 0.02), the behavior in which is determined by the choice in downstream threshold values
for I and A. For the given set of parameters, it is clear that I has the capability of attaining a
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higher maximal value since its transcription rate is an order of magnitude higher than A and
since I has a positive feedback loop (Figure 4.2B and Figure 4.3A). Therefore, one natural
choice is to set the downstream threshold higher for I to account for this difference. With
different I and A threshold values, the inflammatory and anti-inflammatory response curves
overlap such that a mixture of cells exhibiting either response would be observed in the
crossover region (Figure 4.4A). An alternative choice is to set the thresholds to be the same for
both I and A, which leads to no response in the crossover region (Figure 4.4B). Setting a
downstream threshold is an arbitrary process, which merely shifts the inflammatory and anti-
inflammatory response curves, but does identify two distinct crossover region behaviors that may
both have biological relevance.
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Figure 4.4. Cellular decisions can be made by manipulating signal duration. The maximum
amount of I and A observed in 1000 time course trajectories measured out to 2000 min was
compared to an arbitrary threshold and the percentage of trajectories crossing the threshold was
computed for a wide range of signal degradation rates. (A) Different downstream thresholds
were chosen for I and A such that both responses are observed in the intermediate crossover
region. The I threshold was set to 100 molecules, while the A threshold was set to 20 molecules.
(B) Using the same downstream threshold for both I and A leads to no response observed in the
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intermediate crossover region. The I and A thresholds were taken to be 90 molecules.
Parameters for the model were obtained from Table 4.1.
One difficulty in performing this analysis is choosing where to set the long time cutoff for when
an inflammatory or anti-inflammatory response can occur. For instance, it would not necessarily
be biologically relevant if it takes several days of sustained signaling for A to cross its signaling
threshold. For the purposes of this study, we arbitrarily chose this cutoff time to be 2000
minutes (-1.5 days). Immediate early gene transcription is on the order of minutes (21), while
Th 17 differentiation is on the order of 5 days (22). Choosing 1.5 days as the cutoff seemed like a
reasonable intermediate choice. An example of a cellular decision becoming evident after I day
is in Th 17 differentiation, where IL- 17 mRNA starts to be transcribed in appreciable quantities at
this time (unpublished observations). Using 3.5 days as the cutoff time revealed an important
limitation of our model. For any signal with a degradation rate greater than zero, I will
eventually be produced in significant quantities if the simulation goes out to long enough times
(Figure A4.5A). The cause of this limitation is highlighted by the time course of I for a signal
degradation rate of 0 (Figure 4.2). Even with a sustained signal, I does not go to zero since its
potent positive feedback loop coupled with the sustained signal are still active in the moments
when a given A molecule bound to the I gene unbinds or is deactivated, which can counteract the
decrease in I due to its own degradation. For all cases where the signal degradation rate is not
zero, A will eventually decay to zero since it is signal dependent. After A has decayed to low
enough numbers, it can no longer prevent the few remaining I molecules from initiating the
positive feedback loop. Performing the threshold analysis at 3.5 days, I and A thresholds can
still be chosen to allow for a cellular decision to be made based on signal duration changes, but
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the peak in I is broader and the crossover region occurs at smaller values of the signal
degradation rate (Figure A4.5B). One way to deter this limitation is to decrease the degradation
rate of A, so that the negative feedback loop will remain active even at long times (Figure
A4.5C). We do not believe that this limitation would be relevant under most biological
situations since it would take longer than 1.5 days of steady signaling without any other changes
within the cell for it to be an issue. Conceivably, once a pro-inflammatory or anti-inflammatory
response was selected, the cell would have other means for shutting down the other set of genes.
In this sense, the model is not entirely self-contained.
4.3.3 Amplitude only significantly affects cellular decisions in the crossover region
Intracellular signals are generally described by two variables, signal amplitude and duration.
Often in the literature, these two variables are combined into one quantity, the strength of signal.
One interpretation of the strength of signal is the integrated signal, which is the area under the
curve on-a plot of signal strength vs. time. The gene transcriptional network depicted in Figure
4.1 was formulated to allow for disparate cellular decisions based strictly on differences in signal
duration. To declare the cellular decisions made in the transcriptional model as strictly dependent
on signal duration, it was also necessary to study the qualitative effect of modifying the signal
amplitude.
The effects of amplitude modification were determined by setting the initial value of pSTAT3
molecules to different amounts and using the same procedure that was used to generate Figure
4.4. We observed that decreasing amplitude from 100 molecules of pSTAT3 to 10 molecules
shifted the I and A curves to the left without significantly altering their shape (Figure 4.5). The
effects of amplitude modification can be observed within the crossover region from the
115
inflammatory to anti-inflammatory response in that a 10-fold decrease in signal amplitude would
shift the crossover from occurring at a degradation rate of 0.01 min to 0.001 min~'. The
production of A is entirely signal dependent, so significant decreases in the amount of pSTAT3
molecules translates into significant decreases in the amount of A molecules produced during the
lifetime of the signal. As the number of A molecules is reduced, I is less regulated and will
eventually win out. The effect of reducing pSTAT3 on the number of A molecules produced
during the lifetime of the signal can partially be compensated for by increasing the lifetime of the
signal, i.e. decreasing kdeg,T, which accounts for the shift in the curves to the left. The crossover
region is susceptible to these effects since it is at the edges of the inflammatory and anti-
inflammatory response regimes.
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Figure 4.5. Altering the initial signal amplitude shifts the 1 and A curves, but does not affect
their shape. The four sets of curves were generated using initial concentrations of 10, 20, 50, and
100 molecules of pSTAT3, respectively. For each initial concentration, the maximum amount of
I and A observed in 1000 time course trajectories measured out to 2000 min was compared to an
arbitrary threshold and the percentage of trajectories crossing the threshold was computed for a
wide range of signal degradation rates. The I threshold was set to 100 molecules, while the A
116
threshold was set to 20 molecules. Parameters for the model were obtained from Table 4.1
unless otherwise noted.
Amplitude modification also affects significantly transient signals (keeg,T> 0.1 min-1) by shifting
the region of bistability to lower kdegT values as amplitude is decreased. As an example,
consider a kdeg,T value of 0.2 min-1 . At an amplitude of 100 pSTAT3 molecules, 100% of cells
assayed would exhibit an inflammatory response. With a 10-fold decrease in amplitude, 50% of
cells would exhibit an inflammatory response, while the other 50% of cells would exhibit no
response. Therefore, amplitude only affects the number of cells exhibiting a given response for
transient signals, but does not affect the type of response. The shift in the bistable region is also
due to the fact that a decrease in signal amplitude can be partially compensated for by increasing
the lifetime of thc signal. Highly transient, low amplitude signals do not lead to any response
since they do not have enough strength to kick off the positive feedback loop. Signals that are
moderately sustained (kdeg,1<0.001 min-) or moderately transient (0.1 < kdeg,T < 0.01), are
unaffected by these changes in amplitude.
Decreasing the amplitude to five or less leads to both inflammatory and anti-inflammatory
responses for sustained signals in some of the trajectories, unless the threshold for an
inflammatory response is increased from that used to generate Figure 4.5 (data not shown).
Since the transcription rate of I is faster than A, I is able to kick off the positive feedback loop
before appreciable amounts of A are produced in some of the trajectories. At later times when
appreciable amounts of A are produced, the I signal shuts down but had already crossed the
inflammatory response threshold leading to an observed inflammatory response starting at early
times also an anti-inflammatory response at later times.
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4.3.4 Model predicts that IL-6 will promote an anti-inflammatory response in SOCS-/- cells
Another key difference between the IL-1 OR and the IL-6R, besides their differing interactions
with SOCS3, is that the IL-IOR has two motifs for STAT3 activation while the gp130 subunit of
the IL-6R has four, leading to the IL-6R inducing a higher amplitude STAT3 signal (13,23,24).
Given that IL-6 induces a higher amplitude signal than IL-10, one could conclude that strong
signals induce an inflammatory response, while weak signals induce an anti-inflammatory
response. In this definition of signal strength, amplitude is the defining feature. If an experiment
were performed where SOCS3 was no longer able to inhibit IL-6 signaling, the high amplitude
signal would go from being transient to sustained, and thus would have even higher signal
strength than before. Thinking about this problem in terms of signal strength, one would predict
that IL-6 would still induce an inflammatory response when SOCS3 inhibition has been
removed.
A revealing experiment performed by Yasukawa et. al. in which they exposed SOCS3-/-
macrophages to IL-6 and LPS and measured the concentration of two pro-inflammatory
cytokines (TNF and IL-12(p40)) in the supernatant showed just the opposite (12). LPS induces
an inflammatory response in macrophages, so a decrease in inflammatory cytokine production
would be considered anti-inflammatory. As the dosage of IL-6 was increased, the pro-
inflammatory cytokine concentration dropped meaning that IL-6 was acting as an anti-
inflammatory cytokine on the SOCS3-/- macrophages. This puzzling result cannot be explained
by a signal strength model where signal strength is essentially just a measure of the amplitude of
the signal.
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Our model is capable of making a prediction for how IL-6 will act on SOCS3-/- by making very
few assumptions. We assume that IL-6 induces a moderately transient pSTAT3 signal that can
roughly be approximated by a kdeg,T value of 0.1 min-' in WT macrophages. The second
assumption is that IL-10 induces a slowly decaying pSTAT3 signal that can be approximated by
a kdeg,T value of 0.003 min' in both SOCS3-/- and WT macrophages. IL-6 and IL-10 would
conceivably induce similarly decaying pSTAT3 signals in SOC3-/- macrophages, so we can use
the same kdeg,T value. In their experiment, Yasukawa et. al. measure concentrations of secreted
inflammatory cytokines, which in our model translates to counting the percentage of trajectories
(cells) that cross the imposed threshold value of I at any point for a set value of kdegT, which is
characteristic to the macrophage type and the type of cytokine added along with LPS. By
carrying out this analysis for a variety of initial amplitudes, we can make a prediction about how
the macrophages will respond to increasing dosages of either IL-6 or IL-10. Since LPS induces
an inflammatory response on its own, it is assumed that 100% of the cells would be pro-
inflammatory in the absence of IL-6 and IL-10. Therefore, until a large enough amplitude is
reached where gene A can cause a drop in the number of trajectories which cross the threshold
value of I, it is assumed that all the cells will remain pro-inflammatory.
Using these assumptions, it is clear that the model predicts IL-6 will be anti-inflammatory when
acting on SOCS3-/- macrophages (Figure 4.6). The model also captures the observed
phenomenon that as the pSTAT3 amplitude is increased (i.e. the IL-6 dose is increased), IL-6 has
a stronger anti-inflammatory effect. Since there is no distinction between IL-10 acting on
SOCS3-/- or WT macrophages, the model predicts that no distinction will be seen
experimentally, as was observed (12). For transient signals, the model predicts a pro-
inflammatory response, which is why the percentage of inflammatory cells remains at 100% for
119
all amplitudes when WT macrophages are exposed to IL-6. If it were IL-6 alone, there would be
a ramping up of the percentage of inflammatory cells at low amplitudes since a basal level of
signaling is required to initial the positive feedback loop. However, since LPS induces an
inflammatory response on its own, the ramping up period is not observed in the figure. There is
no amplitude range for transient signals where A is capable of decreasing the percentage of
inflammatory cells.
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Figure 4.6. Model predicts that IL-6 will be anti-inflammatory in SOCS3-/- cells when given
some inflammatory stimulus such as LPS for most pSTAT3 signal amplitudes. (A) Percentage
of inflammatory cells predicted for transient pSTAT3 signals (WT) and sustained signals
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(SOCS3-/-) when the cells are exposed to LPS and IL-6. The value Of kdeg,T used to represent the
WT condition was 0.1 min', while a kdeg,T value of 0.003 min-r was used to represent the
SOCS3-/- condition. (B) Percentage of inflammatory cells predicted for sustained pSTAT3
signals (WT and SOCS3-/-) when the cells are exposed to LPS and IL-10. The value of kdeg,T
used to represent these conditions was 0.003 min-. For each initial concentration of pSTAT3,
the maximum amount of I observed in 1000 time course trajectories measured out to 2000 min
was recorded and the percentage of trajectories crossing the inflammatory threshold (100 I
molecules) was determined for a value of kdeg,T corresponding to the signal duration expected for
each condition. Parameters for the model were obtained from Table 4.1 unless otherwise noted.
Yoshimura (10) has proposed that sustained STAT3 signals are essential for anti-inflammatory
responses while transient signals promote inflammation, which is consistent with our model.
The model serves as a tool for visualizing how the duration of the signal can lead to two different
responses from the same genetic network activated by the same transcription factor from two
different pathways. As further evidence of signal duration being a defining feature in
determining the inflammatory response, El Kasmi et. al. also developed a system for analyzing
this problem(1 3). They transfected macrophages with an altered form of the EPO receptor
(EPOR) that activated STAT3 and was not susceptible to SOCS3 inhibition. The unaltered form
of the EPOR activates STAT5. This altered form of the EPOR induced an anti-inflammatory
response indistinguishable from IL-10, which also supports the hypothesis that signal duration is
a determinant of whether or not a response is inflammatory or anti-inflammatory (13).
While it is true that many different cytokines activate STAT3 that may or may not induce an
inflammatory or anti-inflammatory response, often these cytokines activate multiple STAT
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molecules, such as STAT! or STAT5, in addition to STAT3. It is beyond the scope of this
analysis to determine how genes activated by other STATs affect the decision to be pro-
inflammatory or anti-inflammatory. Since different STATs can be activated by the same
receptor, heterodimer formation may be prevalent and it is difficult to predict how this may
impact a network with this structure.
One could argue that the proposed transcriptional network model cannot easily account for
common gene expression. The key wiring in our model that makes it sensitive to changes in
signal duration is the positive and negative feedback loops. Common genes would not
necessarily need to have the same wiring as the anti-inflammatory / inflammatory genes. As an
example, consider the example of a common gene C that is also induced by pSTAT3. If this
gene had a positive feedback loop, significant amounts of C would be produced from both
transient and sustained signals. Even in the absence of a positive feedback loop, a transient
signal still could produce significant amounts of C for high amplitude signals and low values of
the C degradation / deactivation.
We have provided the structure of a gene transcriptional network which is sensitive to changes in
signal duration. The essential feature of the model is that both genes of interest are activated by
the same transcription factor and that one of the genes has a positive feedback loop to sustain
itself in the absence of the main signal, but is also negatively regulated by the opposing gene.
Even though the model was presented in the context of IL-6 / IL-10 signaling, it may be
applicable to a range of biological networks which are sensitive to signal duration. Though most
genetic networks are highly complex, this may be an underlying basic structure. We believe that
the model may be applicable to IL-6 / IL-10 signaling since all essential steps of the model have
been observed except for the positive feedback loop, namely that STAT3 induces both
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inflammatory and anti-inflammatory genes and that the anti-inflammatory genes inhibit the
inflammatory genes. Experimentation would be necessary to identify a positive feedback loop in
the inflammatory gene network in order for the model to be fully validated. Bioinformatic
techniques could be used to determine whether inflammatory genes have the potential to bind to
the promoter region of other inflammatory genes. Gene array analysis could then be used to
verify the binding. Mutations to these promoter sites could then be used to knockout the positive
feedback loop. Our model would then predict that IL-6 would not be able to induce an
inflammatory response (Figure A4.2). Further analysis will be necessary to identify more
systems where the model is applicable.
4.4 References
1. Miller MR, Rao A (2010) NFAT, immunity and cancer: a transcription factor comes of age.
Nat Rev Immunol 10:645-656.
2. Li Q, Verma IM (2002) NF-KB regulation in the immune system. Nat Rev Immunol 2:725-734.
3. Boros J, Donaldson IJ, O'Donnell A, Odrowaz ZA, Zeef L, et al. (2009) Elucidation of the
ELKI target gene network reveals a role in the coordinate regulation of core components of the
gene regulatory machinery. Genome Res 19:1963-1973.
4. Murray PJ (2007) The JAK-STAT signaling pathway: input and output integration. J
Immunol 178:2623-2629
5. Okkenhaug K, Vanhaesebroeck B (2003) P13K in lymphocyte development, differentiation,
and activation. Nat Rev Immunol 3:317-330.
6. Marshall CJ (1995) Specificity of receptor tyrosine kinase signaling: transient versus sustained
extracellular signal-regulated kinase activation. Cell 80:179-185.
7. Kholodenko BN (2007) Untangling the signaling wires. Nat Cell Biol 9:247-249.
8. Santos SDM, Verveer P, Bastiaens PIH (2007) Growth factor-induced MAPK network
topology shapes Erk response determining PC- 12 cell fate. Nat Cell Biol 9:324-330.
9. Murphy LO, MacKeigan JP, Blenis J (2004) Molecular interpretation of ERK signal duration
by immediate early gene products. Mol Cell Biol 24:144-153.
123
10. Yoshimura A, Naka T, Kubo M (2007) SOCS proteins, cytokine signaling and immune
regulation. Nat Rev Immunol 7:454-465.
11. Murray PJ (2005) The primary mechanism of the IL-10-regulated anti-inflammatory
response is to selectively inhibit transcription. Proc NatlAcadSci USA 102:8686-8691.
12. Yasukawa H, Ohishi M, Mori H, Murakami M, Chinen T, et al. (2003) IL-6 induces an anti-
inflammatory response in the absence of SOCS3 in macrophages. Nat Immunol 4:551-556.
13. El Kasmi KC, Holst J, Coffre M, Mielke L, de Pauw A, et al. (2006) General nature of the
STAT3-activated anti-inflammatory response. JImmunol 177:7880-7888.
14. Behar M, Dohiman HG, Elston TC (2007) Kinetic insulation as an effective mechanism for
achieving pathway specificity in intracellular signaling networks. Proc Natl Acad Sci U S A
104:16146-16151.
15. Behar M, Hao N, Dohlman HG, Elston TC (2007) Mathematical and computational analysis
of adaptation via feedback inhibition in signal transduction pathways. Biophys J93:806-821.
16. Gillespie DT (1977) Exact stochastic simulation of coupled chemical reactions. JPhys Chem
81:2340-2361.
17. Artyomov MN, Das J, Kardar M, Chakraborty AK (2007) Purely stochastic binary decisions
in cell signaling models without underlying deterministic bistabilities. Proc Natl Acad Sci USA
104:18958-18963.
18. McClean MN, Mody A, Broach JR, Ramanathan S (2007) Cross-talk and decision making in
MAP kinase pathways. Nat Gen 39:409-414.
19. Losick R, Desplan C (2008) Stochasticity and cell fate. Science 320:65-68.
20. Das J, Ho M, Zikherman J, Govern C, Yang M, et al. (2009) Digital signaling and hysteresis
characterize Ras activation in lymphoid cells. Cell 136:337-351.
21. Sun H, Charles CH, Lau LF, Tonks NK (1993) MKP-1 (3CH134), an immediate early gene
product, is a dual specificity phosphatase that dephosphorylates MAP kinase in vivo. Cell
75:487-493
22. Bettelli E, Carrier Y, Gao W, Korn T, Strom T, et al. (2006) Reciprocal developmental
pathways for the generation of pathogenic effector Thl7 and regulatory T cells. Nature 441:235-
238.
23. Moore KW, de Waal Malefyt R, Coffman RL, O'Garra, A (2001) Interleukin-10 and the
interleukin-10 receptor. Annu Rev Immunol 19:683-765.
124
24. Kamimura D, Ishihara K, Hirano, T (2003) IL-6 signal transduction and its physiological
roles: the signal orchestration model. Rev Physiol Biochem Pharmacol 149:1-38.
125
Chapter 5: Signal specificity amongst STATI and STAT3 inducing
cytokines in the context of Th17 differentiation
Portions reprinted from "Clever Title About Signal Specificity" by Kevin D. Fowler, Anneli
Peters, and Vijay K. Kuchroo, In preparation.
5.1 Introduction
Key orchestrators of the adaptive immune system are CD4+ T cells. Depending on activation
conditions and the cytokine milieu, these cells can differentiate into a variety of effector cells
which are often characterized by the cytokines that they secrete. It was originally believed that
there were two types of effector cells, ThI and Th2 cells". It was later discovered in the
context of autoimmune inflammation that there was another lineage of effector cells, Thl7 cells3'
45. These pro-inflammatory effector cells can be induced in vitro by culturing naYve CD4+ T
cells under activating conditions in the presence of Interleukin-6 (IL-6) and transforming growth
factor-p (TGF-p)6,7 . How these two pathways overlap to lead to the induction of the Thl7
differentiation program remains an outstanding problem in the field of immunology. The first
place to look for overlap between the two cytokines is at the membrane-proximal signaling level.
IL-6 primarily signals through the JAK/STAT pathway8 while TGF-p signals primarily through
the SMAD pathway9 , so there is no obvious overlap in their signaling pathways.
IL-6 is thought to primarily activate Signal Transducer and Activator of Transcription-3
(STAT3)10 , so it is likely that its primary input to the genetic network governing Thl7
differentiation is STAT3. It has been shown quite clearly that STAT3 is necessary for induction
of Thl7 cells as evidenced by a nearly complete loss of IL-17 secretion in its absence". IL-6 is
just one of a number of cytokines that activate STAT3, but yet it remains the most potent inducer
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of IL-17 producing cells. IL-10, an anti-inflammatory cytokine, induces pSTAT3 (the active
form of STAT3) 1, . IL-21 activates STAT3 14 and induces weak, but noticeable, IL- 17
secretion in the presence of TGF-p1 . IL-27 is an anti-inflammatory cytokine16' 17, 18 which
activates STAT319 and is a potent inhibitor of Thl7 differentiation.
How four different STAT3-inducing cytokines can cause such a large range of effects on ThI7
differentiation is another standing question in the field22 . There is another STAT protein induced
by these four cytokines, STAT 122, which adds another layer of complexity to their signaling
pathways and may help account for the differences observed. It has been shown that IL-27
completely loses its ability to inhibit Thl7 differentiation in STATI knockout mice (SIKO)20 ,2 2.
Therefore STAT I must be an inhibitory transcription factor in the Thl 7 differentiation pathway.
A simple theory to account for all of these observations would be that IL-6 induces mostly
pSTAT3, IL-27 induces mostly pSTATI, and IL-21 and IL-10 induce some combination of the
two. One way to test this theory would be to comparatively measure STATI and STAT3
activation amongst the four cytokines. Previous studies have used Western blots or flow
cytometry to measure STAT activation by IL-2123 , IL-6 and IL-10 12, 24, and IL-6 and IL-2719, in
a variety of cell types, but not in the same study or same cell type so it is impossible to compare
the amplitude of STAT activation for all four cytokines.
We sought to investigate the issue of cytokine specificity in the context of Th 17 differentiation
by measuring the STAT I and STAT3 activation profiles for the four different cytokines of
interest (IL-6, IL-10, IL-21, and IL-27) in a systematic way. After obtaining the single cytokine
activation profiles, we will measure the activation profiles for pairs of cytokines to see how the
single cytokine profiles would change upon addition of other cytokines. Next, we see how the
STAT3 activation profiles change for some cytokines in the absence of STATI. These three
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experiments combined will allow us to see how different STATI and STAT3 activation profiles
affect Th 17 differentiation and ultimately allow us to assess how the cytokines of interest can
behave differently despite activating the same two transcription factors.
5.2 Results
5.2.1 Normalization method allows for cytokine comparison
We sought to find a method which would allow us to reproducibly and reliably characterize the
signaling pathways of four cytokines of interest (IL-6, IL-10, IL-21, and IL-27) at early times in
order to gain insight into why the cytokines behave differently despite activating the same two
transcription factors, STATI and STAT3. Measurements of pSTATI and pSTAT3 levels were
made only during the first 3-4 hours for two reasons. First, we wanted to be able to isolate CD4+
T cells, culture them with the various cytokines, stain the cells, and measure the STAT activation
using FACS comfortably in one day, which less than 3-4 hrs of cytokine stimulation allowed.
Second, we wanted to be sure that the STAT activation levels were entirely attributable to the
cytokine of interest and not the sum of activation by the cytokine of interest and other
uncontrolled amounts of secreted cytokines. Measuring at times less than 3-4 hours allowed us
to comfortably neglect the effect of secreted cytokines. While in culture with the various
cytokines, the cells were also exposed to plate-bound a-CD3 / a-CD28 since we were ultimately
interested in comparing these cytokines of interest in the context of Th 17 differentiation, which
requires the presence of TCR stimulation.
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Given all of the conditions we sought to measure to perform a good comparison of the
differences in STAT activation amongst the cytokines of interest, it became apparent that using
Western Blots would not be feasible. The measurement of band intensity is only semi-
quantitative and it would be impossible to put all the conditions onto one membrane to allow for
a good comparison. While it may be feasible to devise a way to normalize using some standard
blot intensity, it was clear that flow cytometry was the better choice due to ease of measurement
and the availability of a more quantitative result. It was impractical to do all of the flow
cytometry measurements in one day so we devised a way to put all of our data collected over
several months of separate experiments onto the same curve. Using the MFI (mean fluorescence
intensity), we were able to extract just one number from each FACS measurement that could be
plotted and compared to other samples. Daily variations in FACS measurements and mouse to
mouse variations could be corrected for by measuring a set condition which gave a high signal
and a set condition which gave a basal signal every day that measurements were taken. After
taking measurements at numerous conditions, it became clear that the maximum signal obtained
for both pSTATI and pSTAT3 was from cells that received 15 minutes of IL-6 stimulation while
the minimum observed signal for both pSTATs was from unstimulated cells (Figure 5.1).
Therefore, in every experiment we always had at least 2 wells of cells that received 15 minutes
of IL-6 stimulation and 2 wells of cells that received no supplemental cytokine stimulation. That
days measurements could then be normalized to all other measurements using Equation 5.1.
Normalized pSTAT = 100 * (MFISample-MFIUntreated) (Equation 5.1(MFlIL6,15min-MFIUntreated)
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In each experiment, IL-6 at 15 minutes will have a value of 100 for both pSTAT1 and pSTAT3,
whereas a value of 0 indicates a basal level of STAT activation. It is important to note that
pSTATI and pSTAT3 are normalized using different values so a value of 100 for pSTATI and a
value of 100 for pSTAT3 does not necessarily indicate that there are equivalent levels of the two
transcription factors at the molecular level. The values observed for MFIIL6,15min / MFluntreated
were typically 1.5-2.0 for pSTAT3 and 8.0-15.0 for pSTATI. As a result, significantly less
variation was observed in the normalized pSTATl measurement since there was much greater
separation between the max signal and the background than that observed with pSTAT3.
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Figure 5.1. Maximum observed signal to noise ratios for pSTATI and pSTAT3. (a,b) Flow
cytometry measurement of (a) pSTAT3 and (b) pSTATI in bulk CD4+ T cells purified from the
lymph nodes and spleen after being cultured with a-CD3 / a-CD28 for one hour and then IL-6 or
no cytokine for 15 minutes. Results are representative of multiple experiments.
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5.2.2 Cytokines induce different STAT activation profiles
STAT activation profiles for the different cytokines of interest were measured and normalized
using the method described in the previous section. There are a couple ways that the data can be
visualized. One way is to compare the cytokines' activation of STATI and STAT3 separately
(Figure 5.2). Another way is to create a "fingerprint" of a given cytokine's signaling pattern by
plotting the time course of pSTATI and pSTAT3 levels on the same graph and then comparing
the fingerprints of the various cytokines (Figure 5.3).
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Figure 5.2. Cytokines of interest induce different time course profiles of pSTATI and pSTAT3.
(a,b) Flow cytometry measurement of (a) pSTAT3 and (b) pSTAT1 in bulk CD4+ T cells and in
some experiments sorted naive CD4+ T cells (CD4+CD25-CD62LHI) purified from the lymph
nodes and spleen after being cultured with a-CD3 / a-CD28 for one hour and then IL-6 (10
ng/mL), IL-10 (10 ng/mL), IL-21 (20 ng/mL), or IL-27 (25 ng/mL) at different time points for up
to 4 hours . Results are the averages of all of the MFIs (mean fluorescence intensities) measured
at a given time point and a given condition, which have been normalized using Equation 5.1
using the MFI of either (a) pSTAT3 or (b) pSTATI induced by IL-6 at 15 minutes on the day
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that a given data point was collected. Data points were collected over the course of several
months and the average MFIs for a given point are the average of anywhere from 4 to 13
measurements.
IL-6 clearly induces the most pSTAT3 out of the 4 cytokines at all time points measured in the
first 4 hours (Figure 5.2A). Comparatively, IL-21 activates roughly half the amount of STAT3
during that time period. IL-27 has a peak activation of STAT3 at 15-30 minutes reaching
roughly 33% of that activated by IL-6 at those time points. IL-27's activation of STAT3 then
drops off to basal levels steadily during the remainder of the first two hours. Given that STAT3
is vital to Thl7 differentiation 1 , it is logical that IL-6 is the best inducer of Thl7 cells (in
combination with TGF-P) since it induces the most pSTAT3. IL-21 is a weak inducer of Thl7
cells and it induces roughly half the amount of pSTAT3 as IL-6. IL-10 and IL-27 do not induce
Thl7 cells and they had the lowest induction of pSTAT3. Perhaps there is simply a threshold of
pSTAT3 induction below that of IL-21 and above that of IL-27 which allows a cytokine to
induce Thl7 cells.
Before these experiments, it was generally believed that IL-27 is a strong inducer of pSTATI
which accounts for its inhibitory effects on Thl7 differentiation since IL-27 does not inhibit
Thl 7 differentiation in STA T1-/- mice2 0' 22 . Thus we were surprised to observe that IL-6 induced
more pSTATI at almost all time points in the first 4 hours than IL-27 (Figure 5.2B). At its peak
induction of pSTATI at 15 minutes, IL-27 only induced roughly 60% of the amount induced by
IL-6. This raises an important question. If pSTAT1 is inhibitory of Thl7 differentiation, how
can IL-6 induce the most pSTATl and still be able to be a strong inducer of Thl7 cells.
Visualizing the data in the form of cytokine fingerprints can possibly assist in addressing this
question. For completeness, IL-21 induced relatively small amounts of pSTATI and IL-10
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induced only trace amounts. Given that IL-10 did not produce very strong measurements of
either pSTATJ or pSTAT3, and since its effects on Thl7 differentiation was not known, we
chose to discontinue our analysis of IL-10 in this study.
Visualizing the data as cytokine fingerprints allows for a comparison of the relative amounts of
pSTAT3 and pSTATl induced at all the time points for a given cytokine (Figure 5.3). Though it
was described in the previous section that the values of pSTAT1 and pSTAT3 cannot be directly
compared, it is still instructive to plot them on the same curve. Regardless of the absolute
number of STATI or STAT3 molecules, it is still valid to compare the ratio of pSTAT3 and
pSTATI over time between the different cytokines since all the data has been normalized the
same way. On this scale, IL-6 has a pSTAT3:pSTATl ratio of 1 at 15 minutes. At all time
points after that, the ratio of pSTAT3:pSTATI increases to 5 at 3 hours. IL-21 has a
pSTAT3:pSTATI ratio of 2 to 3 during the first 3 hours. On this scale, IL-27 was the only
cytokine to have a higher amount of pSTATl than pSTAT3 at any time point. In fact, at all time
points it has more pSTATI than pSTAT3. These observations suggest that the ratio of pSTAT3
to pSTATI is an important quantity in determining whether or not a cytokine will induce Th17
differentiation since on this particular scale, the two cytokines which have a ratio of
pSTAT3:pSTATJ that is greater than I at most or all time points (IL-6 and IL-21) promote Thl7
differentiation while the cytokine which had a ratio of pSTAT3:pSTAT less than I at all time
points inhibits Th 17 differentiation.
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Figure 5.3. Cytokine fingerprints illustrate how the relative amounts of pSTATI and pSTAT3
vary over the first 4 hours. (a,b,c) Flow cytometry measurement of pSTAT3 and pSTATI in
bulk CD4+ T cells and in some experiments sorted naive CD4+ T cells (CD4+CD25-CD62LHI)
purified from the lymph nodes and spleen after being cultured with a-CD3 / a-CD28 for one
hour and then (a) IL-6 (10 ng/mL), (b) IL-21 (20 ng/mL), or (c) IL-27 (25 ng/mL) at different
time points for up to 4 hours . Results are the averages of all of the MFIs (mean fluorescence
intensities) measured at a given time point and a given condition, which have been normalized
using Equation 5.1 using the MFI of either pSTAT3 or pSTAT1 induced by IL-6 at 15 minutes
on the day that a given data point was collected. Data points were collected over the course of
several months and the average MFIs for a given point are the average of anywhere from 4 to 13
measurements.
5.2.3 Ratio of pSTAT1 to pSTAT3 determines whether or not a pair of cytokines inhibits or
induces Th17 cells
To further investigate the impact of the ratio of pSTAT3:pSTATI on a cytokines ability to
induce Thl7 differentiation, we began looking at STAT activation profiles for pairs of cytokines.
We were interested in the STAT activation profiles for pairs of cytokines for three reasons. First,
in experiments which show that IL-27 inhibits Thl7 differentiation, IL-27 is added in addition to
IL-6 and TGF-p at time 0. Therefore, the cell is exposed to both IL-6 and IL-27 at the same
time, so their individual profiles are not directly applicable. Second, we can possibly gain some
mechanistic insight by seeing how individual profiles add. If the sum of the individual profiles
does not equal that of the cytokine pair's profile, then there is either a saturating effect or there
could be some inhibition. Finally, by looking at cytokine pairs, it gives us additional profiles
which we can then compare to see which profiles lead to Thl7 differentiation and which do not.
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We measured the fingerprints of IL-6 (Figure 5.4A), IL-6 with IL-21 (Figure 5.4B), and IL-6
with IL-27 (Figure 5.4C). All measurements were normalized as before with untreated cells as
the baseline and IL-6 at 15 minutes as the maximum. One consequence of this was that it was
possible for the pairs of cytokines to induce pSTATs with values higher than 100 if the profiles
were at all additive since IL-6 is present in all pairs and they are normalized to IL-6 at 15
minutes. The addition of either IL-21 or IL-27 to IL-6 increased the value of pSTATI over 100
at 15 minutes and shifted the IL-6 alone curve upwards in value at all time points while still
maintaining the same shape. Interestingly, the pSTATI profiles for IL-6 with IL-21 and IL-6
with IL-27 are nearly identical. Since it was known that IL-27 inhibits Thl7 differentiation, we
hypothesized that adding IL-21 at time 0 may also inhibit differentiation due to the similarity in
pSTATI profiles. We measured IL-17a producing CD4+ T cells using FACS for TGF-p with
IL-6 (Figure 5.4D), TGF-p with IL-6 and IL-21 (Figure 5.4E), and TGF-p with IL-6 and IL-27
(Figure 5.4F). All samples received IL-23 at 48 hours and were collected on day 4, restimulated
with PMA and lonomycin, and stained for intracellular cytokines. It is quite clear from these
measurements that IL-27 is a potent inhibitor of Thl7 differentiation, while IL-21 does not
inhibit. How can this be when they have almost identical pSTATi profiles?
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Figure 5.4. The ratio of pSTAT 1 to pSTAT3 induced is important in determining whether or not
a pair of cytokines inhibit or induce Th17 differentiation. (a,b,c) Flow cytometry measurement
of pSTAT3 and pSTATI in bulk CD4+ T cells and in some experiments sorted naive CD4+ T
cells (CD4+CD25-CD62LHI) purified from the lymph nodes and spleen after being cultured with
a-CD3 / a-CD28 for one hour and then (a) IL-6 (10 ng/mL), (b) IL-6 (10 ng/mL) and IL-21 (20
ng/mL), or (c) IL-6 (10 ng/mL) and IL-27 (25 ng/mL) at different time points for up to 4 hours .
Results are the averages of all of the MFIs (mean fluorescence intensities) measured at a given
time point and a given condition, which have been normalized using Equation 5.1 using the MFI
of either pSTAT3 or pSTATI induced by IL-6 at 15 minutes on the day that a given data point
was collected. Data points were collected over the course of several months and the average
MFIs for a given point are the average of anywhere from 4 to 13 measurements. (d,e,f) Flow
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cytometry of naive CD4+ T cells cultured for 4 d in the presence of (d) IL-6 or (e) IL-6 and IL-
21 or (f) IL-6 and IL-27, TGF-p, anti-IL-4 and anti-IFN-7 with subsequent IL-23 treatment at 48
h, then stimulated for 4 h with PMA and ionomycin, followed by intracellular cytokine staining
with anti-IL-I 7A and anti-CD4.
The answer can likely be obtained by observing the relative pSTAT3 profiles. The addition of
IL-21 to IL-6 shifts the pSTAT3 curve upward, while the addition of IL-27 to IL-6 shifts the
pSTAT3 curve downward. In the case of adding IL-21 to IL-6, both pSTATl and pSTAT3 are
shifted upwards resulting in a similar pSTAT3:pSTATl ratio for most times to that of IL-6
alone. When IL-27 is added to IL-6, pSTATI is shifted upward and pSTAT3 is shifted
downward resulting in a significant change in the pSTAT3:pSTATI ratio. Thus looking at just
the pSTATI curve alone is misleading since one would infer that IL-21 should be inhibitory to
Thl7 differentiation. This experiment further suggests that he ratio of nSTAT3:pSTAT1 is what
is important and not just the individual profiles themselves.
5.2.4 IL-6 and IL-27 induce similar pSTAT3 profiles in STA Ti-- T cells
It has been shown that IL-27 is unable to inhibit Th17 differentiation in STAT1-/- (SIKO) T cells
since cells stimulated with TGF-p, IL-6, and IL-27 gives a very similar percentage of IL-17
producing cells when compared to TGF-P and IL-6 alone 20,22. Based on our previous results and
given the similarity in Thl7 induction, we expected IL-6 with and without IL-27 to induce
similar pSTAT3 profiles in SIKO T cells. To test this, we measured pSTAT3 in wild-type (WT)
(Figure 5.5A) and SIKO (Figure 5.5B) T cells after stimulation with either IL-6, IL-27, or IL-6
and IL-27 for up to 3 hours. In WT cells, IL-6 induced the most pSTAT3 at all times and IL-27
induced the least amount of pSTAT3. As early as 15 minutes, less pSTAT3 was observed upon
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addition of IL-27 to IL-6. The IL-6 with IL-27 time course of activation for STAT3 fell in
between the time courses of activation by the cytokines alone. However, as predicted in SiKO
cells, the STAT3 activation profiles for IL-6 and IL-6 with IL-27 are quite similar implying that
the presence of STATI is somehow able to reduce the level of activation of STAT3. Another
observation that can be made is that IL-27 induces a similar, albeit slightly less, amount of
pSTAT3 in SIKO compared to the other two conditions. In the absence of STAT1, the ratio
pSTAT3:pSTATl is no longer relevant. As suggested by Figure 5.2A, the absolute level of
pSTAT3 induced may correlate with Thl7 differentiation.
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Figure 5.5. IL-6 and IL-27 induce similar pSTAT3 profiles in STAT1-/- T cells. (a,b) Flow
cytometry measurement of pSTAT3 and pSTATl in sorted naYve CD4+ T cells (CD4+CD25-
CD62L H) purified from the lymph nodes and spleen of either (a) 129S6/SvEvTac mice (WT) or
(b) 129S6/SvEv-Statl(tml Rds) mice (SIKO) after being cultured with a-CD3 / a-CD28 for one
hour and then IL-6 (10 ng/mL), or IL-27 (25 ng/mL), or IL-6 (10 ng/mL) and IL-27 (25 ng/mL)
at different time points for up to 3 hours. Results are the MFIs (mean fluorescence intensities)
measured at a given time point and a given condition, which have been normalized using
Equation 5.1 using the MFI of either pSTAT3 or pSTAT1 induced by IL-6 at 15 minutes.
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5.2.5 IL-27 with TGFp induces Thl7 cells in STA TI-1- T cells
Given the similarity between the pSTAT3 profiles induced by IL-6 and IL-27, we predicted that
in the absence of STATI IL-27 could induce Th17 differentiation when combined with TGF-p.
If correct, this would be quite surprising since both TGF-p and IL-27 are anti-inflammatory
cytokines, so it defies conventional logic that in the absence of one gene, STAT1, these two
could induce a highly inflammatory cell type, Thl7. To test our prediction, we cultured naYve
CD4+ T cells (CD4+CD25-CD62L') from either WT or SIKO mice with APCs and with either
no cytokines (ThO), TGF-p and IL-6, TGF-P and IL-27, or TGF-p and IL-6 and IL-27, for 4
days,(I did not put any IL-23). At the end of the 4 days, the cells were stimulated with PMA and
lonomycin for 3.5 hours and then stained for intracellular cytokines (Figure 5.6A). RNA from a
portion of the cells collected at 4 days for all conditions was used in a TaqMan real-time PCR
assay (Figure 5.6B).
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Figure 5.6. IL-27 with TGFP induces ThI7 cells in the absence of STATI. (A) Sorted naive
CD4+ T cells from 129S6/SvEvTac mice (WT) or 129S6/SvEv-Statl(tmlRds) mice (SIKO)
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were cultured for 4 d in the presence of IL-6+TGF-p, IL-27+TGF-p, IL-6+IL-27+TGF-p, or no
cytokines (ThO), and then stimulated for 3.5 h with PMA and ionomycin. Cytokine production
was measured by intracellular cytokine staining with anti-IL-I 7A and anti-IFNy and subsequent
flow cytometry. (B) mRNA levels of IL-I 7a were measured by Taqman PCR for cells collected
under the same conditions as (A). Data are representative of (A) 2 independent experiments or
(B) 3 independent experiments.
As previously observed in other studies, IL-27 potently inhibits Thi 7 differentiation in WT cells,
but has no effect in S1KO cells 20, 22 (Figure 5.6A). In WT cells, IL-27 and TGF- do not induce
any Thl7 cells. However, IL-27 and TGF-p induce a substantial portion of ThI7 cells in the
SI KO cells as we predicted from observing the pSTAT3 profiles. This same result can also be
observed using real-time PCR (Figure 5.6B). This observation supports the hypothesis that
cytokines do not have an innate ability to be anti-inflammatory or pro-inflammatory. Instead
their properties can be derived based on the ratio of pSTAT3:pSTATI induced over time. Once
the ratio is skewed entirely to pSTAT3, as is the case in S1KO cells, then cytokines should
behave similarly whether or not they are regarded as anti-inflammatory or pro-inflammatory in
WT cells as long as their amplitudes of pSTAT3 induced over time is similar.
5.2.6 IL-27 exacerbates EAE in STA Ti-- mice
We sought to further study IL-27's ability to induce Thl7 cells in the presence of TGF-p by
developing an in vivo experiment. In WT mice which have been immunized to develop EAE
(Experimental Autoimmune Encephalomyelitis), injections of IL-27 will ameliorate disease.
Based on previous studies 20, 22, it would be predicted that injections of IL-27 should have no
effect on the severity of disease in immunized S1KO mice. However, if IL-27 can induce Thl7
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cells in the presence of TGF-p, then we would predict that IL-27 injections should increase the
severity of disease in these mice.
To test this prediction we immunized mice on the 129 background in order to induce EAE.
Our lab had not tried to induce EAE in mice on this background before, so we were not sure how
much peptide to inject in order to make the mice sick in a reasonable amount of time. In our first
experiment, we injected the mice with a lot of peptide in order to increase the chances of them
getting sick. We had four separate cages with 5 mice in each. Cage I contained WT mice, each
of which was injected with IL-27 every other day after immunization. Cage 2 contained SIKO
mice that also received the IL-27 injections. Cage 3 and Cage 4 contained WT and Si KO mice,
respectively, that received PBS injections. As can be seen in Figure 5.7, the WT mice on
average had scores of less than 0.5 when the experiment ended on day 15. The SKO mice
given the PBS injections got sick on day 11, while the SIKO mice given the IL-27 injections got
sick one day earlier and had died by day 15. There is not a very strong difference between the
SIKO mice receiving IL-27 versus PBS, but our results do suggest that IL-27 may make disease
worse, as predicted. However, it is apparent that we injected the mice with far too much peptide
in an effort to make them sick. This experiment will be repeated in the coming weeks, but was
not completed in time to be printed in this thesis.
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Figure 5.7. Addition of IL-27 exacerbates EAE in STAT1-/- mice. WT and STATI-/- mice were
immunized with MOG in CFA and received PT for the development of EAE. Mice were treated
with 250ng IL-27 or PBS every other day from day 0 until day 14. Data shown represent 5 mice
per group.
5.3 Discussion
We are not the first to characterize STAT activation in IL-612, 19,24, IL-'0 2 4, IL-2 123, and IL-
27 1, but we are presumably the first to systematically measure the profiles for all four cytokines
in the same study. This allowed us to be able to directly compare the signals activated by each of
the cytokines. IL-6 activated the most STAT3 of the four, followed by IL-21 which appeared to
correlate with their relative abilities to induce Th17 differentiation. In this analysis, we are
making the assumption that STAT activation in the first 4 hours is relevant in determining a
cytokine's ability to induce Th 17 differentiation, which is a several day process. However, two
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IL-6 induced genes, STAT3 and IL-21 R peak around 2 hours during Th 17 differentiation and
quickly drop off to basal levels for the remainder of the differentiation process (Chapter 6).
Therefore it is relevant to consider STAT activation at early times.
We observed that IL-6 induced the most pSTATI out of all the cytokines tested during the first
four hours. This was unexpected since IL-6 is the best inducer of Th17 cells and STAT1 is
entirely responsible for IL-27's ability to potently inhibit Thl7 differentiation' 2. This is
certainly contradictory to the theory that IL-27 induces a lot of pSTATI; therefore it is inhibitory
to Th 17 cell development. We saw that only considering the total amount of pSTATl induced
leads to faulty conclusions when we predicted that adding IL-21 to IL-6 and TGF-P would
inhibit Thl7 differentiation since the pSTATl profile for IL-6 with IL-21 is the same as the
pSTATl profile for IL-6 with IL-27. IL-21 was not inhibitory and therefore we were missing
something. When adding IL-21 to IL-6, the total amount of pSTATI induced increased, but so
did the total amount of pSTAT3. Thus, the ratio of the two did not significantly change from IL-
6 alone, so IL-21 did not change the amount of IL-17 producers induced. When adding IL-27 to
IL-6, the total amount of pSTATI is increased, while the amount of pSTAT3 is decreased,
leading to a significant change in the ratio. It would appear from this analysis that the important
variables in determining whether or not a cytokine will induce or inhibit Th 17 differentiation is
the total amount of pSTAT3 induced and the ratio of pSTAT3 to pSTATJ. Of the cytokines
tested, IL-27 was the only one which had a higher amount of pSTATI induced loosely compared
to pSTAT3 on the normalized scale.
There are actually three forms of pSTATI and pSTAT3 that can exist in the nucleus as a result of
JAK/STAT signaling. STAT proteins form dimers after they are phosphorylated which reveals a
nuclear targeting sequence that allows for transport into the nucleus. These two particular
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pSTATs can either form homodimers (pSTATI-pSTATI, pSTAT3-pSTAT3) or a heterodimer
(pSTATI-pSTAT3)26, 27, 28. Ultimately what we are alluding to when we say the ratio of
pSTAT3 to pSTATI is the resulting distribution of these three dimeric forms. Conceivably the
highest relative amount of heterodimer will be observed when pSTATl and pSTAT3 are present
near the membrane in similar quantities. The relative amount of heterodimer will decrease as
one of the STATs starts dominating in numbers over the other and the homodimeric form of the
dominant STAT will be present in the highest relative amount. An assay which allows for the
comparison of the relative amounts of transcription factors present in the nucleus is an
electrophoretic mobility shift assay (EMSA). A labeled oligonucleotide that all of the
transcription factors can bind to is necessary to allow for comparison. A part of the c-FOS
promoter referred to as the hSIE sequence29, 30 is capable of binding all 3 dimeric forms
theoretically allowing for the determination of the relative amounts present in the nucleus as has
been done in several studies26' 27, 31 We attempted to use this technique to characterize the
relative amounts of the dimeric forms induced by the different cytokines of interest, but were
unable to reliably come to any conclusions.
The observation that IL-6 and IL-27 induce similar pSTAT3 profiles in CD4+ T cells from
SIKO mice led to our prediction that IL-27 would be able to induce Thl7 differentiation in these
cells when added under activating conditions in the presence of TGF-P. Indeed, IL-27 and TGF-
p could potently induce Thl7 differentiation in the absence of STATI. IL-27 is widely observed
to be an anti-inflammatory cytokine16 , 17, 18 and an inhibitor of Thl7 differentiation 20, 22 so
according to conventional wisdom, this is a very surprising result. In order to reiterate this point,
just consider the fact that in the absence of just one transcription factor, two anti-inflammatory
cytokines (TGF-p and IL-27) when added together are capable of inducing one of the most
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inflammatory effector cells. This unexpected result of two cytokines behaving similarly in the
absence of just protein is reminiscent of two independent studies that showed that IL-6 and IL-10
induce an indistinguishable anti-inflammatory response in SOCS3-/- cells' . Combined these
two results suggest that there is likely nothing inherently special about cytokine receptor for the
cytokines of interest. In other words, induction of unique conformations of the STATs and other
unknown pathways do not need to be invoked to explain why there are circumstances where
cytokines induce similar behaviors or behave completely differently despite activating the exact
same transcription factors.
A built-in assumption in this analysis is that there are no other relevant STATS induced or
MAPK pathways activated that further account for differences. We believe that our results and
verified predictions can be explained by simply considering STATI and STAT3, but we agree
that this is a simplification. An alternative analysis of our IL-27 based induction of Thl7
differentiation is that Thl7 differentiation is more accessible in SIKO cells since IFNy, a potent
inhibitor of Thl7 differentiation and activator of STATI, is unable to inhibit these particular
cells. To test this alternative hypothesis, we measured intracellular IL-17a in IFNy-/- cells after
4 days of stimulation with IL-27 and TGF-p and saw no IL-17 producers compared to a positive
control of this type of cell that had been exposed to normal ThI7 differentiation conditions
(unpublished observation).
IL-27 injection is a viable way to inhibit EAE disease progression due its potent ability to inhibit
Thl7 differentiation. Simply based on previous results, one would conclude that in patients with
STATI defects, that IL-27 treatment would have no effect since Sl KO cells stimulated with IL-
6, IL-27, and TGF-p secrete similar amounts of IL-17 as WT cells stimulated with IL-6 and
TGF- 20, 22 However, our results would suggest that the therapy could actually exacerbate
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disease in these patients. There have been at least two reports of patients that were born with a
defect in STATI signaling . Thus if someone had this defect it would be dangerous for them
to try the therapy according to our initial EAE results.
Further experimentation is required to further understand how the ratio of pSTAT3 to pSTATI is
an important determinant of whether or not a cytokine will be an inducer or inhibitor of Th 17
differentiation. It would be a useful contribution for the field for a group with extraordinary skill
in performing EMSA assays to characterize the homodimer vs. heterodimer distribution for these
cytokines of interest. Additional experimentation will also be necessary to determine the
mechanism for how this distribution translates into induction or inhibition of the Thl7
differentiation program. We feel that this information will lead to a much better understanding
of how STAT inducing cytokines attain signal specificity.
5.4 Methods
Mice
The mice used to perform the experiments which led to Figures 1-4 were 6-8 week old C57BL/6J
mice obtained from Jackson Laboratories.
The mice used to perform the experiments in Figures 5-7 were 6-8 week old 129S6/SvEvTac
mice (WT) and 129S6/SvEv-Statl (tml Rds) mice (SI KO)34 obtained from Taconic. Mice were
housed in a specific pathogen-free, viral Ab-free animal facility at the Harvard Institutes of
Medicine. All breeding and experiments were reviewed and approved by the Institutional Animal
Care and Use Committee of Harvard Medical School.
Intracellular staining of pSTAT1 and pSTAT3
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In a given experiment, cells were plated in a 96-well plate and various wells were given
cytokines at different time points. As an example, if measurements at 30 minutes, 60 minutes,
and 90 minutes were desired in an experiment, the cytokine was added to the 90 minute wells at
time 0, to the 60 minute wells after 30 minutes, and to the 30 minute wells after 60 minutes.
This way all the cells could be collected and fixed after 90 minutes. The rest of the details can
be found in Appendix 1.
Thl7 differentiation in vitro.
Our procedure for Th 17 differentiation can be found in Appendix 1.
Real-time PCR
RNA was extracted from cells using the RNeasy Kit (Qiagen) according to the manufacturer's
instructions. 1 ptg RNA was then transcribed into cDNA using the iScriptT M cDNA Synthesis Kit
(BIO-RAD) according to the manufacturer's instructions. Quantitative PCR primers and probes
were purchased from Applied Biosystems (IL-17A: Mm00439619_ml, f-Actin: 4352341 E).
EAE
WT and STATI-/- mice were immunized s.c. with 150ug MOG35-55 in Complete Freund's
adjuvants containing 8mg/ml of Mycobacterium tuberculosis H37 RA (DIFCO Laboratories).
Mice also received 200 ng of pertussis toxin i.v. (List Biological Laboratories) on day 0 and day
2 post immunization. Mice were injected i.v. with 250 ng of recombinant murine IL-27
(BioLegend) or PBS every other day from day 0 until day 14. Mice were monitored daily for
development of disease and scored according to the following criteria: 0, no disease; 1, decreased
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tail tone; 2, hind limb weakness or partial paralysis; 3, complete hind limb paralysis; 4, front and
hind limb paralysis; 5, moribund state.
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Chapter 6: A clustering algorithm analysis of Th17 differentiation
Portions reprinted from "A clustering algorithm analysis of Thl7 differentiation" by Kevin D.
Fowler, Hulin Jin, Arup K. Chakraborty and Vijay K. Kuchroo, In preparation.
6.1 Introduction
Several years ago a new lineage of helper T cells, Thl7 cells, was discovered which brought
about a change to the classic Th1 / Th2 paradigm" . These cells were characterized by their
ability to secrete IL-17 and IL-22, as well as their highly inflammatory nature. Shortly after their
discovery, two groups concurrently determined that Th17 cells could be obtained in vitro by
adding the cytokines Interleukin-6 (IL-6) and transforming growth factor-beta (TGFp) in culture
with naYve CD4+ T cells along with some form of T cell receptor (TCR) / CD28 stimulation.
However, since their discovery, the precise mechanisms governing Th17 differentiation have
remained elusive.
To determine Th I 7-important genes, frequently researchers just measure gene expression after
differentiation. Measuring gene expression in Thl7 cells only after differentiation could miss
out on some genes of interest, since it tells us nothing about changes in gene expression
throughout the differentiation process. Thus we sought to follow all genes involved in Th17
differentiation as a function of time. It is impossible to follow the expression of all genes
continuously over several days so we needed to choose time points at which to measure. It
would be ideal to do gene array at as many time points as possible, but it is an expensive
technique so we needed to get an idea of which time points are most important. We chose to use
6
real-time PCR to measure the relative mRNA levels of five transcription factors (RORyt
RORa 6 , Cmaf7 , STAT38 , and Foxp39), six cytokines (IL-9 0 , IL-10", IL-17a", IL-17f12 , IL-21 13,
154
and IL-22 ) and two cytokine receptors (IL-21R 13 and IL-23R'), which are all genes of known
interest in Th 17 differentiation, at eighteen different time points over 4 days. While possibly not
directly linked to Thl7 differentiation, IL-10 was chosen since it is a prevalent anti-inflammatory
cytokine 1 . Our goal of these measurements was to identify time points to be used in the array in
a future study, observe the time course of transcription of numerous genes of interest, and to
determine as much information as possible from the data set using a method for determining
correlations between time series of intermediate system size, which is ideally suited to analyze
PCR time courses. Determining clusters of genes that behave similarly can give insight into the
mechanisms involved in Thl7 differentiation. Ultimately, understanding the mechanisms
governing Th17 differentiation would lead to a better understanding of inflammatory
autoimmune disease progression and would aid in the development of suitable pharmaceutical
therapies.
6.2 Methods
Mice.
C57BL/6J mice obtained from Jackson Laboratories were used in this study.
Thi 7 Differentation.
The Th 17 differentiation protocol can be found in Appendix 1.
Real-time PCR.
RNA was extracted with the RNAeasy columns (Qiagen), then cDNA was transcribed as
recommended (Applied Biosystems) and was used as template for quantitative PCR 5 .
Expression of RORyt, RORa, STAT3, Foxp3, c-MAF, IL-9, IL-10, IL-17A, IL-17F, IL-21, IL-
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22, IL-21R and IL-23R was assessed with specific primers and probes (Applied Biosystems) 5 .
The Applied Biosystems 7500 Fast system was used for Taqman analysis. Gene expression was
normalized to expression of the 'housekeeping' gene Actb (encoding p-actin or GAPDH)15 . Most
of this excerpt was taken verbatim from a previously published paper by co-author Hulin Jin' 5 .
The experiments were performed by him and because he has since moved to Germany, I was
unable to obtain the exact protocol for this thesis. However, the method presented here is what
he used.
6.3 Results
6.3.1 Normalization of real-time PCR measurement data of genes during Th17
differentiation allows for comparison of expression levels
T cells were cultured under Th17 conditions and were collected at a number of time points
during four days of differentiation. Real-time PCR was used to measure the expression of levels
of numerous genes. A wide range of relative expression between all of the genes of interest was
observed over the course of differentiation (Figure 6.1). The relative expression of IL-i 7f peaked
at close to 200,000, while the relative expression of IL-22 peaked around 25. Therefore, peak
expression levels varied as much as four orders of magnitude, making it difficult to interpret
trends in expression by plotting them all on the same graph. Several observations can be made
by plotting the time courses on four different scales of expression (Figure 6.1). The cytokines,
IL-I 7a, IL-I 7f, IL-9, and IL-21 are all expressed at higher levels than the measured transcription
factors. In general, secreted cytokines are expressed at higher levels than transcription factors,
since transcription factors can have functional relevance at low expression levels. Measurements
were made with and without IL-23 added after 48 hours, but it only made a significant impact on
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the expression of IL-23R. This implies that there is some positive feedback loop between IL-23
signaling and the expression of the IL-23R. The effects of IL-23 on all other genes of interest
are not plotted since it does not significantly affect the shape of their curves.
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Figure 6.1. Relative expression levels of the genes of interest in Th 17 differentiation plotted in
four different scales to better visualize the shapes of the trajectories. Measurements were made
using real-time PCR with the method described in the Methods section.
In addition to just looking at the profiles of all the genes of interest, we wanted a means of
observing similar trends of behavior just by looking at the curves. As previously stated, the
expression levels vary too much to compare the time courses of the different genes. It is possible
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that some highly expressed cytokine is regulated by the same machinery as a transcription factor
expressed at low levels. To compare these curves, we must normalize the data. All of the time
courses were normalized by dividing by the maximum relative expression level observed within
a given time course and multiplying by 100, which allowed ready comprehension of expression
irrespective of the level. Each gene expression time course is normalized by a different constant
since all of the trajectories have different peaks expression levels. Once all of the time courses
are on the same curve after normalization it is easier to look for trends in expression level
(Figure 6.2). Three genes, Cmaf, IL-21, and RORa, peak in the first ten hours, drop down to
lower levels, and then steadily increase throughout the next 70 hours. Two genes, IL-21R and
STAT3 peak in the first few hours and then rapidly decay to low expression levels and remain
low throughout the differentiation. Three genes, IL-9, IL-22, and Foxp3, remain low during the
first day, peak between 24 and 48 hours and then decay. Most of the rest of the measured genes
start off low during the first day and then steadily increase across the differentiation.
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Figure 6.2. Normalized expression levels of the genes of interest in Thl7 differentiation. All
trajectories were normalized by dividing the relative expression levels at all times for a given
gene by the maximum observed relative expression and multiplying by 100.
To get a better view of the behavior of a few important genes, we plotted their time courses
separately (Figure 6.3). The interplay between Foxp3 and RORyt is easily visualized. At time
zero, Foxp3 is up and RORyt is down. Foxp3 then decreases and remains low while RORyt
increases and remains relatively constant throughout day 1. During day 2, RORyt decreases,
while Foxp3 increases. During day 3, RORyt increases while Foxp3 decreases down to low
levels. It is known that these two transcription factors can interact so it is interesting to observe
the opposing nature of nature of their expression during the differentiation process' 16 . One
could argue that the observation that RORyt reaches a local minimum at 48 hours is just an
artifact due to experimental error. However, we repeated measurements around this point
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numerous times and regularly found that there was a minimum around 48 hours. STAT3, which
is induced by IL-6 peaks early and then levels out at low expression levels by hour 10. IL-17a
does not start to be expressed at significant quantities until the end of day 1. After the first day it
steadily increases over the next 3 days.
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Figure 6.3. Normalized expression levels of a few genes of interest in Th17 differentiation
along with an indication of the three different assumed phases of differentiation.
6.3.2 Simple algorithm allows for determination of correlations between genes during Th17
differentiation
We sought to attain a more quantitative measure to determine the degree of similarity in the time
courses of various genes in a given phase of the differentiation process. One possible way to
analyze correlations between genes would be to use random matrix theory, which was first
17applied in the field of physics to study the spectra of heavy atoms . More recently it has been
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applied in the analysis of stock correlations 18, responses in the brain to auditory stimuli' 9, and
mutations in HIV . The first step in random matrix theory is to determine the correlation matrix
which has pairwise correlations of all the time series as elements. Next, the eigenvalues are of
the correlation matrix are computed and compared to the eigenvalues of a random matrix of
equivalent size. The corresponding eigenvectors of any eigenvalue larger than the largest
eigenvalue of the random matrix contain information about significant correlations between
different time series.
To obtain a measure of the correlation between two genes (gene i and gene j), we calculate the
elements of the correlation matrix Cij using the expression
Y S,(t-3)- S. |xS Fs(t.) - S;]
A |_ L 1 u '\ / /J L .1 '-'\ J//j
Cij= a 2 (Equation 6.1)
[S,(t,) -(S,)]I S(t,) - (S
where Si(ta) is a measure of the relative expression of gene i at time a and Sj(ta) is a measure of
the relative expression of gene j at time a (Kwapian et al.). In the equation, the summations run
over all of the time points in the time series. The net result is a matrix whose elements give the
relative correlation between the various genes computed over numerous time points. It is
important to note that computing one pairwise correlation between two genes using the full 96
hour time courses would not be instructive since the two genes could be highly correlated at
early times and highly uncorrelated at later times which would average out to no correlation. For
this reason, separate correlation matrices are computed for each of the different phases indicated
in Figure 6.3.
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A sample histogram of the correlation matrix components for significant genes in the first ten
hours of activation is given in Figure 6.4A. A significant gene in a given phase is defined as a
gene that attains at least 20% of its maximum normalized expression level within the phase.
Non-significant genes are ignored since small fluctuations at low expression levels are amplified
in this analysis and can lead to spurious correlations. A positive correlation means that the genes
are behaving similarly during a given phase, while a negative correlation means that the genes
are behaving oppositely. A negative pairwise correlation of -1.0 for example would mean that
the genes are moving in the opposite direction at every point in time (e.g. one is increasing while
the other is decreasing). A correlation of zero indicates that there is no significant similarity in
how a pair of genes is expressed.
For random matrix theory to be useful the histogram of the correlation matrix components is
generally centered on low correlations with only relatively few correlations being high in
magnitude. Inspection of Figure 6.4A shows that there are two main peaks at high magnitude
correlations and one at roughly zero. Essentially by choosing genes that we knew were relevant
in Thl7 differentiation, we biased the study towards genes that would likely be correlated
strongly. As a result, random matrix theory is not useful because of our small, biased data set.
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Figure 6.4. Pairwise correlation results for significantly expressed genes in the first ten hours.
Genes are determined to be significant if they increase above a normalized expression of 20 at
any point during the period of interest. (A) Distribution of the correlation matrix elements for
significant genes. (B) Identity of the pairwise correlations corresponding to the distribution of
the correlation matrix elements.
Any "higher-powered" technique used to identify clusters of correlated genes would involve
operations on the correlation matrix. In the case of intermediate numbers of time courses, as is
often the case in collections of real-time PCR time courses, it is easy to construct clusters strictly
by looking at the correlation matrix. One simply must define a threshold correlation value,
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above which all correlations are considered significant. In Figure 6.4A, an obvious choice is 0.5.
In Figure 6.4B, all of the pairwise correlations are sorted according to their Cij value. A cluster
diagram can then be constructed by writing down all of the genes appearing in pairwise
correlations with Cij values greater than 0.5 and then drawing lines between the various genes
which have a significant Cij value. The resulting cluster diagram for the first ten hours would
have a connection between Foxp3, STAT3, and IL-21 R, and also a connection between IL-21,
RORyt, Cmaf, and RORa. IL-21 would only be associated with the RORyt, Cmaf, and RORu
cluster through a connection to RORa. The connectivity of these two clusters makes sense since
they have high positive correlations within the cluster and high negative correlations between the
clusters. We carried out this analysis on both phase 1 (Figure 6.5) and phase 2 (Figure 6.6). It
was not instructive to study correlations in phase 3, since we only have two data points for each
gene.
6.3.3 Clustering algorithm allows for grouping of genes during Thl7 differentiation
In phase 1, we identified three clusters of genes (Figure 6.5a). The first cluster consists of IL-17f
and IL-22. Both of these genes remain at relatively low levels until 16 hours when both are
steadily rising up until the end of phase 1 (Figure 6.5b). They are both Thl7 cell secreted
cytokines so it is not surprising that their expression would be correlated at some point during the
differentiation process. The second cluster consists of Foxp3, IL-21R, and STAT3. The
biological reason for the connection between IL-21 R and STAT3 is clear in that they are both IL-
6 induced genes2 1 . Their behavior at each time point is nearly identical. The mathematical
reason for the connection between Foxp3 and IL-21 R / STAT3 is also clear in that their behavior
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over time after the second time point is quite similar until the end of phase 1. The biological
reason for this connection is not clear. There may be similar regulation of these genes in phase I
or it could just be a coincidence that they behave similarly. This technique only shows the eye
where to look for significant correlation between genes. It does not guarantee that such
significant correlations are biologically relevant and not just a coincidence. Further experimental
testing would be necessary to test connections within clusters. The other cluster in phase I
consists of IL-21, RORyt, RORa, and a loose connection to RORyt. It is termed a loose
connection since the correlation value is right on the edge of not being significant. Biologically,
the connection between Cmaf and IL-21 is clear in that Cmaf has been shown to transactivate IL-
21 (Apetoh, 2010). The order of the curves would suggest that IL-21 induces Cmaf, but Cmaf is
present at nonzero levels at time 0, so there could still be some feedback between these two. A
three component v-shaped cluster can be indicative of very similar shaped curves that are shifted
in such a way that Curve I is correlated with Curve 2 which is then correlated with Curve 3.
Curve I and Curve 3 are not correlated since they are separated sufficiently. This appears to be
the case with IL-21, RORa, and Cmaf in that they are similarly shaped curves separated slightly
in time.
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Figure 6.5. Clustering results for significant genes in phase I of Thl7 differentiation. (A)
Cluster diagram of significant genes. All lines represent a pairwise correlation greater than 0.5.
(B) Color-coded plot indicating the time courses of the different genes that are in a given cluster.
In phase 3, we identified three different clusters (Figure 6.6A). The first "cluster" consists only
of Foxp3, which was significantly expressed in phase three but not significantly correlated with
any of the other genes. The second cluster consists of IL-9 and IL-22. Upon inspection of the
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time courses of the genes in cluster I and cluster 2, it is clear that the shapes of these curves are
all the same, only shifted in time, suggesting all 3 genes should be in the same cluster (Figure
6.6B). However, Foxp3's curve is wider than the other two and shifted in such a way that it does
not have significant overlap with IL-9 and IL-22. Cluster 3 consists of eight total genes. Six of
these genes all have significant connections between each other, which is indicated on the
diagram by having all of these genes touch a circle (Figure 6.6A). RORyt has significant
connections with three of the genes on the circle and IL-10 has significant connections with the
other three. Most of these genes steadily increase throughout phase 3, particularly after 48 hours,
which is when Foxp3 begins to decline.
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Figure 6.6. Clustering results for significant genes in phase 2 of Thl7 differentiation. (A)
Cluster diagram of significant genes. All lines represent a pairwise correlation greater than 0.5.
Any gene touching the circle in the cluster diagram has significant pairwise correlations with all
other genes touching the circle. (B) Color-coded plot indicating the time courses of the different
genes that are in a given cluster.
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6.4 Discussion
Great emphasis was placed on presenting the clustering algorithm and describing the results
obtained from the analysis of the real-time PCR-measured Thl7 differentiation gene activation
profile for numerous genes of interest. It is likely obvious to the reader that not many
conclusions were drawn other than presenting the possible gene clusters in the different phases.
Further experimentation would be required in order to validate whether or not the expression of
the genes in a given cluster are really related. For instance, in phase 1, we observed that Foxp3,
IL21 R, and STAT3 were highly correlated since at every time point they behaved exactly the
same way, except at time 0. The connection between IL-2 I R and STAT3 is likely since they are
both IL-6 induced genes. It is not apparent that Foxp3, which is induced by TGF-p, should or
should not be associated with these two. It may just be a coincidence that they are behaving
similarly and they could be controlled by different mechanisms. The experiments required to
test these sorts of thing are beyond the scope of this thesis.
Several main conclusions can be drawn from these results. It is clear that RORyt and Foxp3
have opposing functions since any time one of them is highly expressed the other is expressed at
low levels, which fits in nicely with the observation that these two transcription factors can
interact9 16 . We also observed that there appears to be three main phases that can be defined
during the four days of differentiation. Each phase has a characteristic set of significant genes
and a characteristic set of gene clusters. We observed that the addition of IL-23 at 48 hours only
significantly affected the expression of a few genes, namely IL-22 and IL-23R. Finally, our
clustering algorithm and normalization method may help others analyze their time course data
for intermediate system sizes (10-50 genes).
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Chapter 7: Concluding Remarks
In the previous chapters, we looked at a range of problems involving different components of the
adaptive immune system. Chapters 2 and 3 addressed the nature of the interaction between DM
and pMHC, as well as DM's role in the loading and unloading of peptides from MHC. These
two manuscripts resulted from a collaboration between experimentalists (Hidde Plough's lab and
Kai Wucherpfennig's lab) and computation / theory people (Arup Chakraborty's Lab). I believe
that these are both fine examples of the work that can be done from such collaborations. The
conclusions made in both studies likely would not have been reached otherwise.
Chapter's 4 and 5 were both examples of cytokines behaving "unexpectedly" similarly in their
effects on immune cells when one gene has been removed. In Chapter 4 we saw that the anti-
inflammatory responses induced by IL-6 and IL-10 were indistinguishable in SOCS3-/- cells,
despite IL-6 being a pro-inflammatory cytokine. Conventional wisdom that IL-6's high
amplitude, transient STAT3 signal is a "strong signal", while IL-10's low amplitude, sustained
STAT3 signal is a "weak signal", led to the association of strong STAT3 signals with a pro-
inflammatory response and a weak STAT3 signal with an anti-inflammatory response. This led
to the conclusion that if a strong STAT3 signal was made even stronger by converting it from a
transient signal to a sustained signal, it should induce an even more potent signal pro-
inflammatory response. Therefore, it was quite unexpected when this resulted in a conversion to
an anti-inflammatory response. This result would not have been unexpected if one de-convolutes
amplitude and signal duration from the definition of a strong signal. This would lead to the
correct conclusion that sustained signals lead to anti-inflammatory responses, while transient
172
signals lead to pro-inflammatory responses. Even though IL-6 and IL-10 are different cytokines
they can behave the same if you make their STAT3 signals equivalent in duration.
Another example of cytokines behaving unexpectedly similar was seen in Chapter 5 where IL-6
and IL-27 were both potent inducers of Th17 differentiation in STATI knockout mice in the
presence of TGF-p. This was "unexpected" since IL-27 has the reputation of being inhibitory
towards Thl7 differentiation through a mechanism involving STAT1. Conventional wisdom
would suggest that the removal of STATI should just remove IL-27's inhibitory properties.
However, we showed that removing STATI resulted in IL-27 inducing a STAT3 signal that is
similar in duration and amplitude to IL-6. The fact that IL-27 can potently induce Thl7
differentiation in the presence of TGF-p shows that there is nothing inherently different between
the IL-6R and IL-27R other than the relative amounts of induced pSTATI and pSTAT3 that they
lead to. The results from both of these chapters challenge the idea that cytokines induce unique
conformations of STATs or other unknown factors in order to make them inherently different
from one another. I think this is the main conclusion of this thesis.
In Chapter 6, we showed a simple algorithm that can be used to cluster genes according to their
levels of activation over time, and showed its properties in the case of Th 17 differentiation. The
other main result from this Chapter was that Foxp3 and RORyt behaved completely opposite
throughout Thl7 differentiation. Whenever one was highly expressed, the other was expressed
at low levels.
In summation, I think this thesis showed the benefits of collaboration and the benefits of
approaching problems mathematically where species are just variables as opposed to attaching
universal properties like "IL-27 is an inhibitory cytokine". Biology is so complex that we need
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such classifications to teach the subject, but great caution must be used when attempting to solve
complicated problems using strictly conventional wisdom.
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Appendix 1: Various Experimental Protocols
A1.1 Flow Cytometry Procedure for pSTAT Measurement
Intracellular staining protocol for signaling molecules and transcription factors - L. Francisco,
Sharpe Lab 2009 (With modifications)
1. Fix cells with 4% PFA (EM Grade real PFA) for 12 min at 37C. In each well add
112.5 p L PBS and then 37.5 pL 16% PFA (in hood). Cover with plate seal.
2. Rinse with PBS.
3. Spin down and resuspend cells in 15 pL PBS. Slowly add 135 pL cold 100%
methanol drop-wise to result in a 90% methanol solution.
4. Incubate on ice for 30 min.
5. Wash out methanol twice with lx eBiosciences Perm Buffer.
6. Block with Perm Buffer + 2% FBS and Fc Block (1:100) for 10 min at RT. For I
antibody staining, this results in adding 87 pL Perm Buffer, 2 pL FBS, and 1 pL Fc
block per well.
7. Stain with antibodies in Perm Buffer for 45 minutes, covered, at RT. Add 10 uL of
the pSTAT antibody of choice in each well.
- pSTATI - Alexa Fluor@ 647 Mouse Anti-STATI (pY70l) BD Biosciences
(#612597)
- pSTAT3 - PE Mouse Anti-STAT3 (pY705) BD Biosciences (#612569)
- pSTAT6 - Alexa Fluor@ 488 Mouse Anti-STAT6 (pY64 1) BD Biosciences
(#558243)
8. Wash extensively (3x with 100 pL Perm Buffer), 2000 rpm 2-3min.
9. Bring to 280 pL PBS in small FACS tube and read on flow cytometer.
A1.2 EMSA (Electrophoretic Mobility Shift Assay) Procedure
Nuclear Extract Isolation:
1. Isolate CD4+ cells from a mouse's spleen and lymph nodes.
2. Incubate cells under different cytokine conditions.
3. Collect cells and transfer to a FACS plate.
4. Transfer cells from FACS plate into 1.5 mL eppendorf tubes.
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5. Spin for 5 minutes at the highest speed.
6. Follow the instructions provided in the NE-PER nuclear and cytoplasmic extraction
reagents kit from Pierce (Prod # 78833).
7. Only keep the nuclear extract (this is where the highest concentration of pSTATs is
located).
8. Measure concentration using the A260 protein concentration program on the NanoDrop
instrument.
9. Freeze at -80C until use.
Oligonucleotide Preparation:
All oligonucleotides were obtained from IDT. Labeled Oligos were 5' end labeled with Li-COR
IR-DYE 700 on both complementary strands. Oligos were delivered at 100 pLL in IDTE Buffer
at pH 8.0. Competitor Oligos were not end labeled.
Sequences:
hSIE - 5'-GTC GAC ATT TCC CGT AAA TC-3'
(From reference chain that begun in Costa-Pereira, A.P. et al, PNAS, 2002)
STATI competitive oligo (SI Oligo) - 5'-CAT GTT ATG CAT ATT CCT GTA AGT G-3'
(Based on Santa Cruz Biotechnologies #2573)
STAT3 competitive oligo (S3 Oligo) - 5'-GAT CCT TCT GGG AAT TCC TAG ATC-3' (Based
on Santa Cruz Biotechnologies #2571)
Labeled Oligo Annealing:
1. Add 10 pL of oligo and 10 p L of complement to an eppendorf tube
2. Place in I OOC heating block for 5 min, then turn off heat and allow to cool in block for
75+min.
3. In 15 mL tube, add 2.5mL of nuclease free water and 5 ptL of annealed oligo from step 2.
This gives a 100 nM / I ptL solution when added to the 20 pL reaction mixture.
Competitor Oligo Annealing:
1. Add 20 ptL of oligo and 20 ptL of complement to an eppendorf tube.
2. Place in I OC heating block for 5 min, then turn off heat and allow to cool in block for
75+min.
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3. Add 60 pL of nuclease free water to eppendorf tube. This gives a 20 uM / I pL solution
when added to the reaction mixture, which is 200x the Labeled Oligo concentration.
EMSA Solutions:
Some of these solutions are obtained from the Li-cor Odyssey EMSA Buffer Kit (#829-07910).
This kit contains 10 labeled tubes of various solutions, which I will indicate as (tube #) to show it
is from the kit and what tube it is found in.
100 mM HEPES - 100 pL IM HEPES in 900 pL nuclease free water
10 mM EDTA - 5 pL 200 mM EDTA (tube 9) in 95 pL nuclease free water
15 mM MgCl2 - 15 pL 100 mM MgCl2 (tube 8) in 85 pL nuclease free water
20 mg/mL BSA - 0.2g BSA in 10 mL nuclease free water.
"Master Mix"
100 mM HEPES -2 pL
15 mM MgCl2 - 2 pL
10 mM EDTA - 2 ptL
50% Glycerol (Tube 5) - 2 ptL
20 mg/mL BSA - 1 pL
25 mM DTT/2.5% Tween 20 (Tube 2) - 2 pL
I pg/ ptL Poly(dl.dC) (Tube 3) - I ptL
Gel Preparation:
Filtered water - 25.33 mL
5x TBE -8 mL
30% Acrylamide - 6.67 mL
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15% APS -444 pL
TEMED - 33.35 pL
Mix the above ingredients and add in between two 15 cm glass plates (1.5 mm separation).
Place 15 well comb in the top of the gel and let gel form for 30 minutes.
Run the gel in 0.5x TBE for 45 minutes at 150V.
DNA Binding Reaction:
1. Add 12 pL of the "Master Mix" to a small eppendorf tube.
2. The total reaction size should be 20-22 pL. Therefore it is necessary to calculate how
much nuclease free water to add (if any to bring up the reaction size to that amount).
3. Add 5 ptg of nuclear extract.
4. Let sit for ~10 min so that the poly (di.dc) can take up non-specific binders.
5. Add supershift antibody (-5 ug) if doing supershift or add competitive oligo for 20 min.
Listed below are the supershift antibodies I used, and the competitive oligos were
described earlier.
6. Add labeled oligo for 30 min (keep in dark). (Note: Steps 5 and 6 can be swapped.)
7. Add 2 ptL of orange loading dye (tube 10).
Supershift Antibodies (supplied at 2 ug/ [tL):
Monoclonal STAT3 AB (S3m) - Santa Cruz Biotechnologies #8019x
Polyclonal STAT3 AB (S3p) - Santa Cruz Biotechnologies #482x
Monoclonal STATI AB (SIm) - Santa Cruz Biotechnologies #464x
Polyclonal STAT I AB (Si p) - Santa Cruz Biotechnologies #346x
Gel Loading and Measurement:
1. Add 20 pL of the reaction mixture to a lane in the gel.
2. Cover gel apparatus with a box.
3. Run at 150V for 2.5 hours (or until orange loading dye reaches the bottom).
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4. Measure results using Li-cor Odyssey instrument.
A1.3 Th17 Differentiation
1. Isolate CD4+ cells using autoMACS instrument (magnetic bead isolation)
2. For 3 mice (~60 million cells), put in 5 mL FACS buffer and stain with:
a. CD4 PeCy7 - 5.25pL
b. CD62L Fitc - 3.75ptL
c. CD25 PE - 3.75pL
3. Let sit on ice for 20 minutes
4. Spin at 1500 RPM for 5 min and resuspend in complete medium
5. Spin at 1500 RPM for 5 min and resuspend in complete medium (ImL / mouse used)
6. Filter by pipetting through cell strainer
ort using rAC ARIA - collect ID4I+C62Lhigh-
8. Rinse 3 times!!
9. Make 24 well plate coated with a-CD3 (4ig/mL) and a-CD28 (2ptg/mL) and incubate for
2 hours
10. Prepare Master Mix
a. 6811.7 piL culture medium, 113.87 pL a-IL-4 (1.23 mg / mL stock), 63.92 pL a-
IFNy (2.19 mg/mL stock), 10.5 pL TGF-p (2ptg/mL) stock
11. Split sorted cells into 7, 15-mL tubes, I for each well on the 24 well plate and resuspend
tubes 2-7 in lmL Master Mix and tube I in lmL culture medium (control)
12. For wells with IL-6, add 1.2 ptL IL-6 (25 pg/mL stock). For wells with IL-21, add 3 pL
IL-21 (10 pg/mL stock). For wells with IL-27, add 1.5 pL IL-27 (20 pg/mL stock)
13. Add tubes to respective wells and put in incubator for 48 hours.
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14. After 48 hours have passed, carefully remove 500 ptL from the top of each well.
15. Prepare Master Mix
a. 3452 ptL culture medium, 28.5 tL a-IL4, 16 tL a-IFNy, 3.5 pL IL-23 (10 ptg/mL
stock)
16. Add 500 pL of solutions to each well (Master Mix to wells 2-7 and culture medium to
well 1)
17. Transfer cells to a new uncoated 24-well plate
18. Incubate for 48 hours
19. After 48 hours have passed, prepare restimulation solution
a. 5 pL PMA (1:2000 dilution), 10 pL lonomycin (1:1000 dilution), 10 ptL Golgi
stop (1:1000 dilution), 10 mL culture medium
20. Carefully collect 400 pL supernatant and put in lmL eppendorf tubes and freeze for elisa
21. Add fresh medium and transfer to 5mL coered FACS tubes
22. Spin down and resuspend in restimulation solution
23. Incubate for 3.5 hours (129 mice) or 4 hours (B6 mice)
24. Spin down and rinse a few times.
25. Transfer cells into FACS plate and split into 4-5 samples
26. Resuspend in PBS: 89 ptL PBS, I pL FC block in each well and place in fridge for 10min
27. Add 10 ptL of (6 pL PBS, I pL CD4-Fitc, 3 ptL 7AAD (FL3)) and place in fridge for
25min
28. Rinse 2 times in PBS
29. Fix in 100 plL BD Cytofix/cytoperm on ice for 25-30min
30. Rinse 2 times in lx perm buffer
180
31. Block with 87 iL perm buffer, 2 RL FBS, I ptL FC block per well and place in fridge for
10 min
32. Stain with 1:200 IL-1 7a APC (0.5 pL/well) and 1:300 IFNy PE (0.33 ptL/well) for 25-30
min in fridge.
33. Rinse 2 times with Ix perm buffer
34. Resuspend in FACS buffer and measure on 4-channel FACS Calibur
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Appendix 2: Supplemental Materials for Chapter 2
Figure A2.1
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Figure A2.1. (A) Monitoring dissociation of photocleavage products with an N-terminal or C-
terminal Alexa647 fluorescent group on the photocleavable peptides MBP-C647 and MBP-
N647. (B) Association of MBP-488 was followed in the 488nm channel. Open symbols
represent complexes without UV irradiation (7 = MBP-C647, 0 = MBP-N647), closed symbols
complexes with UV irradiation (U = MBP-C647, 0 = MBP-N647). The MBP-488 association
phase following cleavage of MBP-N647 mirrored the early rapid dissociation kinetics of the N-
terminal N647 fragment (A). A higher FP reading was observed following cleavage of DR2
loaded with MBP-N647, due to more efficient photocleavage of this peptide. (C) Effect of DM
on displacing MBP-N647 or MBP-C647, monitored by binding of MBP-488. DM accelerated
exchange of the MBP-N647 and MBP-C647 peptides by MBP-488, but the N-terminal Alexa647
group in the MBP-N647 peptide reduced the activity of DM on this complex compared to the
MBP-C647 peptide, consistent with mutagenesis data that mapped the DM binding site close to
the peptide N-terminus (Doebele et al., 2000).
Table A2.1: Yield of DR2-peptide complexes and affinity of peptides for DR2
MBP89 MBP-P1* MBP-P2* MBP-P3* MBP-P4* MBP-P5*
Yield complex' ~300 pg -3 pg -30 pg -30 g -300 pg -50 pg
Affinity differencet 1 306 52 355 3 11
t Recovery after all purification steps
t Fold difference affinity for DR2 compared to index MBP,, 5 g
Peptide Synthesis
Standard Fmoc-based solid-phase peptide chemistry was employed for the synthesis of peptides
MBP-P1* - MBP-P5*. N-terminal capping was accomplished by coupling of a 4-aminobutyric
acid succinimide ester endowed with a dinitrophenyl (Dnp) moiety. Cleavage from the resin and
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concomitant removal of the side-chain protecting groups was followed by HPLC purification and
lyophilization of the final products. LC/MS analysis and MALDI TOF MS confirmed the
identity and homogeneity of the peptides.
Purified peptides of the sequence Dnp-C(SStBu)NPVVHF-Anp-KNIVTPC were labeled with
thiol-reactive maleimide derivatives of AlexaFluor647 C2-maleimide (Invitrogen, Carlsbad, CA).
The attachment of the fluorecent probe to the C-terminal cysteine was accomplished using a
modified procedure of the manufacturers instructions. Typically, in an eppendorf tube, shielded
from light with alumium foil, 77 pL of a stock solution of peptide Dnp-C(SStBu)NPVVHF-Anp-
KNIVTPC in N,N-dimethylformamide (10 mM) was diluted with 77 ptL water and 30 pL
phosphate buffer (1 M, pH 7) after which a stock solution of AlexaFluor647 C2-maleimide in
water (10 mM) was added. The reaction was allowed to proceed overnight with gentle shaking.
LC/MS analysis confirmed quantative consumption of the starting material. The crude mixture
was then purified by HPLC. Fractions containing the desired product were pooled and solvents
evaporated in vacuo. Lyophilization of the final product afforded 1.1 mg, 0.35 Dmol of MBP-
N647.
The N-terminal derivitization with the AlexaFluor647 C2-maleimide (Invitrogen, Carlsbad, CA)
required initial blocking of the C-terminal free thiol, followed by release of thio-tert-Butyl
protecting group under the agency of tributylphosphine. Therefore, to 65 PL of peptide stock
Dnp-C(SStBu)NPVVHF-Anp-KNIVTPC (10 mM in DMF) was added 65 tL water and 7 pL
phosphate buffer (1 M, pH 7) as well as 3.25 ptL of N-ethylmaleimide (IM in DMF). After
shaking for 2 hours, the reaction was quenched by the addition of 4.9 pLL of 2-mercaptoethanol
(IM in DMF) which was allowed to react for an additional hour. Having exposed the N-terminal
free thiol, the peptide was HPLC purified and reacted with AlexaFluor647 C2-maleimide
(Invitrogen, Carlsbad, CA) as described above to furnish 1.0 mg, 0.32 Emol of the final product
MBP-C647.
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Modeling Methods
Each of the three models discussed in the main text were fit to the experimental data using a
nonlinear regression package in MATLAB. All of the experiments used for parameter
estimation involved the addition of MBP-488 after 10 minutes of UV exposure to a well
containing eMHC with or without DM. The relevant ordinary differential equations were solved
to determine the concentrations of all species as a function of time and the concentration of
fpMHC was plotted with the experimental data. In the analyses, the concentration of MBP-488
was set to 0 nM for the first 10 minutes. After 10 minutes, the concentration was set to 200 nM
to simulate the addition of MBP-488 after the UV exposure. A good initial estimate for the
unknown parameters was necessary to get the regression package to converge on a reasonable
solution. To obtain a good initial estimate, the unknown parameters were varied manually until
the predicted fpMHC trajectory overlapped considerably with the experimental data. The
nonlinear regression package was then used to refine the parameter estimates.
All reactions were assumed to be elementary, which means that reactions involving one species
are first order, two species are second order, etc. A list of all of the possible reactions found in
the three proposed models in the main text is shown in Table A2.2, along with the corresponding
rate expressions. Reaction 2 was assumed to be irreversible because peptide removal to form
eMHC is slow in the absence of UV and DM. Reactions 7 and 8 involve the UV cleavage of the
peptide and the subsequent dissociation of the peptide fragments from DR2, respectively. These
two events are assumed to be first order and fast. Reaction 9 is written in a completely general
manner using the aggregation number, N, since the number of eMHC molecules involved in the
reaction is unknown. In the event that the aggregation number is 1, then this reaction represents
the reversible unfolding of eMHC to an unreactive form. If the aggregation number is greater
than 1, then this reaction represents the reversible aggregation of N eMHC molecules. All rates
are written on a concentration basis, with concentrations in nM.
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Table A2.2: List of possible reactions and corresponding rate expressions
The set of equations corresponding to model I (Eq. 2.1) are given as
d
-[pMHC]= 
-r, = -k,[pMHC]
dt
d-[p*MHC]= r,-r = k7 [pMHC]- kj[p*MHC]
dt
d
-[eMHC]= r - r2 = k8 [p*MHC]- k,[eMHC][MBP-488]dt
d
-[fpMHC] r2 = k2[eMHC][MBP-488]
dt
[MBP-488]= [MBP-488] 0-[fpMHC] (A2. 1)
where an algebraic species conservation relation is necessary in addition to the ordinary
differential equations to calculate the concentration of MBP-488 at each time point using species
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Index Reaction Rate Expression
2 eMHC+MBP-488 -> fpMHC r2=k,[eMHC][MBP-488]
5 DM-eMHC+MBP-488 -+ fpMHC rj=k[DM-eMHC][MBP-488]-k 5 [DM][fpMHC]
7 pMHC -> p*MHC r7=k7[pMHC]
8 p*MHC -+eMHC r=k[p*MHC]
9 N eMHC - iMHC rg=k[eMHC]N-k_,N[iMHC]
10 eMHC+DM -+ DM-eMHC ri0=k 1o[eMHC][DM]-k 1 [DM-eMHC]
conservation. The values of both k7 and k8 were set to I min-], which allowed these reactions to
go to completion during the 10 minute UV step as observed in experiments. No value of k2 was
able to capture the experimentally observed behavior at both short and long times.
The set of equations corresponding to model 2 (Eq. 2.2) are given as
d
-[pMHC] = -r= -k 7 [pMHC]dt
d [p*MHC]= r7 - = k7 [pMHC]- k8[p*MHC]
dt
d
-- [eMHC] r8 - -r, = k8[p*MHC]-k 2[eMHC][MBP-488] - (k,[eMHC]N -k_,N[iMHC])dt
d
-[iMHC] r, = k,[eMHC]N -k_9 N[iMHC]dt
d
-[fpMHC] = r2 = k2 [eMHC][MBP-488]dt
[MBP-488]= [MBP-488]0 -[fpMHC] (A2.2)
where an aggregation reaction has been added in order to account for the experimentally
observed behavior at short and long times. This model has four parameters, in addition to k7 and
k8 that were fit to the experimental data. A comparison of the model prediction and the
experimental data for one set of parameters is shown in Fig. 2.7B.
The set of equations corresponding to model 3 (Eq. 2.3) are given as
d
-[pMHC] = -r= -k 7 [pMHC]dt
d
-[p*MHC] r - r = k7[pMHC]- kj[p*MHC]
dt
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d
-[eMHC]=- r. - r2 - r, - rodt
= k8[p*MHC] - k2[eMHC][MBP-488] 
- (k,[eMHC]N -k-9N[iMHC]) - (k 1O[eMHC][DM]-k j [DM-eMHC])
d
-[iMHC] = rg = k,[eMHC]N -k_N[iMHC]
dt
d
-[DM-eMHC] =ro -r5dt
= k1o [eMHC] [DM]-k 1 [DM-eMHC] - (k5 [DM-eMHC][MBP-488]-k_5 [DM][fpMHC])
d
-- [fpMHC]= r2 + rdt
= k2[eMHC][MBP-488] + (k5[DM-eMHC][MBP-488]-k_5 [DM][fpMHC])
[MBP-488]= [MBP-488] 0 -[fpMHC]
[DM]= [DM]0 - [DM-eMHC] (A2.3)
where two additional algebraic species conservation relationships are necessary to calculate the
concentrations of DM and MBP-488 at all time points using species conservation. The values of
the parameters obtained from model 2 (used to prepare the curve in Fig. 2.7B) were fixed and the
additional parameters were fit to experiments where the amount of DM was varied. A
comparison of the model predictions and the experimental data for one set of best-fit parameters
is shown in Fig. 2.7C. Due to the large number of experiments, only a representative set of
curves are shown in the figure. A summary of the quality of fit for all experiments can be found
in Table A2.3. The maximum and minimum percent deviations for each set of conditions were
determined by first calculating the percent deviation of the model from the experimental data at
all time points using the following equation
%dev(t = - = [fpMHC],,iac (t = )[ fpMHC],pr,,,,,,/ (t = r )
[fpMHC]epermen,,,,(t = I-) (A2.4)
where %dev is the percent deviation and -c is a generic time value.
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Table A2.3: Quality of fit for all DM experiments used for parameter estimation. All quality of
fit parameters have been calculated using data points collected within the first 100 minutes of
each experiment. The largest magnitude of the percent deviation for all experiments occurred
within the first two time points. Values of R2 are also reported to show that the overall quality of
the fit is excellent for all sets of data as in Fig. 7C.
Parameter sensitivity
As indicated in the main text, we performed parameter sensitivity studies for all models, and
found other sets of parameters that also fit the data well. The main mechanistic point derived
from the kinetic analyses is that k5 is greater than k2, thereby indicating that DM-bound MHC is
more peptide receptive than the receptive state of MHC alone. This result is robust to parameter
sensitivity using model 3. As noted in the main text, it is also robust to other models that we
explored which were designed such that lower values of k5 might be able to fit the data. For
example, we determined the smallest value of k5 that could predict the large initial slope
observed in the experiments where DM was added. To obtain this smallest value, k-5 and k-10
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DM Concentration Maximum % Minimum %
(nM) R2 Deviation Deviation
0 0.956 18.91 0.14
150 0.988 24.52 0.20
300 0.995 12.66 0.03
500 0.979 61.55 0.03
1000 0.985 31.27 0.00
2000 0.976 24.61 u.u1
5000 0.899 24.86 0.17
were set to zero since reversible reactions would reduce the initial slope (requiring larger values
of k5). The value of k]O was set to a large value since this would create the largest concentration
of DM-eMHC, which results in the smallest value of k5 necessary to obtain the same rate. The
initial slope of the data for 150 nM DM is the smallest in our experimental data set, and so fitting
the initial slope of this data with this model would yield the smallest possible value of k5. The
initial slope could only be fit if k5 was at least two times greater than k2. So, even in such a
model designed to obtain the smallest possible value of k5, its value must be greater than k2 in
order to be in harmony with experimental data.
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Appendix 3: Supplemental Materials for Chapter 3
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Figure A3.1. Minimal background binding by a HLA-DR mutant compared to the streptavidin
surface. In SPR experiments, the sensor detects refractive index changes when only buffer or
protein in buffer is injected. Therefore, it is a widely accepted convention in Biacore studies to
subtract the response in a control flow cell from the experimental flow cell. Such a control also
addresses non-specific binding. We went one step further to rigorously control for non-specific
binding: we designed a HLA-DM mutant that closely resembled the biophysical properties of
wild-type HLA-DM but which had no catalytic activity and did not bind to HLA-DR-peptide
complexes (HLA-DM Mut2). The HLA-DM Mut2 control surface (flow cell 3, Fc3) did not show
increased background binding compared to the streptavidin surface (flow cell 2, Fc2) in all
experiments that were performed. The two graphs compare results from HLA-DR2 WT (a) and
the HLA-DR2 S53D mutant (b) for three surfaces: HLA-DM WT, HLA-DM Mut2 and
streptavidin (SA). HLA-DR2 binding curves were very similar when HLA-DM Mut2 and
streptavidin surfaces were compared. Data are representative of more than five (a) and of two (b)
independent experiments, respectively. m - m
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Figure A3.2. Absence of significant rebinding of HLA-DR to HLA-DM (mass transport).
(a) HLA-DR2-CLIP complexes (2 pM) were run through HLA-DM WT and HLA-DM Mut2
flow cells (1000 RU of immobilized protein) for 5 minutes at the indicated flow rates in a citrate-
phosphate buffer with a pH of 5.35 at 30 *C. This was followed by injection of buffer (stage 2)
and 20 pM CLIP8 7 .10 1 (stage 3). Binding in the HLA-DM Mut2 flow cell was subtracted from
measurements in the HLA-DM WT flow cell. Data are representative of two independent
experiments as shown and of more than three independent experiments under similar conditions.
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Figure A3.3. The complex of HLA-DR and HLA-DM in stage 2 is devoid of peptide. (a)
Specific binding of the DNP antibody to a DNP-labeled peptide bound to HLA-DR2. HLA-
DR2-CLIP (control, no DNP group on peptide) or HLA-DR2-MBP(85-99)-DNP (500 RU of
each protein) were immobilized on a streptavidin chip. DNP or control antibody (at the indicated
dilutions) were injected for 2 min (25 'C, 15 1l/min), followed by injection of buffer (citrate-
phosphate buffer, pH 6). Binding in the HLA-DR2-CLIP (no DNP) control flow cell was
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subtracted from binding in the two experimental flow cells. (b) The stable complex of HLA-DM
and HLA-DR in stage 2 is devoid of peptide. HLA-DR2-CLIP(87-10 l)-DNP (5 pM) was
injected for 10 minutes (25' C, 15 gI/min), followed by injection of buffer and a 2 minute
injection of antibody (DNP or control antibody at 2 pg/ml) in citrate-phosphate buffer (pH6). The
SPR assay was carried out in consecutive flow cells with immobilized HLA-DM WT or HLA-
DM Mut2 (500 RU of each protein) in citrate-phosphate buffer (pH 5.35). Binding in the HLA-
DM Mut2 flow cell was subtracted from measurements in the HLA-DM WT flow cell. Data are
representative of two independent experiments. (c) The DNP antibody detects the DNP group of
a covalently linked peptide. HLA-DRI-HA6 P2P 1 complex (0.5ptM) with a C-terminal DNP
group on the linked peptide was injected (as in b), followed by injection of DNP or control
antibody in stage 2.
a b
50 250-
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300 150 + DR2-CLIP +DM
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* DR2-M8P DR2-CUP
100 DR2-MBP
S 300 600 00 1200 0 20 40 60 80 100
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Figure A3.4. Comparison of the kinetics of HLA-DM binding and HLA-DM catalysis for low-
affinity versus high-affinity HLA-DR-peptide complexes. (a) Comparison of HLA-DM binding
by low-affinity HLA-DR2-CLIP and high-affinity HLA-DR2- MBP85. 99 complexes. HLA-DR2
complexes preloaded with the indicated peptides (10 iM) were injected for 10 minutes (stage 1),
followed by injection of buffer (stage 2) and 5 pM MBP85. 99 (stage 3). The SPR assay was carried
out in consecutive flow cells with 500 RU of immobilized HLA-DM WT and HLA-DM Mut2 in
a citrate-phosphate buffer (pH 5.35) at 37 *C at a flow rate of 15 pl/min. Measurements from the
HLA-DM Mut2 flow cell were subtracted from data obtained from the HLA-DM WT flow cell.
HLA-DM binding by HLA-DR2-MBP85 .99 was 8.7-fold slower compared to HLA-DR2-CLIP,
based on measurement of the initial rates. (b) Comparison of HLA-DM susceptibility of HLA-
DR2-CLIP and HLA-DR2-MBP85.99 complexes. Binding of 200 nM Alexa488-labeled MBP8 5 99
to HLA-DR2 (200 nM) preloaded with the indicated peptides was measured in the presence or
absence of 100 nM HLA-DM in 50 mM citrate phosphate buffer (pH 5.3) containing 150 mM
NaCl. The initial rate of HLA-DM-catalyzed peptide binding was 11.8-fold slower when HLA-
DR2-MBP85. 99 rather than HLA-DR2-CLIP was used as the input protein in the reaction. Data
are representative of two independent experiments as shown (a, b) and of more than three under
similar conditions (a) (FP assays were performed in triplicates).
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Figure A3.5. Production of homogenous disulfide-linked HLA-DR1-peptide complexes. (a-c)
Purification of disulfide-linked complexes of HLA-DRI P6 Cys and HA 6 P2Pi 1 peptide. (a)
Removal of excess free DNP-labeled peptide following peptide loading and disulfide bond
formation. HLA-DR1-P 6 Cys molecules were separated from DNP-labeled HA6 P2P1i peptide by
gel filtration (Superose 12). The blue trace (280nm) represents protein absorbance, the red trace
(350 nm) DNP absorbance. The peak between 11-1 5ml contains the HLA-DR-peptide complex,
the later peak the free peptide. (b) Affinity purification of disulfide-linked HLA-DR1-HA6 P2PiI
complexes by DNP affinity chromatography from other HLA-DR species. Protein and peptide are
traced as described in (a). The earlier peak represents the flow-through, the later peak the
peptide-loaded complex (elution with CAPS buffer, pH 11.5). (c) Analysis of disulfide linkage of
HA6 P2P 11 peptide to the HLA-DRa chain by non-reducing SDS PAGE. Data are representative
of at least four independent experiments.
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Figure A3.6. Biochemical characterization of HLA-DRI molecules with covalently linked full
length or partial peptides. (a, b) Affinity purification of disulfide-linked HLA-DR1-HA 6 (a) and
HLA-DR1-HA 6 P2 Pi I (b) complexes by DNP affinity chromatography from other HLA-DR
species. The blue trace (280nm) represents protein absorbance, the red trace (350 nm) DNP
absorbance. The earlier peak represents the flow through, the later peak the peptide-loaded
complex (elution with CAPS buffer, pH 11.5). The scales of 280 nm and 350 nm readings were
adjusted based on prior experiments with affinity purified, fully loaded HLA-DR-peptide
complexes such that identical peak heights reflected full occupancy of the peptide binding groove
by DNP-labeled peptide. Based on these measurements, the peptide binding groove of both HLA-
DR1-HA6 (a) and HLA-DR1-HA 6 P2 P11 (b) was fully occupied. (c) Immunoprecipitation of
covalent HLA-DRI -peptide complexes by conformation-sensitive antibodies to HLA-DRa and
HLA-DRp chains. HLA-DRI - HA 306-318 peptide complexes (without covalent linkage) as well as
HLA-DR1-HA 6 and HLA-DR1-HA 6 P2P1 I complexes were immunoprecipitated with a control
mAb (W4F.5B), mAb L243 (to HLA-DRa chain) or mAb 9.3.F10 (to HLA-DR chain). The
Western blot was labeled with a polyclonal anti-DR serum, followed by a polyclonal HRP-
labeled rabbit IgG antiserum. (d) Low-affinity HA 6 P2 P11 peptide exchanges quickly from HLA-
DRI upon reduction of the disulfide bond. Binding of Alexa488-labeled HA306.31s (65 nM) to the
indicated HLA-DRI complexes (200 nM) was followed by FP with or without prior reduction of
the disulfide bond between the peptide and the HLA-DRa helix. Equilibrium binding data are
shown for reactions in which either the HLA-DR1-HA 6 P2P11 complex or the HLA-DR1-
CLIPi, complex (positive control) were used as input proteins. Data are representative of at least
two independent experiments (FP assay performed in triplicate).
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Figure A3.7. HLA-DM binding to HLA-DR loaded with full-length peptide is highly
temperature dependent. (a,b) Temperature profiles for HLA-DM binding by HLA-DR molecules
loaded with CLIP peptide (HLA-DR2-CLIP, a) or a low-affinity CLIP variant (HLA-DRl-
CLIPiow, b). (a,b) HLA-DR2-CLIP complexes (0.5 pM, a) and HLA-DRI- CLIPIO, complexes
(1 ptM, b) were run over the HLA-DM WT and HLA-DM Mut2 flow cells (500 RU of
immobilized proteins) at a flow rate of 15 p1/min in a citrate-phosphate buffer with a pH of 5.35
at the indicated temperatures. This was followed by injection of buffer and injection of 20 pM
CLIP (a) or 50 pM HA 306. 3 18 (b). Binding in the HLA-DM Mut2 flow cell was subtracted from
measurements in the HLA-DM WT flow cell. Data are representative of two independent
experiments shown (a, b) and of at least four independent experiments under similar conditions
(a).
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Figure A3.8. Kinetic parameters for HLA-DM binding to HLA-DR1 -HA 6 P2PII complex. (a-c)
HLA-DR 1-HA 6 P2 PiI complexes (0.1 to 5 gM) were injected into HLA-DM WT and HLA- DM
Mut2 flow cells at temperatures ranging from 20 to 37 'C. The datasets were fitted as in Fig. 3.7c
and ka, kd, and Kd values were plotted against the corresponding temperatures. Data are
representative of two independent experiments.
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Figure A3.9. Slower dissociation of HLA-DM-HLA-DR complex at lower pH. (a) Low pH
increases HLA-DM binding to HLA-DR-CLIP and slows dissociation of HLA-DM- HLA-DR
complexes. HLA-DR2-CLIP complexes (5 gM) were run over the HLA-DM flow cell (500 RU
of immobilized HLA-DM) and the SA flow cell for 10 minutes at a flow rate of 15 pl/min in a
citrate-phosphate buffer with the indicated pH at 30'C, followed by injection of buffer (stage
2) and CLIP87-101 at a concentration of 20 pM (stage 3). Binding in the SA flow cell was
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subtracted from the measurements in the HLA-DM WT flow cell. (b) pH dependent peptide
binding to HLA-DR2 molecules after photolysis of bound peptide. HLA-DR2-MBP85 99
complexes preloaded with UV-cleavable MBP peptide were UV irradiated for 10 minutes in 10
mM Tris pH 7.0 on ice to generate empty HLA-DR2 molecules. Binding of Alexa-488 labeled
MBP85. 99 (30 nM) to empty HLA-DR2 (150 nM) was measured directly following UV-cleavage
using FP at the indicated pH. Data are representative of at least two independent experiments
(FP assay performed in triplicates).
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Figure A3.10. Model of the interaction of HLA-DM with HLA-DR. HLA-DR molecules with a
fully bound peptide (1) do not interact with HLA-DM. Partial peptide dissociation at the N-
terminus (2) enables HLA-DM binding (3). HLA-DM catalyzes peptide removal and forms a
long-lived complex with HLA-DR in the absence of peptide (4). Binding of a high-affinity
peptide to this complex will most likely result in its dissociation (5), while the HLA- DM-HLA-
DR complex is more likely to remain intact upon binding of a low-affinity peptide (6). Low-
affinity peptide can be removed by the catalytic action of HLA-DM (editing) and the complex of
empty HLA-DR and HLA-DM (4) is then again available for peptide binding. The
conformational change in HLA-DR molecules upon release of the N-terminal peptide segment is
indicated here by a change in color, compared to HLA-DR molecules with tightly bound
peptides. For all individual molecular steps, the corresponding stages of SPR experiments are
indicated (stages 1-3).
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Figure A4.1. Only the nonzero stochastic solution trajectories follow the mean field solution to
the model equations for molecule I at a signal degradation rate of 1.0 min~'. Time course
trajectories obtained by solution of the model equations using a mean field ODE solver (red
curve), ten times using the Gillespie Algorithm (10 blue curves), average at each time point of
the nonzero stochastic trajectories (green curve), and average at each time point of all the
stochastic trajectories (cyan curve). Parameters for the model were obtained from Table 4.1.
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Figure A4.2. Upon deletion of the positive feedback loop, A is produced in greater quantities
after 2000 min for sustained signals, while neither is produced in significant quantities for
transient signals. Histogram for (A) molecule I and (B) molecule A obtained by solving the
model equations for a sustained signal of Kdeg,T equal to 0.0 min- using the Gillespie Algorithm
1000 times and recording the number of molecules at 2000 min. Histogram for (C) molecule I
and (D) molecule A obtained by solving the model equations for a transient signal of Kdeg,T equal
to 1.0 min-] using the Gillespie Algorithm 1000 times and recording the number of molecules at
2000 min. Parameters for the model were obtained from Table 4.1.
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Figure A4.3. Upon deletion of the negative feedback loop, both I and A are produced in
significant quantities after 2000 min for sustained signals, while only I is produced in significant
quantities for transient signals. Histogram for (A) molecule I and (B) molecule A obtained by
solving the model equations for a sustained signal of Kdeg,T equal to 0.0 min' using the Gillespie
Algorithm 1000 times and recording the number of molecules at 2000 min. Histogram for (C)
molecule I and (D) molecule A obtained by solving the model equations for a transient signal of
Kdeg,T equal to 1.0 min' using the Gillespie Algorithm 1000 times and recording the number of
molecules at 2000 min. Parameters for the model were obtained from Table 4.1.
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Figure A4.4. Upon deletion of the positive and negative feedback loops, both I and A are
produced in significant quantities after 2000 min for sustained signals, while neither is produced
in significant quantities for transient signals. Histogram for (A) molecule I and (B) molecule A
obtained by solving the model equations for a sustained signal of Kdeg,T equal to 0.0 min~1 using
the Gillespie Algorithm 1000 times and recording the number of molecules at 2000 min.
Histogram for (C) molecule I and (D) molecule A obtained by solving the model equations for a
transient signal of Kdeg,T equal to 1.0 min-' using the Gillespie Algorithm 1000 times and
recording the number of molecules at 2000 min. Parameters for the model were obtained from
Table 4.1.
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Figure A4.5. At long very times model breaks down and I dominates for nonzero signals. This
is due to the fact that A is entirely signal dependent, so once the signal is gone it also decays to
zero rendering it incapable of inhibiting the production of I. Since I has not decayed to zero, its
positive feedback loop allows it to ramp up production when A is incapable of inhibition. (A)
Mean field solution for molecule I at a signal degradation rate of 0.002 min~' plotted out to 5000
min. (B) The maximum amount of I and A observed in 1000 time course trajectories measured
out to 5000 min was compared to an arbitrary threshold and the percentage of trajectories
crossing the threshold was computed for a wide range of signal degradation rates. The I and A
thresholds were set to 100 molecules. The parameters given in Table 4.1 were used, thus Kdeg,A
is equal to 0.001 min-. (C) Reducing the degradation rate of A (Kdeg,A) to a value of 0.0001 min-
counteracts the effect of measuring out to 5000 minutes. The I threshold was set to 100
molecules, while the A threshold was set to 20 molecules. Sampled trajectories were 5000
minutes long.
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Figure A4.6. Depiction of sensitivity analysis results. Three values were varied for nine
different classes of parameters (High, medium, and low), where the description of the classes and
their respective high, medium, and low values are defined by Table A4. 1. Of all the trajectories
leading to a positive result, (i.e. signal duration allows for a decision between I and A), a certain
percentage had high, medium, and low values of each parameter, which is depicted in the figure.
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Discussion of Sensitivity Analysis
The results presented in this Chapter 4 were generated using the parameters listed in Table 4.1.
Since this was just one parameter set, it was important to verify that the qualitative results of the
model were the same for a wide set of parameters. The model contains less than 100 reactions so
computation times for the Gillespie simulations were quite short. This allowed us to run a great
number of simulations over a wide range of parameter sets and actually visualize the effect of
varying parameters, which is not feasible for larger networks. Despite there being 91 possible
reactions in the network, only 17 of the rate constants were unique, as indicated in Table 4.1.
We further reduced this down to nine to make it feasible to test all possible combinations of three
different values for each of the nine classes of parameters. The nine parameter classes along
with the low, mid, and high values used for the sensitivity analysis of the parameters is given in
Table A4.1.
The sensitivity analysis was performed by first generating all 19,683 combinations of the three
values for each of the nine parameter classes. Each of these combinations was given a label of
the form, LMHLMHLMH, which means parameter I (kon) had its low value, parameter 2 (koff
11)had its mid value, etc. Twenty trials were run for each parameter set for three different values
of signal degradation (Kdeg,i= 0.001 min I, 0.01 min- , 0.1 min 1). In each individual trial, the
program records the maximum value of I and A obtained at any point in the 2000 minute
trajectory. At the end of each trial, these max values are compared to the previous trials, such
that at the end of all twenty trials, the program records the highest and lowest maximum value of
I and A obtained in any trial. Therefore, the output for each parameter set is Imax, Imin, Amax, and
Amin obtained at three different values of signal degradation (Kdeg,T= 0.001 min~', 0.01 min~', 0.1
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min-1). Using these 12 values, we can determine whether or not a cellular decision has been
made. If Imin is greater than Amax for one signal degradation rate, and Amin is greater than Imax at
another signal degradation rate, then a signal duration dependent decision has been made. It may
be easier to think about this as a comparison of two distributions, I and A. For the A distribution
to be great then I, its lowest tail must be greater than the upper tail for I and vice versa. If a
decision has been made, the parameter set is given a plus, and if no decision has been made, it is
given a minus.
It is also possible for I to be bistable, which would mean that Imin would be 0 and using the above
procedure it would have been given a minus. However, it is probable that Imax would be much
greater than Amin as observed in the main text. For this reason, we also recorded which
parameter sets led to bistable results for the two transient signals (Kdeg,T= 0.001 min-', 0.01 min-
). Whenever the positive feedback loop was initiated, it usually resulted in I values much
greater than 50, so the test for bistability was whether Imin was 0 and Imax was much greater than
50. Parameter sets marked bistable may lead to a cellular decision, but it is difficult to test since
Imin is 0.
The sensitivity analysis revealed that there were 1809 parameter sets that led to a cellular
decision, 15529 that did not, and 2345 that were bistable. Even though there were many
parameter sets that did not lead to the same qualitative results, we consider the 1809 positive
results to indicate that this is a fairly robust qualitative phenomenon for this model considering
the range of parameters tested. Also, bistable results may still lead to a cellular decision at lower
values of the signal degradation rate. There are various methods for analyzing sensitivity results.
We chose to focus our efforts on analyzing the positive results. Within the subset of positive
results, we calculated the percentage that had either a low, mid, or high value for each parameter
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class (Figure A4.6). The sensitivity of the results to a given parameter can be inferred by the size
of the spread in the percentages for that given parameter class. If all of the positive results had
an equal spread of low, mid, and high parameter values for a given parameter class, then the
results were insensitive to changes in that parameter. The three least sensitive parameter classes
were kdeg,m, ktri, and ktrx I,A. The low sensitivity to kdeg,m when one of the values tested was 0
justifies setting this value to 0 in the simulations given in the main text. Clearly the most
sensitive parameters are the transcription rates, and the low value for kon and the high value for
kdeg 1,A were too extreme.
Some additional information can be obtained by analysis of the sensitivity results. Of the 1809
positive results, 80 had A transcription rates higher than I. Therefore, it is not required for I to
have a higher transcription rate than A for this model to be sensitive to signal duration. One
assumption used to make the model in the main text was that the transcription factors unbind
from the gene after each transcription event. It also may be possible that the transcription factors
remain bound and transcription can occur until they unbind according to their respective ko,
value. We also created a model to test whether or not this type of model would lead to the same
qualitative model. As a quick test, we ran the sensitivity analysis program with the parameter set
in Table A4.1 and found that 1900 parameter sets led to positive results. This is actually greater
than the model presented in the text so the uncertainty about whether transcription factors unbind
after each transcription event does not affect the qualitative results of the model. Another
assumption made in the model presented in the main text was that molecules pSTAT3, I, and A
were able to be deactivated while bound to genes I and A. We tested the effect of this
assumption by creating a model where the molecules were not allowed to be deactivated while
bound to genes. Using this new model, we ran the sensitivity analysis program with the
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parameter set in Table A4.1 and found that 1939 parameter sets led to positive results, indicating
that the qualitative results are not significantly affected by the nature of this assumption.
Table S1. Listing of the parameter classes and their corresponding
used in the sensitivity analysis.
low, mid, and high values
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Parameter Class Description Low Mid High
kon (molec~ min-) On-rate for all molecules 0.0015 0.015 0.15
on all genes
koff A,B(min~) Off-rate of A and B 0.01 0.5 1.0
koff C (min-) Off-rate of C from gene B 0.01 0.5 1.0
ktrx B (min') Transcription rate of B in 0.01 0.1 1.0
the absence of C
ktr, c(min-) Transcription rate of C 0.01 0.1 1.0
.t 1 Transcription rate of B in
ktrx B,C (min') tepsncofC0 0.00 1 0.009he presence of C
ktri (min-) Translation rate of B and C 0.01 0.5 1.0
kdeg,m (min) mRNA degradation rate 0 0.001 0.01
_ i Degradation rate of B and 0 0.001 0.01
kdegB,C(min) C
